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Kidney disease is defined as an abnormality of kidney structure or function with 
implications for the individual on health, which can occur abruptly, and either resolve 
or become chronic.1 Acute kidney injury (AKI) is one of the acute kidney diseases and 
disorders. Criteria for acute kidney diseases and disorders were first proposed in the 
2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline 
for AKI and include markers of kidney damage or a glomerular filtration rate (GFR) <60 
ml/min/1.73 m2 for ≤ 3 months.2, 3 The criteria for AKI comprise a sudden decrease in 
GFR manifested by an increase in serum creatinine or oliguria within 48 hours to 7 
days.2 Chronic kidney disease (CKD) is a general term for multiple, heterogeneous 
disorders affecting kidney structure and function with variable clinical presentation, 
severity, and rate of progression. The KDIGO definition on CKD includes structural or 
functional alterations of the kidney for >3 months with a GFR <60 ml/min/1.73 m2.1 
The overall prevalence of CKD in European children ranges from 55-75 per million.4, 5 
Kidney failure is defined as a GFR <15 ml/min/1.73 m2 or the requirement for kidney 
replacement therapy.1 Kidney transplantation is mostly the preferred treatment for 
children in need of kidney replacement therapy. In the Netherlands, approximately 
25-35 children below the age of nineteen receive a kidney transplant each year.6 
Afterwards, most children are treated with an immunosuppressive regimen that 
includes tacrolimus.7, 8 The common adage in pediatrics that children are not little 
adults, definitely applies to pediatric nephrology patients as well, which was recently 
highlighted by the American Society of Pediatric Nephrology.8 The causes of CKD in 
children, for instance, are different from adults. In adults, diabetic nephropathy and 
hypertension are the main causes of CKD, whereas CKD in children is often caused by 
congenital abnormalities of kidneys and urinary tract, hereditary nephropathies, and 
glomerular disorders.4, 5, 9 Moreover, in addition to the differences in disease entities, 
large differences exist in the pharmacokinetics (PK) and pharmacodynamics (PD) of 
drugs between the adult and pediatric population.10 The exact interplay between age 
and disease on PK, PD, and dose requirements remains poorly understood.11 
Consequently, prescribing drugs and optimizing treatment in children with kidney 
diseases poses several challenges and is often debated. Glomerular disorders, including 
nephrotic syndrome, are an important cause of AKI, CKD, and kidney failure in children 
worldwide, accounting for 5-14% of children with CKD and 15-29% of children with 
kidney failure.5, 12-14 The main aim of this thesis is to optimize treatment in children 
with nephrotic syndrome. Moreover, other aspects of treatment optimization in 
pediatric nephrology are addressed, including the impact of CKD on the PK and PD of 
drugs, and optimization of tacrolimus treatment after kidney transplantation.
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CHAPTER 1
PART I Diagnosis and classification of nephrotic syndrome
Nephrotic syndrome is one of the most common glomerular disorders in children and 
affects 1-7 per 100,000 children per year (Dutch data: 1.52/100,000/year) with a male 
predominance (2:1).15, 16 The disease is characterized by the triad of severe proteinuria, 
hypoalbuminemia, and edema.16, 17 As (periorbital) edema is frequently attributed to 
allergy and treated accordingly, patients often face a significant delay in accurate 
diagnosis.18 Nephrotic syndrome may be classified on the basis of response to steroid 
therapy, pattern of relapse, histopathology, or by genetic mutations. Kidney biopsies 
are not routinely performed anymore in children with nephrotic syndrome as the 
response to therapy cannot be predicted on the basis of biopsy results.19, 20 Therefore, 
classification is often based on clinical response to steroid therapy.17 Over 80% of 
children with nephrotic syndrome achieve complete remission with steroid treatment 
within 4 weeks, which is referred to as steroid sensitive nephrotic syndrome (SSNS).21 
After initial complete remission, around 80% of these children experience one or 
several relapses requiring additional courses of high dosed steroids, which may be 
associated with substantial morbidity.21, 22 Half of these patients suffer from frequently 
relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome 
(SDNS).21, 23 Approximately 10% of children with nephrotic syndrome do not respond 
to steroids and are considered steroid resistant. The 2012 KDIGO Clinical Practice 
Guideline on Glomerulonephritis includes clear descriptions of these definitions 
related to childhood nephrotic syndrome.24 As the classification based on steroid 
response is widely used and important for both clinical practice and research, the use 
of uniform definitions is essential. However, despite KDIGO recommendations, wide 
variation seems to be present in the definitions used in clinical care and research.
Pathologically, nephrotic syndrome is characterized by podocyte foot process 
effacement (Figure 1.1). Along with the glomerular basement membrane and the 
fenestrated endothelium, the podocyte forms the glomerular filtration barrier.17 
The podocyte contains an extensive actin cytoskeleton that is critical for normal 
podocyte function and preservation of the integrity of the glomerular filtration 
barrier.25, 26 The actin network is essential for formation and arborization of podocyte 
foot processes, for maintaining slit diaphragm turnover, and the formation of stress 
fibers.27 Moreover, the actin cytoskeleton enables the glomerular filtration barrier to 
withstand the substantial capillary hydrostatic pressure.28 Podocytes are terminally 
differentiated cells with minimal regeneration capacity and are therefore vulnerable to 
injury.17 Detriment of normal podocyte structure, foot processes or the slit diaphragm 
can result in the loss of proteins such as of albumin in the urinary space.29 (Figure 1.1) 
The exact mechanism of childhood nephrotic syndrome is still largely unknown and 
often debated. Different subgroups of the disease are likely to have a different 
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pathogenesis and several etiologies have been investigated over the years, including 
involvement of the immune system with a potential role for T-cells and B-cells, the 
presence of one or more circulating permeability factors, and genetic mutations 
affecting podocyte proteins and/or podocyte functions.30, 31 Involvement of the 
immune system in the pathogenesis of nephrotic syndrome is highly likely as relapses 
often occur after the immune system is triggered by an infection, allergy, or vaccination, 
and steroid treatment is effective in most patients. Nephrotic syndrome has been 
considered a T-cell disorder based on several observations, including remission 
following measles infection, the association with Hodgkin’s disease, and the response 
to immuno suppressive drugs.31 Furthermore, a potential role for B-cells has been 
proposed due to the effectiveness of B-cell depletion with rituximab in patients with 
nephrotic syndrome.31, 32 A proportion of childhood nephrotic syndrome patients is 
likely to have an immune-mediated circulating permeability factor disease.31, 32 The 
existence of one or more circulating factors was first hypothesized on the basis of 
observations that plasma taken from nephrotic syndrome patients was able to induce 
proteinuria in previously non-nephrotic subjects.33, 34 Moreover, the existence of a 
circulating permeability factor would explain the rapid recurrence of proteinuria after 
kidney transplantation in some patients with nephrotic syndrome.35 Many candidates 
for the circulating permeability factors have been identified over the years, however 
the definitive factor(s) remain to be discovered.36, 37 Finally, damage to the filtration 
Figure 1.1 Foot process effacement in nephrotic syndrome
In the presence of a normal glomerular basement membrane (GBM), with healthy podocyte foot processes, 
serum proteins (mainly albumin) remain in the blood. Mechanisms, that are not fully elucidated yet, modify 
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CHAPTER 1
barrier may also be caused by genetic defects directly affecting podocyte proteins 
and/or podocyte functions. Patients with an underlying genetic defect are often resistant 
to steroids and to date over 60 genes associated with steroid resistant nephrotic 
syndrome (SRNS) have been identified.27, 38, 39 Comprehensive genetic screening 
identifies hereditary podocytopathies in up to 33% of children with SRNS.38, 40, 41 
Interestingly, approximately 1% of individuals carries mutations in genes that function 
within the coenzyme Q10 (CoQ10) biosynthesis pathway. These patients may be responsive 
to CoQ10 supplementation.40, 42 However, several issues in the diagnosis, monitoring, 
and treatment of primary CoQ10 deficiency are still under debate.43 
PART II Optimization of pharmacotherapy in pediatric nephrology patients
Nephrotic syndrome
Steroids have been the cornerstone of the treatment of childhood nephrotic syndrome 
for over 60 years. Treatment guidelines for the first manifestation and a relapse of 
SSNS are mostly based on small clinical studies performed by the International Study 
of Kidney Disease in Children (ISKDC) and Arbeitsgemeinschaft für Pädiatrische 
Nephrologie (APN).24, 44, 45 The optimal steroid regimens are still under debate, which 
leads to variability in the management of children with nephrotic syndrome. 
Approximately 50% of children with nephrotic syndrome progress to a frequently 
relapsing or steroid dependent course of disease. To limit steroid toxicity in these 
patients, second-line non-steroid immunosuppressive drugs are considered.46 
Non-steroid immunosuppressive drugs may provide longer periods of remission and 
enable steroids to be withdrawn or reduced, however are associated with significant 
adverse effects as well. Several options are currently available including alkylating 
agents (cyclophosphamide and chlorambucil), levamisole, calcineurin inhibitors (CNIs, 
tacrolimus and cyclosporine), mycophenolate mofetil (MMF), and rituximab.24 The 
alkylating agents prolong remissions in children with SSNS who relapse frequently.46 
Due to the risk of carcinogenesis and infertility their use is limited to one or two 
courses, leading to research into and increased use of other immunosuppressive 
drugs.47, 48 A recent Cochrane review by Larkins et al. concluded that comparative 
studies of CNIs, MMF, levamisole, and alkylating agents have demonstrated little or no 
differences in efficacy but, due to insufficient power, clinically important differences in 
treatment effects cannot be excluded.46 Treatment of SRNS is an even greater 
challenge due to its heterogeneous etiology, frequent lack of remission, and 
complications.49 Recently, the International Pediatric Nephrology Association (IPNA) 
published a clinical practice recommendation for the diagnosis and treatment of 
patients with SRNS.50 Start of renin-angiotensin-aldosterone system (RAAS) inhibition 
with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor 
562850-L-bw-Schijvens




blockers (ARB) is recommended in combination with a CNI.50-52 Steroid treatment 
should be tapered once the diagnosis of SRNS is established.50
Prognosis
Children with SSNS generally have a good prognosis with resolution of the disease over 
time. Approximately 15% of patients continue to experience relapses in adulthood.53 
Despite ongoing relapses, kidney outcomes remain excellent, with a risk of progression 
to CKD estimated to be less than 5% in those with SSNS 10 years after diagnosis.54 
Nevertheless, significant long-term adverse effects of repeated steroid therapy and 
second-line immunosuppressive agents may be present.53, 55 Steroid resistance is 
associated with a severely increased risk of kidney failure. In fact, children with SRNS 
account for approximately 15% of all children with CKD requiring kidney replacement 
therapy.49 Identification of a gene defect is important to determine the chance on 
treatment response to steroids and CNIs, and the prognosis on kidney function. 
Patients with monogenic SRNS have a poor therapeutic response and high risk of 
kidney failure, however no post-transplant recurrence.56, 57 Genetic-testing negative 
patients with SRNS, who show a complete response to intensified immunosuppression 
rarely progress to kidney failure. In contrast, genetic-testing negative patients who do 
not respond to intensified immunosuppression appear to have poor kidney survival 
and high post-transplant recurrence rates.56, 58 
Treatment optimization
The current steroid regimens for the treatment of nephrotic syndrome are associated 
with pronounced steroid associated toxicity. The major adverse effects of steroid 
treatment comprise obesity, striae, hypertrichosis, cataract, glaucoma, arterial 
hypertension, psychological disturbances, growth failure, and osteoporosis.47, 59-61 
The cumulative dose over time is the main determinant of both short- and long-term 
toxicity. Therefore, establishing the most effective and least toxic therapeutic regimen 
for children with SSNS is important. As it was previously suggested that longer initial 
steroid treatment would benefit the disease course and reduce subsequent relapses62, 
several trials have focused on prolonging the treatment of a first episode of nephrotic 
syndrome and show no benefit of steroid therapy beyond 12 weeks.63-66 Currently, 
the 8 weeks ISKDC protocol and 12 weeks APN protocol are among the most frequently 
used protocols for the treatment of the first episode of nephrotic syndrome in 
Europe.67 In the Netherlands, patients are treated according to the 12 week APN 
protocol (6 weeks of daily steroids [60 mg/m2] followed by 6 weeks of alternate day 
steroids [40 mg/m2]). Taken into account the toxicity in children receiving steroid 
treatment, the question is whether the 8 and 12 weeks regimens are equally effective 
and the standard treatment should shift towards 8 weeks steroid treatment. The 
optimal steroid treatment of a nephrotic syndrome relapse is still under debate as well. 
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CHAPTER 1
As stated in the 2012 KDIGO Clinical Practice Guideline on Glomerulonephritis “there 
are no randomized controlled trials examining relapse regimens with corticosteroids 
in infrequent relapsing nephrotic syndrome”.24 In the Netherlands, the treatment of a 
relapse consists of daily steroids (60 mg/m2) until proteinuria is absent for 3 days, 
followed by 4-6 weeks of alternate day steroids (40 mg/m2).68 Recently, results of 
the PROPINE study were published in which patients were randomized to receive, 
from day 5 after remission, either 18 doses (≈5 weeks) of 40 mg/m2 of prednisone 
on alternate days, or the same cumulative dose tapered over double the time for an 
infrequent relapse of nephrotic syndrome. The results suggest that prolonged tapering 
of prednisone treatment for relapses of SSNS is not beneficial.69 Nevertheless, the 
question remains whether a relapse of nephrotic syndrome can be treated safely with 
a restricted steroid regimen. 
Taken together, the course of disease in childhood nephrotic syndrome is largely 
unpredictable and highly variable among patients. Effort should be made to minimize 
steroid toxicity and provide tailored therapy. Moreover, this approach should not be 
limited to childhood nephrotic syndrome patients, but to the management of pediatric 
nephrology patients in general, including CKD and pediatric kidney transplant patients. 
Several factors, including PK, PD and pharmacogenetics should be taken into account 
when prescribing drugs to these vulnerable patient groups. 
Chronic kidney disease
One of the major challenges in the field of pediatric nephrology is the prescription of 
drugs in pediatric CKD patients. CKD is associated with multiple physiological changes 
and may therefore influence various PK parameters.70 For pediatric patients, the impact 
of maturation on drug disposition and action should be taken into account as well.11, 71 
PK describes the individual steps that determine drug disposition in the body, namely 
absorption from an extravascular site of administration, distribution to various tissues, 
and elimination from the body based on metabolism and excretion (Figure 1.2).72 
Absorption describes the process by which an intact drug proceeds from the site of 
administration to the site of measurement within the body. After absorption, drugs 
distribute to target tissues and sites of elimination in the systemic circulation. 
The volume of distribution (Vd) represents the parameter relating the concentration 
of a drug in the plasma to the total amount of the drug in the body. Elimination is 
the irreversible loss of drug from the site of measurement. Elimination occurs by two 
processes, excretion and metabolism. Metabolism is the conversion of one chemical 
compound to another and comprises the major mechanism for elimination of drugs 
from the body. Finally, the drugs and its metabolites are excreted from the body which 
predominantly occurs via biliary excretion or excretion via the kidneys.72
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A well-known consequence of CKD is a reduction in kidney clearance due to a decrease 
in GFR. The impact of an impaired kidney function on the PK of drugs is, however, 
not limited to a decreased elimination of drugs excreted by the kidneys.70, 73 In fact, 
CKD appears to be associated with multiple physiological changes and may therefore 
influence extrarenal PK processes.70, 74, 75 Pediatric patients with impaired kidney 
function are more at risk of altered drug exposure or toxic effects than individuals with 
normal kidney function.76 Little information is available on the exact interplay between 
age and disease on PK, PD, and dose requirements. Taken together, it is difficult to 
develop generic drug dosing guidelines for pediatric CKD patients due to a large 
variability in PK changes in CKD and maturational changes in children. Nevertheless, 
identifying the relevant PK changes in this patient group to ultimately guide and 
optimize drug therapy is essential.
Kidney transplantation
CNIs are the cornerstone of immunosuppressive therapy after kidney transplantation. 
Tacrolimus was introduced in the 1990s as an alternative to cyclosporine and is now 
widely used to prevent rejection after solid-organ transplantation in both adult and 
pediatric transplant recipients.77 At the time of discharge after transplantation, 
approximately 70% of pediatric kidney transplant patients are treated with tacrolimus.7 
Tacrolimus is poorly absorbed and extensively bound to erythrocytes and plasma 
proteins. Metabolism occurs by the cytochrome P450 (CYP) system and finally, 
tacrolimus is mainly eliminated through biliary excretion.78, 79 Tacrolimus is characterized 
by a narrow therapeutic index: low concentrations are associated with an increased 
Figure 1.2 Overview of pharmacokinetic processes
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CHAPTER 1
risk of acute rejection of the transplanted organ, while high concentrations are 
associated with toxicity, malignancy, and infection.80, 81 A wide variety of tacrolimus 
associated toxicities have been described including acute and chronic kidney 
parenchymal injury, electrolyte derangements, and harmful effects on the endocrine, 
nervous, and cardiovascular systems.82 Furthermore, the intra- and interindividual PK 
variability is high.77 Several factors influencing the intra- and interindividual variability 
have been reported and include age83-85, ethnicity77, body weight86, 87, concomitant 
medication88, inflammation89, hematocrit86, 90, and albumin levels.77 In addition, 
genetic factors, especially single nucleotide polymorphisms (SNPs) in the CYP3A4 and 
CYP3A5 genes, may have a major influence on the efficacy of the drug and risk of 
adverse effects.91 The efflux transporter p-glycoprotein (P-gp), encoded by the ABCB1 
gene, also plays a role in the PK of tacrolimus.92 Nevertheless, associations between 
the ABCB1 3435C>T polymorphism and tacrolimus exposure or clinical response remain 
inconclusive.93 With the strong link of CYP genotype with tacrolimus metabolizing 
activity, dose adjustments have been proposed for the first tacrolimus dose after 
kidney transplantation.
Individualizing tacrolimus dosing regimens by performing therapeutic drug monitoring 
(TDM) to optimize the therapeutic effect and minimize adverse effects is essential. For 
pediatric kidney transplant patients, little is known about the optimal targets for 
tacrolimus exposure. Prospective clinical outcome studies are lacking in pediatric 
transplant patients to investigate the potential benefits of area under the concentration 
time curves (AUCs) monitoring compared with trough level-guided therapy.94 
Therefore, both whole blood trough concentrations and AUCs are used to adjust the 
tacrolimus dosing regimen of an individual patient. As reference values for target 
exposure based on clinical trials in pediatric patients are lacking, adult targets are 
currently used.80, 95, 96 Yet, large differences exist between the pediatric and adult 
population in terms of PK and physiology, for instance in hematocrit values, and the 
need for different drug formulations.94, 97 These factors should be taken into account 
when optimizing tacrolimus treatment in pediatric kidney transplant patients. 
Aims of the thesis
1. To optimize diagnosis and classification of childhood nephrotic syndrome 
2. To review and optimize treatment strategies for pediatric patients with nephrotic 
syndrome
3. To review the effect of CKD on PK parameters to guide drug prescription in 
pediatric CKD patients
4. To optimize tacrolimus TDM and treatment in pediatric kidney transplant patients
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PART I - Diagnosis and classification of nephrotic syndrome
• How can we optimize and accelerate the diagnosis of nephrotic syndrome in children?
• What are the differences and challenges in the currently used definitions for childhood 
nephrotic syndrome? 
• What is known on the diagnosis and treatment of patients with a CoQ10 deficiency 
presenting with nephrotic syndrome?
PART II - Optimization of pharmacotherapy in pediatric nephrology patients
a. Nephrotic syndrome 
• What are the common practice patterns of Dutch pediatricians and pediatric 
nephrologists in the management of childhood nephrotic syndrome? Which aspects 
of nephrotic syndrome management are often debated?
• What is known on pharmacology and pharmacogenetics of prednisone and 
prednisolone in pediatric nephrotic syndrome patients? What are the mechanisms 
of glucocorticoid action?
• What is the optimal steroid regimen for the first episode of childhood nephrotic 
syndrome? 
• What is the effectiveness and safety of a reduced steroid regimen for a relapse of 
childhood nephrotic syndrome?
b. CKD 
• What is known about the influence of maturation on PK and dose requirements in 
pediatric CKD patients?
• Which PK parameters should be taken into account when prescribing drugs in 
pediatric CKD patients?
c. Kidney transplantation 
• What is the impact of hematocrit correction on the evaluation of tacrolimus target 
exposure in pediatric kidney transplant patients?
• What is the relative bioavailability of the extemporaneously prepared tacrolimus 
oral suspension compared with oral capsules in pediatric kidney transplant patients?
562850-L-bw-Schijvens
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Outline of the thesis
PART I of the thesis focuses on the diagnosis and classification of childhood nephrotic 
syndrome. In Chapter 2 the synergy with atopic constitution is outlined for general 
practitioners. Currently, diagnosis of nephrotic syndrome in children is often delayed 
and therefore the key message to perform urinalysis when a child presents with 
periorbital edema is emphasized. Nephrotic syndrome may also be caused by a rare, 
but important mitochondrial disease, CoQ10 deficiency. A review on mitochondrial 
diseases and the kidney is provided in Chapter 3 with a special focus on CoQ10 
deficiency. Chapter 4 highlights the importance of using uniform definitions in the 
management of childhood nephrotic syndrome, in clinical as well as research settings. 
PART II of the thesis focuses on pharmacological aspects of different disease entities 
in the field of pediatric nephrology. Section A concentrates on the immunosuppres-
sive treatment of children with nephrotic syndrome. The optimal treatment of children 
with nephrotic syndrome is often debated. Previously conducted studies have shown 
significant variability in nephrotic syndrome management. In Chapter 5 variation in 
the management of nephrotic syndrome in the Netherlands is shown. Differences 
were identified in several aspects of the treatment including steroid tapering, the 
choice of steroid sparing agents, and kidney biopsy practice. In Chapter 6 the 
mechanisms of glucocorticoid action and clinical PK and PD of prednisone in nephrotic 
syndrome patients are outlined. Currently, the optimal steroid treatment for a first 
presentation as well as a relapse of nephrotic syndrome is under debate. Several trials 
have focused on the steroid treatment of a first episode of nephrotic syndrome. 
Well-conducted trials clearly show no benefit of steroid therapy beyond 12 weeks and 
shorter courses are considered to be preferable. The 8 weeks protocol and 12 weeks 
protocol are among the most frequently used protocols in Europe. Chapter 7 includes 
an individual patient data (IPD) meta-analysis to determine whether the 8 weeks 
steroid regimen for a first episode of nephrotic syndrome in children is equally effective 
as the 12 weeks steroid regimen. Similarly, the optimal treatment for a relapse of 
childhood nephrotic syndrome is often discussed, however, clinical trials investigating 
the relapse treatment are currently lacking. Chapter 8 includes the study protocol of 
the RESTERN study, an international, double-blind, placebo-controlled, randomized 
controlled trial to assess the safety and effectiveness of a reduced alternate day steroid 
schedule for treatment of a nephrotic syndrome relapse in comparison with the 
standard therapy. Moreover, an update on the clinical trial is provided in this chapter. 
Finally, several trials have been published to investigate the optimal treatment of FRNS 
and SDNS. Chapter 9 provides a discussion on the importance of TDM to enable 
accurate comparison of different second-line immunosuppressive agents for the 
treatment of FRNS and SDNS. Treatment optimization is not limited to childhood 
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nephrotic syndrome, but to the management of pediatric nephrology patients in 
general, including CKD and pediatric kidney transplant patients. A well-known 
consequence of CKD on PK is a reduction in kidney clearance due to a decrease in GFR. 
In Section B, Chapter 10, the impact of impaired kidney function on different PK 
parameters is displayed and guidance for clinical practice is provided. Section C 
focuses on the tacrolimus treatment in pediatric kidney transplant patients. Tacrolimus 
is characterized by a narrow therapeutic index. Moreover, intra- and interindividual PK 
variability is high. In Chapter 11, the impact of hematocrit correction on tacrolimus 
target exposure in pediatric kidney transplant patients in evaluated. In the Netherlands, 
immediate release tacrolimus is available in capsules, as well as 0.2 mg granules. As 
granules for oral suspension are considered inappropriate due to the large number of 
sachets required and due to liquid formulations not being commercially available, 
hospitals rely on extemporaneously prepared formulations. In Chapter 12, the relative 
bioavailability of tacrolimus oral suspension versus oral capsules is studied. Finally, 
Chapter 13 provides a summary and discussion with future perspectives on the studies 
performed in this thesis.
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CHAPTER 2
Klinische les 
Denk aan nefrotisch syndroom 
bij kind met atopie en dikke ogen
Clinical lecture – Consider nephrotic syndrome in children 
in case of swollen eyelids and atopic constitution
Anne M. Schijvens, Eiske M. Dorresteijn, Marcel van Hest, Marieke van Meel, 
Joanna A. van Wijk, Boukje van Dijk- van Casteren, Michiel F. Schreuder
Huisarts en Wetenschap 2017;60(6):370-2.
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Het nefrotisch syndroom is de meest voorkomende glomerulaire ziekte bij kinderen en 
wordt gekenmerkt door de trias proteïnurie, laag serum albumine en oedeem. Bij 
kinderen zijn de eerste symptomen vaak zwelling van de oogleden en/of het gelaat. Bij 
dikke ogen denkt men vaak als eerste aan een vorm van allergie, zeker door de 
frequente atopische constitutie in deze groep, om vervolgens onderzoek in deze 
richting te doen. Dit vertraagt de juiste diagnostiek en therapie in geval van een 
nefrotisch syndroom. Huisartsen kunnen aanvullend onderzoek doen met een dipstick 
van de urine. Als deze positief is voor eiwit, kan de huisarts de patiënt snel gericht 
verwijzen voor adequate behandeling, zodat ernstige complicaties kunnen worden 
voorkomen.
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Inleiding
Huisartsen krijgen op hun spreekuur geregeld patiënten met zwelling van de oogleden 
en/of het gelaat. Vaak wordt dan automatisch gedacht aan een vorm van allergie, 
vooral bij een atopische voorgeschiedenis of een met atopie belaste familieanamnese. 
Periorbitaal oedeem kan echter ook een uiting zijn van een zeldzaam ziektebeeld, het 
nefrotisch syndroom, dat ook geassocieerd is met een atopische constitutie. In 
Nederland stelt men de diagnose nefrotisch syndroom jaarlijks bij 55 tot 60 kinderen 
en ongeveer 500 volwassenen, waarmee het de meest voorkomende glomerulaire 
ziekte bij kinderen is.15 In deze klinische les beschrijven we vier ziektegeschiedenissen 
van kinderen met het nefrotisch syndroom die op het spreekuur kwamen met oedeem, 
waarbij de arts aanvankelijk dacht aan een allergie. Beperkt aanvullend onderzoek in 
de vorm van simpel urineonderzoek kan snel tot de juiste diagnose leiden, zodat 
gerichte verwijzing en adequate behandeling kunnen worden ingezet.98, 99
Casus A
Een jongen van zeven jaar kwam samen met zijn moeder bij de huisarts met sinds 
enkele maanden gezwollen oogleden, een toename van de buikomvang en dikke 
enkels. De klachten waren het meest prominent in de ochtend en werden minder in de 
loop van de dag. Elf maanden na het ontstaan van de klachten heeft de huisarts een 
allergietest verricht, waarna deze de patiënt voor verder onderzoek naar de dermatoloog 
heeft verwezen. De dermatoloog heeft de jongen naar de kinderarts doorverwezen 
met het vermoeden van de diagnose nefrotisch syndroom. Aanvullend onderzoek bracht 
een hypoalbuminemie en een forse proteïnurie aan het licht (Tabel 2.1). De patiënt 
kreeg prednison voorgeschreven volgens het (inter)nationale behandelprotocol (Tabel 
2.2), waarmee remissie van het nefrotisch syndroom werd bereikt.
Casus B
Een jongen van negen jaar met in de voorgeschiedenis eczeem, hooikoorts en lactose- 
intolerantie kwam bij de huisarts met sinds enkele weken dikke oogleden, voornamelijk 
in de ochtend en na het zwemmen. De familieanamnese was positief voor eczeem, 
astma en hooikoorts. De huisarts dacht aan een allergie en startte met een neusspray. 
Het effect hiervan bleef uit en in de daaropvolgende weken werd de jongen steeds 
vermoeider en oedemateus. Bovendien nam zijn gewicht toe en kreeg hij koorts. De 
huisarts stelde een streptokokkeninfectie vast, waarvoor de patiënt antibiotica kreeg. 
De jongen meldde zich enige tijd later opnieuw bij de huisarts, omdat zijn klachten 
aanhielden. Aanvullend urine- en bloedonderzoek toonde een forse proteïnurie en 
hypoalbuminemie, waarop de huisarts de jongen naar de kinderarts verwees (Tabel 
2.1). Nadat het nefrotisch syndroom na behandeling met prednison niet in remissie 
kwam, verrichte de kinderarts-kindernefroloog aanvullend een nierbiopsie, waarna de 
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diagnose focale segmentale glomerulosclerose (FSGS) gesteld werd. Uiteindelijk is de 
aandoening in remissie gekomen met aanvullende immunosuppressieve behandeling.
Casus C
Een meisje van veertien maanden, met in de voorgeschiedenis een perifere pulmonalis-
stenose, was sinds enkele maanden onder controle bij de kinderarts vanwege 
recidiverende bovenste luchtweginfecties. De familieanamnese was positief voor astma. 
Sinds de leeftijd van zes maanden had ze vooral in de ochtend gezwollen oogleden, 
waarvoor de kinderarts adviseerde het hoofdeinde van het bed omhoog te zetten. 
Bij een controleafspraak acht maanden later had het meisje duidelijk gezwollen oog - 
leden en een bolle buik, waarna de kinderarts aanvullend onderzoek deed (Tabel 2.1). 
Daaruit bleek een forse hypoalbuminemie met proteïnurie, waarop de kinderarts het 
meisje naar de kinderarts-kindernefroloog verwees. Gezien de jonge leeftijd van de 
patiënte verrichtte deze een nierbiopsie, waarna hij startte met prednison. Vooralsnog 
is hiermee, zes maanden later, geen remissie bereikt, maar wel een vermindering 
van de proteïnurie en een verbetering van het serum albumine. Aanvullend genetisch 
onderzoek toonde een mutatie in het NPHS2 gen aan, hetgeen past bij de diagnose 
SRNS.
Casus D
Een driejarige jongen kwam met zijn ouders bij de huisarts met sinds enkele dagen 
dikke ogen, wat in de loop van de dag minder werd. Daarbij hadden zijn ouders scrotaal 
oedeem opgemerkt. Een dag eerder hadden de ouders contact gehad met de 
huisartsenpost, waarbij gemeld werd dat er een rood plekje onder het oog zat. 
De dienstdoende huisarts trok de conclusie dat het waarschijnlijk een allergische 
reactie op een insectenbeet betrof. Bij controle door de eigen huisarts de volgende 
dag was het gelaat opnieuw gezwollen, met daarbij een duidelijk bolle buik. Vanwege 
het vermoeden van ascites heeft de huisarts de jongen diezelfde dag verwezen naar 
een kinderarts. Aanvullend onderzoek in het ziekenhuis liet een hypoalbuminemie en 
proteïnurie zien, waarop de kinderarts de diagnose nefrotisch syndroom stelde. 
Er werd gestart met prednison, met aanvankelijk een goed effect op de proteïnurie. 
Helaas ontstond na afbouwen van de prednison naar een om-de-dag dosering opnieuw 
proteïnurie, waarop de prednison weer naar een dagelijkse dosering ging. Acht dagen 
na de tweede poging tot afbouwen naar om-de-dag prednison, ontstond een tweede 
recidief. In verband met de steroïdafhankelijkheid is er aanvullend een nierbiopsie 
verricht, hetgeen het beeld van een minimal change nefrotisch syndroom opleverde. 
De kinderarts-kindernefroloog begon met rituximab, waarmee de jongen na vier 
weken in remissie kwam.
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Beschouwing
Interpretatie
Het nefrotisch syndroom wordt gekenmerkt door de trias proteïnurie, hypoalbumine-
mie en oedeem. Meestal is er tegelijkertijd sprake van een hyperlipidemie, als gevolg 
van een verstoring van het vet metabolisme.100 De arts stelt de diagnose op de 
aanwezigheid van gegeneraliseerd oedeem, proteïnurie (urine eiwit-kreatinine ratio 
>200 mg/mmol of 3+ eiwit gemeten met een urine dipstick, overeenkomend met een 
eiwit concentratie in de urine van >3 g/l) en een serum albumineconcentratie van 
minder dan 25 g/l. Bij kinderen wordt na de diagnose vaak direct gestart met 
behandeling, zonder voorafgaande nierbiopsie. Bij volwassenen wordt echter in vrijwel 
alle gevallen een nierbiopsie verricht. Dit verschil zit in de oorzaak van het nefrotisch 
syndroom: bij kinderen is meestal (in 80%) sprake van een minimal change nefrotisch 
syndroom. Als het nefrotisch syndroom zich in het eerste levensjaar manifesteert, is 
de kans op een genetische oorzaak groot.101 Minder vaak voorkomende oorzaken bij 
oudere kinderen zijn FSGS of membranoproliferatieve glomerulonefritis. Bij volwassenen 
is er vaak sprake van membraneuze nefropathie of FSGS.102, 103 
De initiële behandeling van het nefrotisch syndroom bij kinderen bestaat uit prednison 
(Tabel 2.2). Hiermee komt 80-90% van de kinderen in remissie.24, 104 Daarnaast zijn er 
in de acute fase ondersteunende behandelingsmogelijkheden zoals natriumbeperking, 













Patiënt A Normaal 17 ↓ 13,3 ↑ 3,3 ↑ 7,2 ↑
Patiënt B Normaal 10 ↓ NV >10 ↑ NV
Patiënt C Normaal 8 ↓ 8,5 ↑ 3,8 ↑ 23,5 ↑
Patiënt D Normaal <10 ↓ 11,7 ↑ 2-10 ↑ 17,7 ↑
EKR, eiwit-kreatinine ratio; N, normaal; NV, niet verricht; dikgedrukt is afwijkend 




40 mg/m² om de dag
Eerste presentatie 6 weken 6 weken
Recidief Tot 3 dagen in remissie 6 weken
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zo nodig in combinatie met diuretica, vochtbeperking en antihypertensieve medicatie.105 
Uit gegevens van een landelijke studie uit Nederland blijkt dat bij meer dan 80% van de 
kinderen één of meer recidieven ontstaan en bij 50% zelfs 4 of meer per jaar.63
Vanwege de zeer ernstige, soms levensbedreigende complicaties van het nefrotisch 
syndroom, zoals gedissemineerde waterpokken, streptokokken peritonitis en trombose, 
is het van groot belang om de diagnose zo spoedig mogelijk te stellen en te starten met 
adequate behandeling.16, 106, 107
Commentaar
De casuïstiek laat zien dat de symptomen vaak al gedurende lange tijd bestaan voordat 
de diagnose nefrotisch syndroom wordt gesteld. (Ouders van) kinderen met het 
nefrotisch syndroom geven bij de kinderarts-kindernefroloog vaak aan dat ze graag 
willen dat artsen bij klachten van gezwollen oogleden aan het nefrotisch syndroom 
denken. De symptomen van het nefrotisch syndroom zijn vaak niet specifiek, wat het 
stellen van de juiste diagnose bemoeilijkt. In alle gevallen stond oedeem, vooral in de 
ochtend, op de voorgrond. In de huisartsenpraktijk komt oedeem in het gelaat bij 
kinderen met enige regelmaat voor, waarbij insectenbeten, infectie en allergie de 
meest voorkomende oorzaken zijn.108 
Een andere reden voor het doctor’s delay is dat een atopische voorgeschiedenis, 
dan wel atopie in de familieanamnese, de kans op een allergie als verklaring voor de 
klachten groter maakt. De casus laten zien dat atopie niet differentieert tussen allergie 
en het nefrotisch syndroom. Uit eerder onderzoek bleek dat bij ongeveer 30% van de 
kinderen met het nefrotisch syndroom tevens sprake is van atopische constitutie of 
atopie bij eerstegraadsfamilieleden.109, 110 Bovendien heeft men recidieven van het 
nefrotisch syndroom beschreven nadat de patiënt aan allergenen was blootgesteld. 
Er zijn weinig aanwijzingen dat allergieën een direct pathogene rol spelen bij het 
ontstaan van het nefrotisch syndroom. Het is waarschijnlijker dat het immuunsysteem 
van de individuele patiënt predisponeert tot het ontwikkelen van beide aandoeningen.18 
De doorgaans uitstekende werkzaamheid van prednison bij beide aandoeningen 
ondersteunt dat ook.
Bespiegeling
Soms is het mogelijk om op basis van een gerichte anamnese en lichamelijk onderzoek 
onderscheid te maken tussen oedeem bij nefrotisch syndroom en oedeem door 
andere oorzaken (Tabel 2.3). Het oedeem bij nefrotisch syndroom ontstaat in de loop 
van dagen tot weken en kan leiden tot gewichtstoename, in tegenstelling tot oedeem 
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bij allergische reacties, dat in minuten tot uren kan ontstaan en niet tot een gewichts-
toename leidt. In het geval van een allergische reactie beperkt het oedeem zich 
meestal tot de oogleden. Bij het nefrotisch syndroom is het gelaat een voorkeurs-
plaats, maar zien we oedeem ook vaak in de benen (vooral de enkels), buik en bij 
jongens in het scrotum. Het is van belang om bij een kind met gezwollen oogleden te 
kijken of er elders wellicht ook zwellingen zijn.111
Hypertensie is aanwezig bij 13 tot 55% van de kinderen met het nefrotisch syndroom.105 
De interpretatie van de bloeddrukmeting kan moeilijk zijn: hypertensie kan ontstaan 
als reactie op intravasculaire ondervulling, maar kan ook wijzen op glomerulone fritis.68 
Gezien de afwezigheid van therapeutische consequenties in de huisartsenpraktijk en 
de praktisch vaak moeilijke uitvoerbaarheid bij kinderen, behoort bloeddrukmeting 
niet tot onze standaardadviezen. 
Wij adviseren om bij ieder kind met oedeem een gerichte anamnese af te nemen en 
een willekeurige urineportie te controleren op eiwit door middel van een dipstick. Als 
er sprake blijkt te zijn van proteïnurie, kan het kind snel verwezen worden naar de 
Tabel 2.3  Gerichte anamnese en lichamelijk onderzoek door de huisarts 
bij verdenking nefrotisch syndroom
Onderdeel Wat te vragen/doen? Voorbeeld Reden
Anamnese Beloop van de klachten 
in de tijd
Snel aankomen in 
gewicht, knellen van 
kleding
Aanwijzing voor 
allergische reactie of 
nefrotisch syndroom
Aard, lokalisatie en duur 
van oedeem
Gelaat, buik, enkels, 
scrotum/labia
Onderscheid lokaal en 
gegeneraliseerd oedeem
Allergieën Hooikoorts, voedsel, 
insectenbeten







Inspectie oedemen Gelaat, buik, enkels, 
scrotum/labia
Onderscheid lokaal en 
gegeneraliseerd oedeem 














Oedeem door ontsteking 
of infectie
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kinderarts voor verdere diagnostiek en behandeling. Zo kan men complicaties mogelijk 
voorkomen. Meer informatie over het vervolgtraject en de begeleiding van patiënten 
met het nefrotisch syndroom wordt gegeven in de NHG huisartsenbrochure Nefrotisch 
syndroom.99
Conclusie
Het nefrotisch syndroom is de meest voorkomende glomerulaire aandoening bij kinderen. 
Wanneer de ziekte niet tijdig herkend wordt, heeft deze potentieel ernstige complicaties. 
Het is van belang om te bedenken dat een atopische constitutie op zich niet differentieert 
tussen allergie en nefrotisch syndroom. Met behulp van een gerichte anamnese en een 
eenvoudig urineonderzoek (dipstick op eiwit in de urine) bij kinderen met oedeem kan 
de diagnose nefrotisch syndroom ook in de huisartsenpraktijk gemakkelijk en snel worden 
gesteld, en het risico op een gecompliceerd beloop worden verkleind. 
De kern
- Bij elk kind met oedeem aan de ogen dienen huisartsen een gerichte anamnese af 
te nemen.
- Bij ieder kind met oedeem moeten huisartsen laagdrempelig urineonderzoek op 
eiwit (de dipstick-methode) verrichten. 
- De aanwezigheid van atopie differentieert niet tussen allergie en het nefrotisch 
syndroom. 
- Het nefrotisch syndroom kan gepaard gaan met ernstige complicaties. Daarom is het 
van belang het nefrotisch syndroom snel op te sporen en vervolgens met behandeling 
te starten.
- Meer informatie over het nefrotisch syndroom is te vinden in de NHG huisartsenbrochure 
Nefrotisch syndroom.
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Mitochondrial disease and 
the kidney with a special focus 
on CoQ10 deficiency
Anne M. Schijvens, Nicole C. van de Kar, Charlotte M. Bootsma-Robroeks,
Elisabeth A. Cornelissen, Lambertus P. van den Heuvel, Michiel F. Schreuder 
Kidney International Reports 2020 Oct 10;5(12):2146-2159
doi: 10.1016/j.ekir.2020.09.044.
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Mitochondrial cytopathies include a heterogeneous group of diseases that are 
characterized by impaired oxidative phosphorylation, leading to multi organ 
involvement and progressive clinical deterioration. Most mitochondrial cytopathies 
that cause kidney symptoms are characterized by tubular defects, but glomerular, 
 tubulointerstitial, and cystic diseases have also been described. Mitochondrial 
cytopathies can result from mitochondrial or nuclear DNA mutations. Early recognition 
of defects in the CoQ10 biosynthesis is important, as patients with primary CoQ10 
deficiency may be responsive to treatment with oral CoQ10 supplementation, 
in contrast to most mitochondrial diseases. A literature search was conducted to 
investigate kidney involvement in genetic mitochondrial cytopathies and to identify 
mitochondrial and nuclear DNA mutations involved in mitochondrial kidney disease. 
Furthermore, we identified all reported cases to date with a CoQ10 deficiency with 
glomerular involvement including three patients with variable renal phenotypes in 
our clinic. To date, 144 patients from 95 families with a primary CoQ10 deficiency 
and glomerular involvement have been described based on mutations in PDSS1, 
PDSS2, COQ2, COQ6, and COQ8B/ADCK4. This review provides an overview of kidney 
involvement in genetic mitochondrial cytopathies with a special focus on CoQ10 
deficiency.
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Mitochondrial cytopathies include a heterogeneous group of diseases with impaired 
oxidative phosphorylation.112 Mitochondrial disorders are characterized by a progressive 
clinical deterioration of the disease and the presence of some degree of encephalopathy 
in most patients. However, other organs with high metabolic rates can also be severely 
affected.113 The kidney is an energy-demanding organ in the human body and all 
nephron segments have different mitochondrial densities and distributions due to 
different energy demands along the nephron.114-116 Kidney symptoms caused by 
mitochondrial dysfunction are often characterized by tubular defects, however, glomerular, 
tubulointerstitial, and cystic diseases have also been described.117 Moreover, kidney 
manifestations are rarely isolated and often part of a multisystemic disorder with 
symptoms of encephalopathy, cardiomyopathy, sensorineural hearing loss, muscle 
weakness, retinopathy, and/or diabetes mellitus.113 Mitochondrial cytopathies are 
caused by inherited or sporadic mitochondrial DNA or nuclear DNA mutations in genes 
that affect mitochondrial functions. Disease-causing mutations that result in disorders 
of mitochondrial energy metabolism have been reported at present in >250 genes.118 
Although each individual defect is rare, the overall prevalence of mitochondrial 
disorders in the general population is approximately 1 in 4300.42, 119 For mitochondrial 
diseases with kidney involvement two important genetic causes should be highlighted: 
defects in the mitochondrial DNA 3243A>G and in the CoQ10 biosynthesis. The m.3243A>G 
mutation in the transfer ribonucleic acid (RNA)Leu gene is one of the most common 
mitochondrial DNA point mutations. The phenotypic expression of m.3243A>G 
mutation can be highly variable and cause a wide range of clinical manifestations. 
Although kidney involvement is not very common, several patients with the m.3243A>G 
mutation have developed proteinuria and kidney failure.120 In patients with primary 
CoQ10 deficiency, proteinuria and/or kidney dysfunction might be the only manifestation 
at presentation. CoQ10 deficiency is highly relevant for clinicians as, in contrast to 
most mitochondrial disorders, patients with primary CoQ10 deficiency may respond 
to treatment with CoQ10 supplementation.121 Early diagnosis is crucial as oral 
 supplementation of CoQ10 can limit disease progression, prevent neurological 
deterioration, and improve clinical symptoms.122 As established neurologic and/or 
kidney damage is irreversible, this underlines the importance of early diagnosis and 
treatment. In this review, an overview of kidney involvement in genetic mitochondrial 
cytopathies is provided with a special focus on CoQ10 deficiency.
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The mitochondrial genome is composed of a single double-stranded circular loop that 
lacks introns and contains 37 genes, encoding two ribosomal RNA, 22 transfer RNAs, 
and 13 structural protein subunits of the respiratory chain complexes I, III, and IV, and 
protein complex V.123-125 Complex II contains only nuclear DNA-encoded subunits, 
whereas the other respiratory chain complexes and complex V are comprised of both 
mitochondrial DNA-encoded and nuclear DNA-encoded subunits.42 The mitochondrial 
respiratory chain is composed of four protein complexes and two electron carriers: 
CoQ10 and cytochrome c (Figure 3.1). CoQ10, also known as ubiquinone, is present in 
all cell membranes as a lipid molecule with a variety of biological functions.126 Besides 
its function as electron carrier, CoQ10 is involved in the beta-oxidation of fatty acids, 
pyrimidine synthesis, detoxification of hydrogen sulfide, and protection from reactive 
oxygen species (ROS).113, 127-129 Mitochondrial cytopathies refer to inherited or 
sporadic mitochondrial DNA or nuclear DNA mutations in genes that affect mito -
chondrial functions. Different from nuclear DNA, various amounts of mitochondrial 
DNA copies are present in a cell depending on its energy demand. Mitochondrial DNA 
is highly susceptible to damage and mutations, with a 10- to 1,000-fold greater 
mutation rate than nuclear DNA.130 The threshold level for mitochondria to become 
dysfunctional can vary between tissues due to differences in energy dependence. 
The threshold for disease is lower in tissues that are highly dependent on oxidative 
metabolism, such as kidney tubules.113, 131 Defects in oxidative phosphorylation cause 
two major problems: a reduction in adenosine triphosphate (ATP) production and an 
increase in ROS production. In approximately one-third of patients the first symptoms 
of mitochondrial defects develop within the first weeks of life and more than 80% of 
patients are symptomatic by the age of 2 years.132 
Kidney manifestations of genetic mitochondrial cytopathies 
Kidney symptoms caused by mitochondrial dysfunction are often characterized by 
tubular or glomerular defects. Tubulointerstitial and cystic kidney diseases have also 
been described; however, the molecular mechanisms remain to be elucidated.130
Tubular defects 
Tubular disorders are frequently reported in patients with mitochondrial cytopathies. 
Mutations in both mitochondrial and nuclear genes have been described to cause 
tubular defects (Table 3.1, Table 3.2 and Figure 3.2).120, 133-180 Excellent overviews of 
mitochondrial and nuclear gene mutations causing tubular defects are provided in 
various reviews.42, 130, 181-183 The most reported problem is a proximal tubular defect 
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as proximal tubular cells are relatively vulnerable to oxidative stress. Most patients 
present with partial defects, including renal tubular acidosis, aminoaciduria, glycosuria, 
hypermagnesuria, or a combination of the above.42, 182 Renal Fanconi syndrome has 
been reported in children with specific mitochondrial syndromes, including Kearns- 
Sayre syndrome, Pearson syndrome, Leigh syndrome, and CoQ10 deficiency.179, 184-188 
Kearns-Sayre syndrome typically includes chronic progressive external ophthalmoplegia, 
ptosis, and pigmentary retinopathy in individuals less than 20 years of age.189 Pearson 
syndrome occurs in infancy, and characteristically includes sideroblastic anemia and 
exocrine pancreatic dysfunction.190 Hypomagnesaemia has been described in different 
Figure 3.1 Mitochondrial energy-generating system
Acetyl-CoA, the terminal product of carbohydrate and lipid metabolism, enters the Krebs cycle to generate 
CO2, NADH, and FADH2. Electrons derived from cellular dehydrogenases in the Krebs cycle are passed along 
four protein complexes and two small carriers. The flow of electrons from NADH or FADH2 through the protein 
complexes, leads to the pumping of protons from the mitochondrial matrix to the intermembrane space. The 
electrons are shuttled from complex I and II to complex III by the electron carrier CoQ10 and then transferred 
to complex IV by cytochrome c. These processes create an electrochemical gradient that is used by ATP 
synthase (complex V) to synthesize ATP from inorganic phosphate and ADP. 
Acetyl-CoA, Acetyl Coenzyme A; ADP, adenosine diphosphate; ATP, adenosine triphosphate; C, cytochrome c; 
e, electron; FADH2, reduced form of flavin adenine dinucleotide; NADH, nicotinamide adenine dinucleotide 
hydrogen; CoQ10, coenzyme Q10; I, complex I; II, complex II; III, complex III; IV, complex IV; V, complex V.
Mitochondrial matrix
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mitochondrial syndromes, for instance in patients with Kearns-Sayre syndrome.191, 192 
Moreover, Wilson et al. describe a cluster of metabolic defects, including hypomagne-
saemia, caused by a mitochondrial transfer RNAIle mutation.153 
Glomerular diseases
Podocytes are highly differentiated cells with limited regenerative capacity.194 The 
main metabolic pathway for podocytes is anaerobic glycolysis and the fermentation of 
glucose to lactate.195 Therefore, the mechanism of glomerular dysfunction is probably 
different from tubular dysfunction in patients with mitochondrial cytopathies. 
Brinkkoetter et al. hypothesize that a change in podocyte metabolism rather than the 
loss of mitochondrial oxidative phosphorylation is essential for damage to the 
podocyte.195 Two major mitochondrial cytopathies associated with glomerular 
dysfunction are due to a m.3243A>G mutation in tRNALeu gene or to genetic defects in 
the CoQ10 biosynthesis pathway.42 (Table 3.1 and Table 3.2, Figure 3.2)
m.3243A>G mutation in transfer RNALeu gene
The m.3243A>G mutation in the transfer RNALeu gene is one of the most common 
mitochondrial DNA point mutations, but the phenotypic expression can be highly 
variable. This mutation is associated with a wide range of clinical extrarenal 
manifestations including deafness, diabetes mellitus, neuromuscular involvement, 
hypertrophic cardiomyopathy, macular dystrophy.196 The m.3243A>G mutation was 
initially described in mitochondrial myopathy encephalopathy with lactic acidosis and 
stroke like episodes (MELAS) syndrome, a mitochondrial syndrome manifested in 
patients that are typically less than 40 years of age.130, 197 Low m.3243A>G mutation 
heteroplasmy levels cause maternally inherited diabetes and deafness syndrome.198 
The m.3243A>G mutation is associated with FSGS, tubulointerstitial nephritis, and 
cystic kidney disease (Table 3.1).133 The kidney disease associated with the m.3243A>G 
mutation generally corresponds to a glomerulopathy with proteinuria, which is below 
the nephrotic range in two-thirds of patients. The majority of patients are diagnosed 
with kidney disease in their second or third decade of life and CKD is present in half of 
these cases.196 
CoQ10 deficiency
Primary CoQ10 deficiency is a clinically and genetically heterogeneous disorder. Clinical 
phenotypes range from fatal infantile multisystem disorders to isolated glomerular 
involvement. In addition, variability exists regarding the age of onset, the different 
organs involved, and clinical response to CoQ10 supplementation. CoQ10 is present in 
the normal diet, but at insufficient levels to supply mitochondria. Therefore, de novo 
biosynthesis in mitochondria is needed, a complex pathway that involves several 
proteins encoded by COQ genes (Figure 3.3).126, 199-201 Currently, mutations in 10 
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Table 3.2   Genotype phenotype correlation of nuclear DNA mutations involved in  
mitochondrial cytopathies with kidney involvement
Gene nDNA mutation Consequences on protein level
Respiratory chain assembly and function
BCS1L c.830G>A p.Ser277Asp
c.296C>T p.Pro99Leu
c.464C>G, c.1057G>A p.Arg155Pro, Val353Met
SURF1 c.312del10insAT, c.688C>T p.Pro104_Leu105insTer, p.Arg230Ter
c.834G>A p.Trp278Ter
c.312del10insAT, 820–824dupTACAT p.Pro104_Leu105insTer, out-of-frame duplication
COX10 c.612C>A p.Asn204Lys
TMEM70 c.317-2A>G Splice site mutation
c.317-2A>G, (c.470T>A, c.628A>C, 
c.118_119insGT or c.251delC)
Splice site mutation, 
(ND, p.Thr210pro, p.Ser40CysfsTer11 or ND)
c.238C>T p.Arg80Ter
c.316 + 1G>T Splice site mutation
c.336T>A p.Tyr112Ter
c.578_579delCA p.Thr193Serfs
c.535C>T, c.359delC p.Tyr179His, ND
UQCC2 c.214-3C>G Splice site mutation







Posttranslational modification of mitochondrial proteins
XPNPEP3 c.1357G>T p.Gly453Cys
c.931_934delAACA p.Asn311LfsX5
DGUOK c.165G>A, c.487_c490dupGACA p.Try65Ter, frame shift mutation
c.677A>G, c.592-4_c.592-3delTT p.His226Arg, splice site mutation
TSFM c.934C>T p.Arg312Try
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Predominant kidney phenotype Extrarenal symptoms Ref
Proximal tubulopathy Hepatic involvement, encephalopathy 159-161
Tubulopathy Hypotonia, developmental regression, 
encephalopathy
162
Tubulopathy Neurological deterioration, leukodystrophy 163
Renal tubular acidosis, hydronephrosis, 
kidney failure
Neurological involvement, cardiomyopathy 164, 165
Tubular dysfunction Severe intrauterine growth retardation, lactic acidosis 166
Crescentic glomerulonephritis Ethylmalonic encephalopathy 167
Renal tubular acidosis Muscular hypotonia, developmental delay 168
Tubulopathy, hypomagnesemia,  
progressive kidney failure
Pulmonary hypertension (HUPRA syndrome) 169, 170
Tubulopathy Myopathy, lactic acidosis, anemia 171
Tubulopathy Hypertrophic cardiomyopathy 172
Kidney failure Limited to mild neurologic involvement with 
sensorineural hearing loss and essential tremor
173
Mental retardation, seizures, cardiomyopathy
Tubulopathy Developmental delay, hypotonia 174
Tubulopathy Hypotonia, liver insufficiency 175
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different genes, involved in the CoQ10 pathway, have been reported (PDSS1, PDSS2, 
COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A/ADCK3, COQ8B/ADCK4, COQ9).202 A 
literature search was conducted to identify all reported cases with glomerular 
involvement to date (February 2020). References of the identified articles were used to 
search for additional case reports. In total, approximately 200 patients from 130 
families with a primary CoQ10 deficiency have been described in the literature.203 
Mutations in PDSS1, PDSS2, COQ2, COQ6, and COQ8B/ADCK4 have been associated 
with glomerular involvement.42 Supplemental Table S3.1 summarizes the clinical and 
genetic data of all 144 patients with a PDSS1, PDSS2, COQ2, COQ6, and COQ8B/ADCK4 
mutation with glomerular involvement reported to date. An overview of the clinical 
characteristics of these mutations is provided in Table 3.3. Three cases from our 
tertiary referral center are described in detail in the Supplemental Case Description, 
Supplemental Table S3.2, and Supplemental Figures S3.1 and S3.2.
PDSS1 and PDSS2 encode a subunit of the enzyme required for synthesis of the 
decaprenyl tail of CoQ10 (Figure 3.3). Only one patient with a PDSS1 mutation and 
glomerular involvement has been reported in literature.204 The patient presented 
before the age of 6 months with nephrotic syndrome, failure to thrive, and a 
developmental delay. She rapidly developed kidney failure and died at the age of 16 
months. To date, PDSS2 mutations have been identified in seven patients with 
glomerular mitochondrial cytopathies associated with CoQ10 deficiency from five 
unrelated families. Gasser et al. showed that a PDSS2 haplotype was associated with a 
Table 3.2   Genotype phenotype correlation of nuclear DNA mutations involved in  
mitochondrial cytopathies with kidney involvement
Gene nDNA mutation Consequences on protein level
Posttranslational modification of mitochondrial proteins
TK2 c.547C>G, c.760C>T p.Arg183Gly, p.Arg254Ter
COQ2 Various (Supplemental Table S3.1) Various (Supplemental Table S3.1)
COQ6 Various (Supplemental Table S3.1) Various (Supplemental Table S3.1)
COQ8B/
ADCK4
Various (Supplemental Table S3.1) Various (Supplemental Table S3.1)
COQ9 c.730C>T p.Arg244Ter
All mutations are described as pathogenic in the literature.
CNS, central nervous system; CoQ10, coenzyme Q10; DNA, deoxyribonucleic acid; HUPRA, hyperuricemia,  
pulmonary hypertension, kidney failure and alkalosis; n, nuclear; ND, no data (not reported); Ref, reference.
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significantly increased risk for FSGS and collapsing glomerulopathy in European 
American patients.205 Although the number of reported patients with a PDSS2 
mutation is limited, the patients generally presented at young age and rapidly 
developed kidney failure. Furthermore, severe extrarenal involvement was reported in 
these patients resulting in a poor prognosis. Saiki et al. showed that CoQ10 supplemen-
tation rescued proteinuria and interstitial nephritis in PDSS2 deficient mice.206 In 
clinical practice, CoQ10 supplementation (5-20 mg/kg/day) was started in 4 patients, 2 
of them showed improvement in clinical condition.207
COQ2 encodes the enzyme para-hydroxybenzoate-polyprenyl-transferase required 
for the second step of the final pathway of CoQ10 biosynthesis (Figure 3.3).208 SRNS 
usually develops within the first two years of life, and often represents the first 
symptom of the disease, with or without neurologic symptoms. As shown in Table 3.3, 
12/19 patients showed a rapid decline in kidney function. Furthermore, 17/25 of the 
patients showed some degree of extrarenal involvement. Patients who presented with 
decreased kidney function did not show improvement of kidney function after CoQ10 
supplementation. In patients presenting with nephrotic syndrome, a decrease in 
proteinuria may occur. Patients with severe neurological involvement showed 
neurological deterioration irrespectively of treatment with CoQ10, even when started 
immediately after birth (Supplemental Table S3.1). As expected, no recurrence of 
proteinuria occurred after kidney transplantation. In contrast to other genes involved 
in the CoQ10 biosynthesis, there is a genotype-phenotype correlation for mutations in 
Predominant kidney phenotype Extrarenal symptoms Ref
Tubulopathy CNS and skeletal muscle involvement 177
(steroid resistant)  
nephrotic syndrome




(steroid resistant)  
nephrotic syndrome




(steroid resistant)  
nephrotic syndrome




Renal tubular dysfunction Neonatal lactic acidosis, seizures, global 
developmental delay, hypertrophic cardiomyopathy
178, 179 
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the COQ2 gene.209 Mutations in the COQ2 gene have been associated with a wide 
spectrum of phenotypes including a rapidly fatal, neonatal onset, multisystemic 
disease210, SRNS which can be associated with encephalopathy, and late-onset 
encephalopathy with retinopathy mimicking multiple system atrophy.42, 209, 211, 212 As 
previously described by Desbats et al., patients with severe phenotypes harbored two 
alleles that significantly impaired CoQ10 production.209 In contrast, patients harboring 
a compound heterozygous COQ2 mutation showed a milder clinical phenotype 
including a higher age of onset, less severe clinical symptoms, and absence of extrarenal 
manifestations. 
The enzyme CoQ10 monooxygenase 6 (COQ6) is required for biosynthesis of CoQ10 and 
catalyzes the C5 hydroxylation step of the quinine ring (Figure 3.3). Ozeir et al. showed 
that Coq6 is not required for the C1-hydroxylation.213 As shown in Table 3.2, most of 
the affected children presented with SRNS and sensorineural deafness, generally at 
Figure 3.2 Mitochondrial disease and the kidney
Kidney manifestations reported in the setting of mitochondrial cytopathies include tubular dysfunction, 
interstitial nephritis, glomerular pathology, and, in rare cases, cystic disease. Various mitochondrial DNA and 
nuclear DNA mutations are involved, as depicted in Tables 3.1 to 3.3. 
H2S, hydrogen sulfide; mt, mitochondrial; n, nuclear; OXPHOS, oxidative phosphorylation; ROS, reactive 
oxygen species; tRNA, transfer ribonucleic acid.
Mitochondrial disease and the kidney
Tubular defects
Tubulointerstitial kidney disease

































































Figure 3.3 Schematic overview of the CoQ10 biosynthesis pathway 
At least 15 genes are involved in the CoQ10 biosynthesis pathway; however, the biochemical pathway is not 
yet completely understood. The function of COQ genes shown in italics (COQ8A/ADCK3, COQ8B/ADCK4, 
and COQ9) has not been fully elucidated. COQ8A/ADCK3 and COQ8B/ADCK4 have a regulatory role,199 COQ9 
is a lipid-binding protein interacting with COQ7.201 The question mark indicates that the enzyme involved in 
the reaction has not been identified. 
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older ages than those reported for patients with COQ2 mutations.214 The effect of 
CoQ10 supplementation was not easy to evaluate as most reported patients rapidly 
developed kidney failure. However, patients who did not rapidly develop kidney failure 
showed improvement of proteinuria (Table 3.3, Supplemental Table S3.1). In contrast, 
CoQ10 supplementation did not improve sensorineural deafness in most patients. 
COQ8B/ADCK4 (AarF Domain Containing Kinase-4) interacts with components of the 
CoQ10 biosynthesis pathway (Figure 3.3).215-217 COQ8B/ADCK4 is expressed in 
podocytes and localized to mitochondria and foot processes.216 Eighty-two patients 
with an COQ8B/ADCK4 mutation and kidney involvement have been reported to date 
(Table 3.2). Symptoms typically present in puberty and CKD was diagnosed at 
presentation in a quarter of the reported patients. Moreover, 54 out of 74 (73%) 
patients developed kidney failure, with a median time to kidney failure of one year. In 
most patients, a kidney biopsy showed FSGS. Interestingly, Park et al. reported 
accompanying medullary nephrocalcinosis in six Korean patients.218 Treatment with 
CoQ10 was started in <50% of the reported patients. In 17 out of 30 patients (57%) no 
improvement of kidney function was seen, especially in patients who already presented 
with impaired kidney function. However, if started early, patients did show a decrease 
in proteinuria (Table 3.3). 
CoQ10 in depth
Primary CoQ10 deficiency is a clinically and genetically highly variable disorder as 
illustrated by the patients reported in Supplemental Table S3.1. Early diagnosis is 
crucial as oral supplementation of CoQ10 can limit disease progression and improve 
clinical symptoms. 
Diagnostic methods and monitoring
The diagnosis of primary CoQ10 deficiency is established with the identification of 
pathogenic variants in any of the genes encoding for the proteins directly involved in 
CoQ10 biosynthesis (Figure 3.3). Nowadays, genetic testing using next generation 
sequencing is substantially less time intensive than a few years ago, however, as 
treatment should be started as early as possible, additional diagnostic tests are still 
indispensable to enable rapid identification of CoQ10 deficiency. Classic biochemical 
analyses remain important in the diagnostics of mitochondrial cytopathies. Specifically 
for CoQ10 deficiency, analysis of the combined activity of complex I-III and/or II and III 
is important. Furthermore, initial diagnostic testing should include measurement of 
blood lactate and alanine (as a measure of impaired energy production in skeletal 
muscle and long-standing pyruvate accumulation, respectively), even though normal 
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levels do not exclude CoQ10 deficiency.219, 220 In addition, assessment of CoQ10 levels 
may be helpful in diagnosis and follow-up. Measurement of CoQ10 in skeletal muscle is 
considered the gold standard test for diagnosing CoQ10 deficiency, however with the 
availability of relatively rapid genetic diagnostics, muscle biopsies are not routinely 
performed anymore.219, 221 Measurement of CoQ10 levels in skin fibroblasts may be 
another option in patients with a primary CoQ10 deficiency.200 Nevertheless, a less 
invasive screening test is desirable. CoQ10 levels can be measured in different biological 
specimens.203, 222-226 CoQ10 levels in plasma appear to be highly dependent on dietary 
intake and are therefore not reflective of the levels in tissues.227 Moreover, CoQ10 
levels in peripheral cells do not seem to accurately reflect the amount of CoQ10 in 
tissues and the exact value of other biological specimens in the diagnostics of CoQ10 
deficiency remains to be elucidated. 
Pathophysiology
The pathogenesis of CoQ10 deficiency involves different aspects. Interestingly, variable 
degrees of CoQ10 deficiency appear to cause different defects of ATP synthesis and 
oxidative stress. Quinzii et al. show that severe CoQ10 deficiency (<20% of normal) 
results in significant bioenergetic defects without oxidative stress. In contrast, 
intermediate CoQ10 deficiency (30-40% of normal) causes moderate bioenergetic 
defects but a significant increase in ROS production, indicating that residual activity of 
the respiratory chain is indispensable to produce ROS.228 Podocytes are known to be 
susceptible to oxidative damage229, whereas impaired mitochondrial biogenesis did 
not result in a developmental or pathological change in podocytes.195 This supports 
the concept that podocytes are independent from mitochondrial ATP production but 
susceptible to oxidation. In line with this, Desbats et al. show that patients with a 
severe presentation of CoQ10 deficiency (presentation at birth with multi-organ 
failure) due to a COQ2 mutation, harbored two alleles that markedly impaired CoQ10 
production. In contrast, patients with a milder phenotype including isolated nephrotic 
syndrome, had at least one allele which allowed significant residual CoQ10 biosynthesis 
for ROS production.209 Zhu et al. used a Drosophila model to investigate COQ2 
nephropathy. Silencing coq2 led to abnormal localization of slit diaphragms, collapse of 
lacunar channels, and dysmorphic mitochondria. Furthermore, increased levels of ROS 
were found in this model, and dietary supplementation with CoQ10 partially rescued 
these defects.230 Mutations in COQ8B/ADCK4 account for the highest number of 
patients with kidney disease secondary to CoQ10 deficiency (Supplemental Table 
S3.1). Ashraf et al. showed that knockdown of COQ8B/ADCK4 in zebrafish resulted in 
the characteristic triad of nephrotic syndrome.216 Moreover, COQ8B/ADCK4 is required 
for CoQ10 biosynthesis and mitochondrial function in podocytes.231 Compared to 
other CoQ10 biosynthesis defects, mutations in COQ8B/ADCK4 seem to result in a less 
severe clinical entity, with a more prominent kidney phenotype, higher age at onset of 
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SRNS, and good patient survival owing to the lack of extrarenal manifestations. The 
selective glomerular phenotype of patients with COQ8B/ADCK4 mutations may be the 
result of relative enrichment of COQ8B/ADCK4 and lacking expression of the related 
protein COQ8A/ADCK3 in podocytes, whereas COQ8A/ADCK3 expression exceeds that 
of COQ8B/ADCK4 in most other body tissues.216 Ashraf et al. showed that knockdown 
of COQ8B/ADCK4 in podocytes reduced their migration phenotype, which could be 
reversed by addition of CoQ10.216 The relatively mild phenotype observed in patients 
with COQ8B/ADCK4 defects is probably related to the fact that the encoded enzyme 
has a modulatory function without catalytic activity, enabling residual CoQ10 synthesis 
even in the complete absence of this protein.42 Moreover, other genes may partially 
compensate for the absence of COQ8B/ADCK4.232
Treatment
Oral administration of CoQ10 is the treatment strategy for affected individuals with a 
CoQ10 deficiency. As was previously shown by Montini et al. and various other clinical 
reports, CoQ10 can block the progression of the disease.122 Although severe 
neurological and kidney damage cannot be reversed, treatment may also be initiated 
to prevent development of additional extrarenal symptoms. Different formulations of 
CoQ10 are available including an oxidized form (ubiquinone), a reduced form (ubiquinol), 
and analogs such as idebenone. Recently, Kleiner et al. proposed that CoQ10 supple-
mentation causes an increase in CoQ10 levels, rescuing sulfide oxidation and thereby 
preventing kidney failure.129 Unfortunately, clinical studies regarding efficiency are 
lacking,202 and the optimal dose and form of oral CoQ10 are still under debate. In the 
literature, the daily dose of CoQ10 ranges from 5 to 100 mg/kg (Supplemental Table 
S3.1), with most clinicians describing a dose between 30-50 mg/kg/day. Atmaca and 
colleagues recently published long-term follow-up results of CoQ10 supplementation 
in patients with a COQ8B/ADCK4 mutation and observed maximum reduction of 
proteinuria at 6 months of treatment.233 After a median follow-up duration of 25.3 
months following CoQ10 administration (20-30 mg/kg/day), proteinuria was 
significantly decreased, whereas kidney function was preserved.233, 234 Of note, 4 out 
of 8 reported patients received ACE inhibitors or an ARB in addition to CoQ10, which 
may have contributed to the decrease in proteinuria. For patients with mutations in 
the COQ2 gene, results were however, less favorable. Eroglu et al. reported 4 patients 
of two different families, in which two patients were started on CoQ10 supplementa-
tion immediately after birth or at first presentation.235 Despite early treatment and an 
initial good response in terms of nephrotic syndrome and hyperglycemia, the patients 
still developed severe neurological problems and eventually died at 31 and 14 months 
of age, respectively.235 Interestingly, three patients with a COQ6 mutation reported in 
literature and one of the patients with a homozygous pathogenic COQ2 mutation from 
our clinic (Supplemental File) showed a response to cyclosporine therapy with regards 
562850-L-bw-Schijvens




to the nephrotic syndrome.40 CoQ10 deficiency can directly lead to the opening of the 
mitochondrial permeability transition pore. Moreover, an increased amount of ROS 
can also induce mitochondrial permeability transition.236 Cyclosporine has the capacity 
to inhibit mitochondrial permeability transition pore through interaction with 
cyclophilin D, an essential component of the mitochondrial permeability transition 
pore, and thereby reduces the permeability.237 In line with this, Heeringa et al. showed 
that incubation of COQ6 knockdown podocytes with cyclosporine had a mild rescue 
effect.214 Our additional hypothesis is that the increase in ROS due to CoQ10 deficiency 
may impact the cytoskeleton of the podocytes. Cyclosporine is known for its podocyte 
stabilizing capacities and might therefore cause a partial response in these patients.238
A new potential therapeutic approach was recently reported for mitochondrial 
dysfunction due to CoQ10 deficiency. The treatment of Coq6 knockout mice with 
2,4-dihydroxybenzoic acid (4-diHB), an analog of a CoQ precursor molecule, prevented 
kidney dysfunction and reversed podocyte migration rate impairment.239 A potential 
role for 2,4diHB was suggested for the treatment of CoQ10 deficiency caused by 
COQ8B/ADCK4 mutations as well.231 Moreover, Ozeir et al. demonstrated that analogs 
of 4-HB can bypass a deficient CoQ biosynthetic enzyme.213 Additionally, hydroxylated 
analogues of 4-HB, 3,4-dihydroxybenzoic acid and/or vanillic acid were marked as a 
potential therapeutic intervention for CoQ10 deficiency due to a COQ6 mutation.240, 
241 
Currently, no curative treatment options for mitochondrial cytopathies are available, 
besides CoQ10 supplementation for patients with a CoQ10 deficiency. Typically, patients 
receive supportive treatment and other treatment options involve dietary supplements, 
vitamins, and antioxidants.242 A 2012 Cochrane review of mitochondrial therapies has 
found little evidence supporting the use of any vitamin or cofactor intervention.243 
Furthermore, there is early evidence for a therapeutic role of L-arginine and citrulline 
therapy for MELAS-related strokes. The evidence supporting the use of CoQ10 in 
mitochondrial diseases other than primary CoQ10 is sparse.242 
Conclusion
In this review, an overview of kidney involvement in genetic mitochondrial cytopathies 
is provided. Kidney manifestations reported in the setting of mitochondrial dysfunction 
include tubular dysfunction, interstitial nephritis, glomerular pathology, and in rare 
cases cystic disease. Special focus on CoQ10 deficiency was presented to emphasize 
early diagnosis of primary CoQ10 deficiency as oral supplementation of CoQ10 may 
limit disease progression and improve clinical symptoms. A combination of genetic and 
metabolic diagnostics, including targeted whole exome sequencing and blood lactate 
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and alanine levels at presentation, should be performed in children with nephrotic 
syndrome presenting in adolescence or at young age (<3 years) and in patients with 
nephrotic syndrome at any age with extra renal symptoms. In case none of these 
criteria are present, we recommend to await steroid responsiveness for 4 weeks. 
In case patients do not respond to steroids after 4 weeks of treatment, we would 
advise to perform genetic diagnostics. Moreover, starting CoQ10 treatment should 
be considered in expectation of the final genetic diagnosis. Lifelong CoQ10 supplemen-
tation should be considered as well as sustained remission of nephrotic syndrome 
has been described and extrarenal symptoms may be prevented. Finally, a multi-
disciplinary approach is required given the number of organs that can be involved in 
patients suffering from a mitochondrial cytopathy.
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Supplemental Table S3.1 Overview of patients reported in literature with a PDSS1, 











































































































3 c.1151C>A p.Ala384Asp Hom 8 At 
birth
M No ND SRNS
4 c.1145C>T p.Ser382Leu Hom 8 1.9 M Yes ND SRNS
































































































ND Yes 50 mg/day 
at age of 
3 m
No effect ND Died at  






deafness and retinitis 
pigmentosa
0.625 Yes 20 mg/kg/
day
No effect Diffuse 
mesangial 
sclerosis
Died at  
8 months of age, 
kidney failure
245
ND ND ND ND ND ND ND 40
Cerebral palsy, 
intellectual disability
ND ND ND ND ND ND 40
Retinitis pigmentosa, 














ND kidney failure, kTx 207
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1-I c.890A>G p.Tyr297Cys Hom 5 1 M Yes Affected sister 
(1-II)
SRNS





















































loss, delayed motor 
development
ND No NA ND Glomerular 
sclerosis
Died at 8 y of 
























































optic nerve atrophy, 
rod-cone retinopathy, 
status epilepticus




























ND No NA NA Not 
performed
Died at 12 
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5 c.437G>A p.Ser146Asn Hom 2 5d M Distantly 
related 
Healthy parents Acute kidney 
failure
6-I c.905C>T p.Ala302Val Hom 5 At 
birth






6-II c.905C>T p.Ala302Val Hom 5 At 
birth














2 F ND ND SRNS
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11 ribs, spade-shaped 
hands, externally 
rotated flat feet, an 
anteriorly placed anus, 
diabetes mellitus
ND No NA NA Autopsy: chronic 






of age, multi 
organ failure
247
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syndrome (at age 
of 4 months)
9 c.545T>G p.Met182Arg Hom 2 At 
birth





































2 M ND ND SRNS
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continua, no visual 
pursuit. 







Died at 5 
months of age
249
Severe lactic acidosis, 
hepatic insufficiency, 
dilation of left 
ventricle
ND No NA NA Not performed Died after 
23 hours 






















Few podocytes with 
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older sister died 
of nephropathy 
at one year of 
age
SRNS





















15-II c.437G>A P.Ser146Asn Hom 2 At 
birth





















































NA (fu age 
1.2 y, fu 3 
months)























with phono- and 
photophobia














ND Yes 30 mg /kg/


















Focal clonic seizures, 
encephalopathy, 
neonatal diabetes








ND Died of multi 
organ failure 
at 31 months 
of age
235




Died at six 
months of 
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1.25 F No ND SRNS
20 c.890T>C p.Tyr297Cys Hom 5 0.4 M Yes ND SRNS
21 c.832T>C
§§
p.Cys278Arg Hom ND 0.5 F Yes 1 healthy sister 
(heterozygous 
mutation 
carrier), 1 sister 
with mucopoly-
saccharides 
(died at age of 
11y), 1 sister 

















23 c.683A>G P.Asn228Ser Hom 3 1.8 F Yes 1 healthy sister SRNS
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ND Died at 14 
months of age
235
ND ND ND ND ND ND ND 40
ND ND ND ND ND ND Remission CsA 
treatment
40
ND ND ND ND ND ND SR, partial 
remission CsA
40























Yes 30 mg/kg/day No recurrence 
proteinuria 



















cFSGS In remission -
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Family history Presenting 
symptoms
1-I c.763G>A p.Gly255Arg Hom 7 6.4 ND Yes 3 affected siblings  
(1-II, 1-III, 1-IV)
SRNS
1-II c.763G>A p.Gly255Arg Hom 7 0.3 ND Yes 3 affected siblings 
(1-I, 1-III, 1-IV)
SRNS
1-III c.763G>A p.Gly255Arg Hom 7 1.2 ND Yes 3 affected siblings 
(1, I, 1-II, 1-IV)
SRNS





2-I c.763G>A p.Gly255Arg Hom 7 0.3 ND Yes 2 affected siblings 
(2-II, 2-III)
SRNS
2-II c.763G>A p.Gly255Arg Hom 7 0.3 F Yes 2 affected siblings 
(2-I, 2-III)
SRNS
2-III c.763G>A p.Gly255Arg Hom 7 0.16 ND Yes 2 affected siblings 
(2-I, 2-II)
Proteinuria 





3-II c.1058C>A p.Ala353Asp Hom 9 2.5 ND Yes 1 affected sibling 
(3-I)
SRNS





































































3.0 No NA NA FSGS Diet at 5.0 y 
of age
214
Seizures 0.4 No NA NA Diffuse 
mesangial 
sclerosis




0.4 Yes 100 mg/day Improvement 
of sensorineural 
deafness





NA (fu 15 
months)









6.5 No NA NA FSGS Kidney failure 214
Sensorineural 
deafness












3.4 No NA NA FSGS Died of sepsis 214
Sensorineural 
deafness
NA No NA NA FSGS ND 214
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1.25 F ND Healthy parents,  











2.1 M ND Healthy parents,  
1 healthy brother
SRNS
12 c.41G>A p.Trp14Ter Hom 1 16 F ND Mother with 













2 F No ND SRNS
14 c.782C>T p.Pro261Leu Hom 7 0.7 M No Healthy parents SRNS












4.5 M No ND SRNS
17 c.1058C>A p.Ala353Asp Hom 9 4 M Yes ND SRNS
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weakness in lower 
extremities





with nystagmus on 
both eyes
2.6 Yes ND ND FSGS Kidney failure 254
Sensorineural 
deafness
















muscle weakness in 
lower extremities
5.0 Yes ND ND FSGS Kidney failure, 
kTx
254
ND, no sensorineural 
deafness.
ND Yes ND Decrease in 
proteinuria
FSGS Decrease in 
proteinuria
255





None 1.7 Yes ND No neurological 
symptoms
MPGN type 1 Kidney failure 252
Cardiovascular 
abnormality, 





NA (fu 2 y) Yes 30 mg/kg/day Decrease in 
proteinuria, 








ND ND ND ND ND MPGN Response to 
CsA
40
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4.5 M No ND SRNS
17 c.1058C>A p.Ala353Asp Hom 9 4 M Yes ND SRNS
18 c.1058C>A p.Ala353Asp Hom 9 3.2 M No ND SRNS
19-I c.1058C>A p.Ala353Asp Hom 9 7 F Yes Brother with 
sensorineural 
hearing loss (19-II). 
Father’s maternal 
cousin with kidney 
failure and hearing 
loss. Healthy 
mother and other 
brother. 
SRNS
19-II c.1058C>A p.Ala353Asp Hom 9 10 M Yes Sister with 
sensorineural 
hearing loss and 
SRNS (19-I).  
Father’s maternal 
cousin with kidney 





deafness, no kidney 
involvement
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ND ND ND ND ND MPGN Response to CsA 40
ND ND ND ND ND FSGS Response to CsA 40





8 Yes 20 mg/kg/day Treatment started 
after kTx. No effect 
on sensorineural 
deafness
FSGS Kidney failure, kTx 258
No neurological 
involvement
NA Yes 20 mg/kg/day No effect on 
sensorineural 
deafness




Processed on: 16-7-2021 PDF page: 74
74
CHAPTER 3














































10 ND No ND SRNS








3-I c.532C>T p.Arg178Trp Hom 7 7 ND Yes One affected sibling 
(3-II)
SRNS













































































































































14.3 No NA NA FSGS Kidney 
failure
259
ND 7 No NA NA GS Kidney 
failure, kTx
216




























None NA Yes 150 mg/day Partial effect, 
decrease in 
proteinuria
FSGS Decrease in 
proteinuria
261






ND 13 No NA NA FSGS Kidney 
failure, kTx
216
ND 12 No NA NA FSGS Kidney 
failure, kTx
216
Hypertension, goiter 15 No NA NA FSGS Kidney 
failure, kTx
216
ND ND No NA NA FSGS ND 216
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9 ND No Two affected 
siblings (9-I, 9-II)
SRNS
10-I c.958C>T p.Arg320Trp Hom 11 12 ND Yes One affected sibling 
(10-II)
SRNS
10-II c.958C>T p.Arg320Trp Hom 11 20 ND Yes One affected sibling 
(10-I)
SRNS
11-I c.1027C>T p.Arg343Trp Hom 11 20 ND Yes One affected sibling 
(11-II)
SRNS
11-II c.1027C>T p.Arg343Trp Hom 11 18 ND Yes One affected sibling 
(11-I)
SRNS
12 c.1199-1200insA p.His400Asnfs*11 Hom 13 <1 M Yes ND SRNS
13-I c.1356-
1362delGGGCCCT





p.Gln452Hisfs* Hom 15 21 ND Yes One affected sibling 
(13-II)
SRNS
14-I c.1339dupG p.Glu447Glyfs*10 Hom 15 14 M ND* Four affected 
siblings (14-II, 14-III, 
14-IV, 14-V)
Mild edema 
14-II c.1339dupG p.Glu447Glyfs*10 Hom 15 7.3 F ND* Four affected 
siblings (14-I, 14-III, 
14-IV, 14-V)
Mild edema
14-III c.1339dupG p.Glu447Glyfs*10 Hom 15 17 F ND* Four affected 
siblings (14-I, 14-II, 
14-IV, 14-V)
Mild edema
14-IV c.1339dupG p.Glu447Glyfs*10 Hom 15 27 F ND* Four affected 




14-V c.1339dupG p.Glu447Glyfs*10 Hom 15 7 F ND* Four affected 
siblings (14-I, 14-II, 
14-III, 14-IV)
Incidental











































ND ND No NA NA FSGS ND 216
Goiter 17 No NA NA FSGS Kidney 
failure
216





20 No NA NA ND Kidney 
failure
216







NA Yes 15 mg/kg/day Disappearance of 
edema, decrease in 
proteinuria
FSGS Decrease in 
proteinuria
216
ND ND No NA NA Collapsing 
FSGS
ND 216
ND ND No NA NA Collapsing 
FSGS
ND 216






12.6 No NA NA FSGS Kidney 
failure
259
None 18 No NA NA Not performed Kidney 
failure
259
None 31 No NA NA Not performed Kidney 
failure
259
None NA (fu age 
12 y)
No NA NA Not performed ND 259
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15-III c.1339dupG p.Glu447Glyfs*10 Hom 15 13.5 M ND* Two affected 
siblings (15-I, 15-II)
Incidental
16-I c.1339dupG p.Glu447Glyfs*10 Hom 15 14.9 M ND* Three affected 
siblings (16-II, 16-III, 
16-IV)
CKD
16-II c.1339dupG p.Glu447Glyfs*10 Hom 15 13.2 F ND* Three affected 
siblings (16-I, 16-III, 
16-IV)
Hypertension
16-III c.1339dupG p.Glu447Glyfs*10 Hom 15 18 M ND* Three affected 
siblings (16-I, 16-II, 
16-IV)
CKD
16-IV c.1339dupG p.Glu447Glyfs*10 Hom 15 9 M ND* Three affected 




17 c.1339dupG p.Glu447Glyfs*10 Hom 15 17.6 M ND* ND CKD
18 c.1339dupG p.Glu447Glyfs*10 Hom 15 12 F ND* ND Nephrotic 
syndrome







































































None 14.9 No NA NA Not performed Kidney 
failure
259
Epilepsy 13.2 No NA NA Not performed Kidney 
failure
259
None 18 No NA NA Not performed Kidney 
failure
259
None NA (fu age 
9.3 y)
Yes 30 mg/kg/day Decrease in 
proteinuria





None 18.0 No NA NA cFSGS Kidney 
failure
259
None ND No NA NA Not reported 
individually






12.5 Yes 20-30 mg/kg/
day







None 10.5 Yes 20-30 mg/kg/
day







None 20.5 Yes 20-30 mg/kg/
day









None 17 Yes 20-30 mg/kg/
day







Seizure 11 Yes 20-30 mg/kg/
day
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21-I c.293T>G p.Leu98Arg Hom 5 5.9 F ND* 1 affected sibling 
(21-II)
Incidental
21-II c.293T>G p.Leu98Arg Hom 5 13.3 M ND* 1 affected sibling 
(21-I)
Mild edema
22-I c.293T>G p.Leu98Arg Hom 5 13.5 F Yes 1 affected sibling 
(22-II)
Moderate edema



































































None NA (fu age 
26 y)












NA (fu age 
14.3 y)





14 No NA NA FSGS Kidney 
failure
259
Lupus like symptoms 16.1 Yes 20-30 mg/kg/
day






None NA (fu age 
30 y)
Yes 9.8 mg/kg/day Drop in proteinuria 
50% within 6 
weeks. Increase 
in proteinuria 




in proteinuria after 
reinstitution of 
CoQ10.





















9 Yes 20-30 mg/kg/
day









9.6 Yes 20-30 mg/kg/
day







None NA (fu age 
40 y)
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5 M No Healthy parents. 
Brother with 
hypoplasia of the 
left ear pinna, an 
atresia of the left 
external ear canal 
with hearing loss 

















30 c.645delT p.Phe215Leufs*14 Hom 8 15.1 M ND* ND Mild edema, 
hypertension
31 c.645delT p.Phe215Leufs*14 Hom 8 14.2 M ND* ND Edema, fatigue, 
CKD, second degree 
heart failure
32 c.1199-1200dupA p.His400Asnfs*11 Hom 13 10.8 M ND* ND Edema





33-II c.1199dupA p.His400Glnfs*11 Hom 13 12 M Yes Three affected 











































None 13.7 No NA NA FSGS Kidney 
failure
259
ND ND No NA NA ND ND 262
ND 6 No NA NA FSGS Kidney 
failure
262









ND NA (fu age 
12 y)









15.2 No NA NA FSGS Kidney 
failure
259





None ND No NA NA Not reported 
individually
Deceased 
at 29 y of 
age
234
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33-III c.1199dupA p.His400Glnfs*11 Hom 13 2 F Yes Three affected 







33-IV c.1199dupA p.His400Glnfs*11 Hom 13 7 M Yes Three affected 















35-I c.1199dupA p.His400Glnfs*11 Hom 13 17.7 F Yes Four affected 





35-II c.1199dupA p.His400Glnfs*11 Hom 13 4.2 M Yes Four affected 




35-III c.1199dupA p.His400Glnfs*11 Hom 13 22.6 F Yes Four affected 




35-IV c.1199dupA p.His400Glnfs*11 Hom 13 7.7 F Yes Four affected 





35-V c.1199dupA p.His400Glnfs*11 Hom 13 23.7 M Yes Four affected 




















































CoQ10. Increase in 
proteinuria after 
































loss after 5 
years
234










Pericardial effusion 17.7 No NA NA Not reported 
individually
Deceased 
at 21.1y of 
age
234















None NA (fu age 
12 y)





irregular use of 
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5.1 F ND* ND Incidental





































10.8 F ND ND Isolated  
proteinuria
40 c.737G>A p.Ser246Asn Hom 9 10.1 F ND ND Isolated  
proteinuria
41 c.737G>A p.Ser246Asn Hom 9 12.8 F ND ND Isolated  
proteinuria, 
nephrocalcinosis















































while on PD; PRES, 
inconsistent defects 
of visual fields, 
agoraphobia

















neoplasm in the 
distal pancreas
























None NA Yes 30 mg/
kg/day
Complete 
remission (to CsA) 






ND NA (fu age 
9.2 y)
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47 c.532C>T p.Arg178Trp Hom 7 14 F Yes Two healthy 
brothers
CKD
§ The patient also harbored a heteroplasmic variant in the mitochondrial genome-encoded NADH 
dehydrogenase subunit 1 (MT-ND1) c.3754C>A
§§ The patient also harbored a single base homozygous mutation in the ARSB gene c.1213+1G>A
§§§ The patient also has two heterozygous mutations in the NPHS1 gene c.1802C>G (p.Gly601Ala), c.1339C>T 
(p.Glu447Lys)
ND* No individual patient data available, however in reference 259 it is stated that patients had mostly 
consanguineous parents and in reference 234, 80% of the patients has consanguineous parents. 
ASD, atrial septum defect; AVSD, atrioventricular septal defect; CKD, chronic kidney disease; CsA, cyclosporine 
A; d, days; F, female; FSGS, focal segmental glomerulosclerosis; fu, follow-up; HD, hemodialysis; Het, 
heterozygous; Hom, homozygous; kTx, kidney transplantation; M, male; m, months; MI, mitral insufficiency; 
MPGN, membranoproliferative glomerulonephritis; NA, not applicable, NOS; not otherwise specified; SRNS, 
steroid resistant nephrotic syndrome; NS, nephrotic syndrome; ND, no data; PD, peritoneal dialysis; 
TI, tricuspid insufficiency; y, years.
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ND NA (fu age 
18.8 y)




tumor in left breast
10.7 No NA NA FSGS, 
nephrocalcinosis 
grade 2 or 3 
kidney 




None NA (fu age 
12 y)




ND 11.7 No NA NA FSGS Kidney failure 262
Mild cognitive 
impairment
14.8 Yes 3 dd 100 





no change in 
mild cognitive 
impairment








Three patients with CoQ10 deficiency were identified in our tertiary referral center 
(Radboudumc Amalia Children’s Hospital) in the Netherlands. 
Patient 1 is a girl, born after an uncomplicated pregnancy of consanguineous parents, 
who presented at the age of 14 years. Medical history revealed a developmental 
language disorder with mild cognitive impairment (IQ 74), diagnosed at the age of four. 
Additional work-up (including cytogenetic testing and metabolic screening) for the 
developmental language disorder revealed no abnormalities at that time, except for a 
mildly elevated serum alanine level, for which no follow-up had taken place. Retro-
spectively, urinalysis at the age of four was performed by the general practitioner and 
showed proteinuria (1 g/l) for which no follow-up was undertaken either. She presented 
at the age of 14 years with nausea and fronto-temporal headache. On physical 
examination her blood pressure was elevated (145/93 mmHg) and initial laboratory 
evaluation showed elevated creatinine levels (262 µmol/l). Additional family history 
revealed CKD with unknown etiology in a distant relative. Renal ultrasound showed 
normal sized kidneys, increased density of the renal cortex, and diminished cortico-
medullary differentiation. Based on multiple urinary tract infections in the early years 
of life reported by the family, the differential diagnosis included CKD due to kidney 
dysplasia or reflux nephropathy. Nine months after presentation hemodialysis was 
started, and a year later the patient received a kidney transplant from a living related 
donor. Genetic diagnostics using whole exome sequencing with a renal disorders gene 
panel (286 genes) to determine the etiology of CKD showed a homozygous c.532C>T 
(p.(Arg178Trp) mutation in the COQ8B/ACDK4 gene (Supplemental Table S3.2), 
previously indicated to be pathogenic.216 She was started on CoQ10 supplementation 
(Q10 softgel capsules, 100 mg 3 times a day, 3.7mg/kg/day). After a few months, sup-
plementation was discontinued at request of the patient due to complaints of 
heartburn, which is a known side effect of CoQ10. No additional extrarenal symptoms 
have been identified over the years.
Patient 2 is a 6-year-old girl, born small for gestational age at 37 weeks of gestation. 
Pregnancy was complicated by the presence of a single umbilical artery. At two years 
of age, she presented at her local hospital with edema and abdominal distension. On 
physical examination she had a mildly elevated blood pressure (98/71 mmHg) and 
periorbital, pedal, and pubic edema. Laboratory investigations showed nephrotic 
proteinuria (6 g/l), hypoalbuminemia (0.9 g/dL), and increased lactate dehydrogenase 
levels (399 U/L) with normal kidney function (creatinine 0.29 mg/dL). Prednisolone, 
diuretics, and albumin infusions were started to treat the nephrotic syndrome and 
accompanying edema, but failed to improve the clinical situation. As the patient did 
not respond to prednisolone after 4 weeks of treatment, a renal biopsy was performed 
562850-L-bw-Schijvens




and showed collapsing FSGS and podocyte foot process effacement (Supplemental 
Figure S3.1a, Supplemental Figure S3.1b). Due to continuous worsening of her 
circulatory state with uncontrollable fluid retention causing respiratory insufficiency, a 
bilateral nephrectomy was performed 6 weeks after diagnosis and hemodialysis was 
started. Six months later the patient received a donor kidney from her mother. As the 
patient was diagnosed with SRNS, genetic analysis using whole exome sequencing with 
renal disorders gene panel (286 genes) was performed to detect possible disease-caus-
ing mutations. Two compound heterozygous COQ2 mutations, c.590G>A; p.(Arg197His) 
and c.683A>G; p.(Asn228Ser), were found, which have previously been reported as 
pathogenic.211, 264 Subsequently, CoQ10 supplementation (30 mg/kg/day) was initiated 
to prevent development of extrarenal symptoms (Supplemental Table S3.2). Baseline 
mitochondrial CoQ10 levels in leukocytes were not available. Currently, the patient is 
doing well and thus far no recurrence of the nephrotic syndrome in the transplant 
kidney nor extrarenal symptoms have developed. 
Patient 3 is a 5-year-old girl, born after an uncomplicated pregnancy. At the age of 19 
months she presented with periorbital and pedal edema. Initial laboratory 
investigations completed the triad of a nephrotic syndrome with hypoalbuminemia 
(albumin 0.9 g/dL) and proteinuria (protein-to-creatinine ratio 33.8 g/10mmol), and 
prednisolone and diuretics were started. As she turned out to be unresponsive to 
prednisolone, a kidney biopsy was performed and additional immunosuppressive 
therapy was started. Kidney biopsy showed partial foot process effacement and signs 
of collapsing FSGS (Supplemental Figure S3.1c). Eventually, the patient went into 
remission with cyclosporine. Lactate levels (32.4 mg/dL) were elevated at the time of 
diagnosis, which raised the suspicion of a mitochondrial cytopathy as a cause of the 
SRNS. Genetic analysis using whole exome sequencing with a renal disorders gene 
panel (286 genes) revealed a homozygous c.683A>G; p.(Asn228Ser) COQ2 mutation. 
This mutation has previously been reported in literature as pathogenic in a patient 
with SRNS.211 Initially, the patient had difficulties with the oral intake of the CoQ10 
capsules due to the taste and size of the capsules. Therefore, she was seen and coached 
by a pediatric psychologist and speech therapist after which the intake of the capsules 
was secured. She is now doing well on CoQ10 supplementation (20 mg/kg/day). Four 
months after start of oral supplementation, CoQ10 levels in the leukocytes increased to 
normal levels after which cyclosporine therapy was discontinued. Currently, 17 months 
after discontinuation of the cyclosporine therapy, the patient is doing well and shows 
no signs of extrarenal involvement. Nevertheless, protein-to-creatinine ratios are 
increasing and CoQ10 levels in leukocytes are near the lower limit of normal. Therefore, 
CoQ10 dose is increased to 30 mg/kg/day and ACE-inhibition is optimized (Supplemental 
Figure S3.2).
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Figure S3.1a Light microscopy image patient 2
Many glomeruli show segmental (or sometimes global) collapse of the capillaries with epithelial hyperplasia in 
Bowman’s space, consistent with collapsing type focal and segmental glomerulosclerosis (indicated with the arrow). 
There are no basement membrane abnormalities. There is tubulopathy with flattening of the cells, irregular 
vacuolation and activated appearance of the nuclei, probably secondary to protein overload. Bar = 50µm
Figure S3.1b Electron microscopy patient 2
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Figure S3.1c Electron microscopy patient 3
Electron microscopy images for patients 2 and 3. There is extensive podocyte foot-process effacement 
(indicated with the arrow) and there are large areas of podocyte detachment from the glomerular basement 
membrane. Segmentally, accumulation of electron-lucent material in the subepithelial space was observed 
(indicated by the asterisks). This material sometimes appeared vaguely laminated but there was no evident 
organization. These findings were considered consistent with massive podocyte injury/collapsing focal and 
segmental glomerulosclerosis. Bar EM patient 2 = 5µm, bar EM patient 3 = 2µm
562850-L-bw-Schijvens
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Figure S3.2 Disease course of patient 3
In this graph the disease course of patient 3 is depicted. The patient went into remission with CsA treatment 
and after adequate CoQ10 intake was guaranteed, CsA was discontinued. 
CoQ10, coenzyme Q10; CsA, cyclosporine A.
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CHAPTER 4
Need for uniform definitions 
in childhood nephrotic syndrome
Anne M. Schijvens, Aditi Sinha, Arvind Bagga, Michiel F. Schreuder
Nephrology Dialysis Transplantation 2021 Apr 26;36(5):941-945. 
doi: 10.1093/ndt/gfaa338.
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UNIFORM DEFINITIONS IN NEPHROTIC SYNDROME
Nephrotic syndrome is one of the most common glomerular disorders in childhood.15, 265 
Although the majority of patients achieve complete remission after steroid treatment, 
over 80% experience one or several relapses.21 A significant proportion of patients 
progress to SDNS or FRNS, which is often an indication for additional immunosuppressive 
treatment.21, 266 Patients who do not achieve remission after several weeks of steroid 
treatment are considered steroid resistant.17
In 2012, the KDIGO guidelines on glomerulonephritis were published including clear 
descriptions of definitions related to childhood nephrotic syndrome.24 FRNS was 
defined as two or more relapses in the first six months of initial response, or four or 
more relapses in any 12-month period. Steroid dependence was defined as two or 
more consecutive relapses during prednisone therapy, or within 14 days of ceasing 
therapy. Interestingly, the definition for SDNS does not mention a minimum dose of 
prednisone. SRNS was defined as failure to achieve complete remission after 8-weeks 
of prednisone therapy. Despite KDIGO recommendations, wide variation is present in 
these definitions that has hampered uniformity of clinical care and research for 
children with nephrotic syndrome. The aim of this letter is to highlight the importance 
of using uniform definitions in childhood nephrotic syndrome, in clinical as well as 
research settings.
In clinical practice, the use of unambiguous and uniform definitions is important as 
FRNS, SDNS and SRNS are the chief reason for use of steroid-sparing therapies. 
Furthermore, FRNS and SDNS are important outcome measures of trials that focus on 
therapy of the first episode or management of relapses. Various second-line immuno-
suppressants are available to reduce exposure to prednisone for children with FRNS 
or SDNS and for the treatment of SRNS, with their respective adverse effects.46, 48 
Several trials have been published on non-steroid treatment of childhood nephrotic 
syndrome.46, 52 In trials that investigate the optimal immunosuppressive treatment, 
SDNS, FRNS and SRNS are important eligibility criteria. To enable correct interpretation 
of trial results, the use of uniform definitions is essential. Finally, as the optimal 
treatment of nephrotic syndrome is still under debate and trial results are often 
conflicting, individual patient data meta-analyses are increasingly used to synthesize 
results from previously conducted trials.267 To enable accurate aggregation of individual 
patient data, the use of uniform definitions is necessary.
Table 4.1 summarizes the definitions currently used in a clinical and research setting 
and illustrates the wide variation in definitions of SDNS, FRNS, and SRNS. For SDNS, 
there is variation in the number of consecutive relapses during or within 14 days of 
ceasing steroid therapy. To highlight the importance of an unambiguous definition for 
SDNS, we analyzed the individual patient data (n=126) of the trial by Teeninga, et al. 
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using the commonly used definitions for SDNS (Table 4.1).63 Using the KDIGO 2012 
guideline (2 or more consecutive relapses during corticosteroid therapy, or within 14 
days of ceasing therapy)24, 30% of the patients met the criteria of SDNS. By contrast, 
when only one relapse was required for the diagnosis of SDNS, 50% of the patients 
were considered steroid dependent. This difference is significant, since this would 
most likely prompt the use of steroid-sparing immunosuppressive therapy. 
Consequently, a significant proportion of patients may unnecessarily be exposed to 
second-line immunosuppressive therapy.
For FRNS, small variations are shown in the number of relapses, however the time from 
which relapses are counted in various definitions are heterogeneous. The KDIGO 
definition includes the number of relapses from the initial response, whereas others use 
‘after completing initial treatment’ or ‘following presentation’ (Figure 4.1, Table 4.1).
Additionally, there is heterogeneity in the definition of SRNS. The duration of 
prednisone treatment before a patient is labeled steroid resistant remains a matter of 
debate.50 Some definitions only comprise the use of oral prednisone ranging from 
4-8 weeks, whereas others include intravenous methylprednisolone pulses as well 
(Table 4.1). The diagnosis of steroid resistance has major clinical consequences, 
including the need for performing genetic studies. Finally, in context of managing 
patients with SRNS, the definitions of complete and partial remission, and non-response 
should be unambiguous and similar.
We emphasize that uniformity in definitions, especially for chronic illnesses, is 
important to allow comparison of data across different centers, harmonization of 
research protocols and implementation of clinical practice guidelines. The benefits of 
this approach have been seen with the widespread application of definitions on CKD 
and AKI. Revised KDIGO guidelines on glomerulonephritis are likely to be published 
soon, which will hopefully clarify the definitions and enable stratification of patients. 
We urge the need for consensus on definitions of key outcomes pertaining to SSNS and 
SRNS, and their uniform implementation by pediatric nephrologists across the world.
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Optimization of pharmacotherapy 
in pediatric nephrology patients
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CHAPTER 5
Practice variations in the 
management of childhood nephrotic 
syndrome in the Netherlands
Anne M. Schijvens*, Lucie van der Weerd*, Joanna A. van Wijk, Antonia H. Bouts, 
Mandy G. Keijzer-Veen, Eiske M. Dorresteijn, Michiel F. Schreuder
*authors contributed equally
European Journal of Pediatrics 2021 Jun;180(6):1885-1894. 
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Nephrotic syndrome in childhood is a common entity in the field of pediatric 
nephrology. The optimal treatment of children with nephrotic syndrome is often 
debated. Previously conducted studies have shown significant variability in nephrotic 
syndrome management, especially in the choice of steroid sparing drugs. In the 
Netherlands, a practice guideline on the management of childhood nephrotic 
syndrome has been available since 2010. The aim of this study was to identify practice 
variations and opportunities to improve clinical practice of childhood nephrotic 
syndrome in the Netherlands. A digital, structured survey among Dutch pediatricians 
and pediatric nephrologists was performed, including questions regarding the initial 
treatment, relapse treatment, kidney biopsy, additional immunosuppressive treatment, 
and supportive care. Among the 51 responses, uniformity was seen in the management 
of a first presentation and first relapse. Wide variation was found in the tapering of 
steroids after alternate day dosing. Most pediatricians and pediatric nephrologists 
(83%) would perform a kidney biopsy in case of SRNS whereas for FRNS and SDNS this 
was 22% and 41%, respectively. Variation was reported in the steroid sparing treatment. 
Finally, significant differences were present in the supportive treatment of nephrotic 
syndrome.
Conclusion
Substantial variation was present in the management of nephrotic syndrome in the 
Netherlands. Differences were identified in steroid tapering, use of steroid coverage 
during stress, choice of steroid sparing agents, and biopsy practice. To promote 
guideline adherence and reduce practice variation, factors driving this variation should 
be assessed and resolved.
562850-L-bw-Schijvens
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PRACTICE VARIATIONS IN NEPHROTIC SYNDROME
Introduction
Nephrotic syndrome, characterized by the triad of proteinuria, hypoalbuminemia, and 
edema, is a common entity in the field of pediatric nephrology.15, 17, 265 For over 60 
years, steroids have been the cornerstone of the treatment of nephrotic syndrome. 
Other aspects of the management of childhood nephrotic syndrome are more 
controversial and often debated among physicians.301-304 As consensus and evidence 
about the most appropriate second line drug are lacking, the choice of therapy mostly 
depends on possible side-effects, the physician’s personal experience with and 
preference for the drug, and patient circumstances. Another matter of debate is the 
indication to perform a kidney biopsy. In the past, many children with nephrotic 
syndrome underwent a kidney biopsy.102 However, as 80-90% of the children respond 
to steroid therapy that could not be predicted on the biopsy results, this evolved to 
performing biopsies only in a selection of children with nephrotic syndrome.19, 20 
Currently, consensus has been reached on SRNS as an indication for kidney biopsy.301-303 
Moreover, kidney biopsies are generally considered in patients with atypical clinical 
characteristics at presentation, including onset at less than 12 months or over 12 years 
of age, macroscopic hematuria, low complement levels, kidney failure not related to 
hypovolemia, and persistent hypertension.293 In the Netherlands, pediatric patients 
with SSNS are treated by both pediatricians and pediatric nephrologists. In case of 
steroid resistance, patients are generally referred to a pediatric nephrologist. In the 
Netherlands a national practice guideline has been available since 2010, including 
information on the steroid treatment of childhood nephrotic syndrome. Recommen-
dations on kidney biopsy practice are less clear. Moreover, minimal guidance is 
provided on the choice of second line immunosuppressive treatment.68 The aim of this 
project is to identify practice patterns of Dutch pediatricians and pediatric nephrologists 
in the management of childhood nephrotic syndrome and subsequently compare the 
results with recommendations in the current Dutch practice guideline and international 
2012 KDIGO Clinical Practice Guideline for Glomerulonephritis.24, 68 
Methods
Design and setting
A detailed, structured web-based survey to evaluate practice patterns in childhood 
nephrotic syndrome was designed. The survey questions (n=72) were reviewed in 
detail by two pediatric nephrologists (ED and MS). The final survey was created using a 
web-based survey program (Castor Electronic Data Capture) and distributed by email 
amongst members of the Pediatric Nephrology section of the Pediatric Association of 
the Netherlands. Invitations, which were sent to 103 pediatricians and pediatric 
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nephrologists, were repeated twice over a period of 5 months (October 2017 – 
February 2018) to optimize response rates. 
Contents of the survey
The survey was divided into topics:
1. Management of SSNS, including the first episode of nephrotic syndrome, infrequent 
relapses of nephrotic syndrome, FRNS, and SDNS.
2. Management of SRNS
3. Kidney biopsy practice
4. Supportive treatment
Dutch pediatric nephrology practice guideline
The current Dutch practice guideline states that the first presentation of childhood 
nephrotic syndrome should be treated with oral prednisolone, 60 mg/m2 once daily 
for 6 weeks, with a maximum dosage of 80 mg/day, followed by 6 weeks of prednisolone 
40 mg/m2 on alternate days.68 In case of a relapse, daily prednisolone 60 mg/m2 
(maximum 80 mg) is prescribed until proteinuria has resolved for 3 days, followed by 6 
weeks of prednisolone 40 mg/m2 on alternate days, based on the original scheme 
from the APN.45, 305 For FRNS, SDNS or SRNS, different options for steroid sparing 
drugs are mentioned in the Dutch practice guideline including cyclophosphamide, 
cyclosporine, MMF, and levamisole.
Definitions
In the questionnaire, definitions were based on the 2012 KDIGO Clinical Practice 
Guideline.24 Infrequent relapse was defined as a relapse within 6 months of initial 
response, or one to three relapses in any 12-month period. The definition of FRNS 
includes two or more relapses within 6 months of initial response, or four or more 
relapses in any 12-month period. Steroid dependency was defined as two consecutive 
relapses during corticosteroid therapy, or within 14 days of ceasing therapy. 
Data analysis
Results are reported using the proportion of total respondents of the individual 
question. For the data analysis, pediatricians and pediatricians with nephrology 
expertise are merged into one group (pediatricians). Pediatric nephrologists in training 
and pediatric nephrologists are analyzed as pediatric nephrologists. Few categorical 
values were analyzed using a Chi-square test. Graphpad was used to create the 
artwork. 
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Results 
Participant characteristics
In total, 103 physicians (pediatric nephrologists (n=23) and pediatricians (n=80)) received 
the questionnaire of whom 51 (50%) completed the survey. Pediatric nephrologists 
showed a significantly higher response rate in comparison with pediatricians (91% 
and 38%, respectively). Supplemental Table S5.1 shows the demographics of the 
respondents. Physicians are distributed across all regions of the Netherlands.
Management of SSNS
First episode of nephrotic syndrome
All pediatricians and pediatric nephrologists start with prednisolone treatment for a 
first presentation of nephrotic syndrome (Table 5.1). Nearly all respondents (98%) use 
mg/m2 dosing with a daily dose of 60 mg/m2, followed by alternate day dosing of 40 
mg/m2. Some variation was present in the maximum dose used which did not depend 
on profession, age, percentage of clinical work or institution (Table 5.1, Supplemental 
Table S5.2). The only respondent who uses the mg/kg dosing, prescribed 2 mg/kg for 
Table 5.1   Steroid regimens for the first presentation and infrequent relapse 
of nephrotic syndrome
First presentation Infrequent relapse
Duration of 
daily steroids
6 weeks 42 (91%) 3 (7%)
4 weeks 2 (4%) 1 (2%)
Based on absence of 
proteinuria
2 (4%) 40 (91%)
Duration of 
alternate day steroids
6 weeks 42 (93%) 24 (56%)
4 weeks 3 (7%) 18 (42%)
Other 0 (0%) 1 (2%)
Maximum dose of daily 
steroids
100 mg 1 (2%)
80 mg 33 (80%)
60 mg 7 (17%)
Maximum dose of 
alternate day steroids
100 mg 1 (2%)
80 mg 18 (44%)
60 mg 15 (37%)
55 mg 1 (2%)
50 mg 2 (5%)
40 mg 4 (10%)
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both the daily and the alternate day dosing with a maximum of 80 mg. The frequency 
of daily dosing ranged from once daily (68%) to 2-3 divided doses daily (26%). The 
majority (80%) of the pediatric nephrologists prescribes prednisolone in one daily 
dose, whereas for the pediatricians this was only 60% (Supplemental Table S5.2). 
Wide variation was found in the tapering of steroids after alternate day dosing for 
the treatment of the first episode of nephrotic syndrome. Approximately one-third 
of the respondents, predominantly pediatricians, follow a schedule for tapering of 
steroids. The tapering schedules vary significantly and include a duration between 2 
and 26 weeks. 
Infrequent relapse of nephrotic syndrome
For a relapse of nephrotic syndrome the majority of the respondents prescribes 
prednisolone daily (60 mg/m2) until proteinuria is absent for 3 days, followed by 6 
weeks of alternate day prednisolone therapy (40 mg/m2) (Table 5.1, Supplemental 
Table S5.2). A quarter of the respondents uses a tapering schedule after alternate day 
dosing. 
FRNS
Additional steroid sparing drugs are prescribed by the majority of the respondents 
(93%) in case of FRNS. Most pediatricians indicated to consult a pediatric nephrologist 
in case the patient progresses to FRNS. In Figure 5.1 the first choice of steroid sparing 
drugs for FRNS is depicted. Table 5.2 shows the duration of maintenance therapy for 
FRNS, SDNS, and SRNS after sustained remission. Over 60% of the respondents 
considers tapering of steroids after the alternate day dosing regimen in FRNS. 
Table 5.2   Duration of maintenance therapy for FRNS, SDNS, and SRNS after 
sustained remission
Duration of maintenance therapy FRNS SDNS SRNS
6 months  4 (14%) 2 (10%) 1 (5%)
12 months 11 (38%) 9 (42%) 11 (52%)
24 months 11 (38%) 8 (38%) 8 (38%)
Between 12-24 months 1 (3%) 1 (5%) -
Dependent on drug of choice 2 (7%) 1 (5%) 1 (5%)
FRNS, frequently relapsing nephrotic syndrome; SDNS, steroid dependent nephrotic syndrome; SRNS, 
steroid resistant nephrotic syndrome
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SDNS
Nearly all pediatricians indicated to consult a pediatric nephrologist in case of SDNS. 
Two-thirds of the respondents who treat SDNS patients indicated to start with steroid 
sparing drugs, whereas one-third indicated to start with low-dose prednisolone 
maintenance therapy. Figure 5.1 shows the preference of steroid sparing drugs used 
in SDNS. 
Rituximab
In the Netherlands, rituximab is available for the treatment of nephrotic syndrome. 
Steroid toxicity was considered an indication for treatment with rituximab in 53% of 
the respondents. Over 40% of pediatricians and pediatric nephrologists considered 
FRNS and SDNS to be an indication for treatment with rituximab, however, usually not 
as a first choice treatment (Figure 5.1). The majority of the respondents (55%) 
prescribes 2 dosages of 375 mg/m2 with an interval of 2 weeks, whereas 22% prescribes 
a single infusion of 375 mg/m2. Moreover, 38% of the respondents considers repeating 
the dosage(s) after B-cell recovery.
Figure 5.1 First choice of steroid sparing drugs for FRNS and SDNS 










































The duration of steroid therapy before labeling a patient as steroid resistant varied 
widely among the respondents, ranging between 4-8 weeks of steroid therapy. As 
shown in Figure 5.2, the preferred treatment for SRNS was methylprednisolone 
followed by a CNI, with a small preference for cyclosporine over tacrolimus (57% versus 
43%, respectively). Similar to FRNS and SDNS, most pediatricians indicated to consult 
the pediatric nephrologist in case of SRNS. Genetic analysis is performed as standard 
of care by 88% of the respondents. Most of the respondents taper and withdraw im-
munosuppressive medication in case of a genetic form of SRNS. Inhibition of RAAS is 
always initiated by 39% of respondents, whereas 26% of the respondent indicated to 
never or rarely prescribe RAAS inhibition in case of SRNS. KDIGO guideline adherence 
for the initiation of RAAS inhibition in SRNS is depicted in Supplemental Table S5.2. In 
case RAAS inhibition is initiated, 69% of the respondents prescribes monotherapy with 
an ACE inhibitor, whereas 13% prescribes a combination of ACE inhibitors and ARBs.
Kidney biopsy practice 
Biopsy practice varied significantly among the respondents. For SRNS most pediatricians 
and pediatric nephrologists (83%) indicated to perform a kidney biopsy, whereas for 
FRNS and SDNS this was 22% and 41%, respectively. Only pediatricians considered 
performing a kidney biopsy in case of FRNS. If CNIs are used, over 50% of the 
respondents performs a kidney biopsy to monitor nephrotoxicity, either prior to the 
start of CNI, after 1-2 years of CNI use and/or in case of rising creatinine. 
Figure 5.2 Choice of steroid sparing drugs for SRNS





























Processed on: 16-7-2021 PDF page: 117
117
5
PRACTICE VARIATIONS IN NEPHROTIC SYNDROME
Supportive treatment
Albumin infusions and diuretics
Albumin infusions are considered in case of low serum albumin (reported range 
between 10-25 g/l) by 10% of the respondents, if severe intravascular depletion is 
present (68% of respondents), or in case of a combination of the two (38% of 
respondents). In general, pediatricians and pediatric nephrologists indicate to use 
diuretics in combination with albumin infusions (always 63%, sometimes 34%), with 
furosemide being the preferred diuretic drug. A minority of the respondents indicated 
to use hydrochlorothiazide (19%) and spironolactone (3%) as preferred diuretic. 
Variation is present among respondents in prescribing diuretics when edema is 
present. Diuretics are sometimes prescribed by 59% of the respondents, whereas 36% 
of respondents indicated to never/hardly ever prescribe diuretics in case of edema. 
Salt and fluid restriction
Salt restriction is ‘always’ advised by 41% of physicians. Sixteen percent of the physicians 
prescribes salt restriction in case of therapy resistant nephrotic syndrome or when 
edema is present. Moreover, most physicians (65%) advise fluid restriction in the acute 
phase of nephrotic syndrome. Fluid restriction is advised by 21% of the respondents in 
case of edema, whereas hyponatremia is an indication for fluid restriction for 19% of the 
respondents. In contrast, 14% of the respondents would never advise fluid restriction. 
When fluid restriction is prescribed, 39% of respondents advices 80% of normal fluid 
intake, a quarter recommends 60% of normal fluid intake. Finally, restriction based on 
insensible loss and diuresis is indicated by one third of the physicians. 
Thrombosis prophylaxis
Thrombosis prophylaxis is considered by almost half of the respondents in case 
albumin levels are below 20 g/l for over a month. Moreover, a quarter of the 
respondents (predominantly pediatricians) indicates to prescribe thrombosis 
prophylaxis in case the thrombocyte count rises above a certain value (ranging 
between 400 – 1200 x109/l). 
Calcium and vitamin D management
Variation was present in the calcium and vitamin D management of nephrotic syndrome 
patients (Figure 5.3). Most respondents do not supply calcium and/or vitamin D at the 
first presentation of nephrotic syndrome. 
Stress dose steroids
After steroid treatment, stress dose steroids may be used to prevent adrenal 
insufficiency. A substantial portion of the participating physicians (38%) indicates to 
always prescribe stress dose steroids. A smaller group (31%) sometimes uses stress 
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dose steroids whereas a quarter never does. A relatively higher percentage of 
pediatricians (44%) indicated to always prescribe stress dose steroids compared with 
pediatric nephrologists (31%). In contrast, the majority of respondents (89%) indicated 
to never/hardly ever use a low dose ACTH test. 
Varicella zoster vaccination
Finally, large variation was seen in the indication and timing of varicella zoster 
vaccination in patients who were not previously exposed to the virus. Indications 
ranged from ‘only in patients treated with second-line immunosuppressive agents’, 
‘patients with low serum albumin levels’, ‘steroid resistant patients’, to never and 
always. Over one third of the respondents indicated to vaccinate siblings of the patient 
in case they were not exposed to the varicella zoster virus yet, without significant 
practice differences in pediatricians compared with pediatric nephrologists. 
Discussion
This study shows significant practice variation in the management of childhood 
nephrotic syndrome in the Netherlands, especially for the treatment of FRNS, SDNS, 
and SRNS. Uniformity seems to be present in the management of a first presentation 
and infrequent relapse of nephrotic syndrome, with the exception of the tapering 
practices. Moreover, variation was present in the choice of steroid sparing agents, 
biopsy practice, the use of a steroid coverage during stress, and supportive treatment. 





























































Processed on: 16-7-2021 PDF page: 119
119
5
PRACTICE VARIATIONS IN NEPHROTIC SYNDROME
As expected, minimal variation was seen in the steroid treatment of a first presentation 
of nephrotic syndrome in the Netherlands. The majority of the pediatricians and 
pediatric nephrologists follow the steroid regimen of the APN, in line with the Dutch 
practice guideline as well as the 2012 KDIGO Clinical Practice Guideline.24, 68 
Interestingly, variation was found in the maximum dose of steroids used. This is most 
likely due to different recommendations on the maximum prednisolone dose for daily 
steroids in the Dutch practice guideline (max. 80 mg) and 2012 KDIGO Clinical Practice 
Guideline (max. 60 mg).24, 68 Even more variation was present in the maximum dose in 
the alternate day dosing period, which is probably due to the lack of a maximum dose 
for the alternate day regimen in the Dutch practice guideline.68 Moreover, wide 
variation was found in the tapering of steroids after alternate day dosing. Although 
tapering is not described in the Dutch practice guideline nor in the recommendations 
of the Gesellschaft für Pädiatrische Nephrologie, this is most likely based on the KDIGO 
Clinical Practice Guideline which states that daily oral prednisolone is given for 4-6 
weeks followed by alternate day medication and continued for 2-5 months with 
tapering of the dose.24, 68, 269 Interestingly, the recommendation of the KDIGO 
guideline for the treatment of a first episode of nephrotic syndrome was recently 
challenged by three well-conducted trials that showed no benefit of prolongation of 
steroid therapy beyond three months.64-66 Moreover, as current steroid regimens for 
the treatment of nephrotic syndrome are associated with pronounced steroid 
associated toxicity, establishing the most effective and least toxic therapeutic regimen 
is important. Recently, the results of a prospective randomized pilot study were 
published in which the efficacy of different doses in achieving remission of nephrotic 
syndrome relapses was investigated in a small cohort of 30 patients with SSNS. The 
results suggest that a lower dose may be as safe and effective as the standard dose.306
In case of FRNS or SDNS steroid sparing agents are often prescribed. Most pediatric 
nephrologists and pediatricians indicated that MMF was their preferred choice, with 
CNI as a second choice. The preferred choice of MMF is most likely based on a favorable 
side-effect profile compared to CNI with the potential nephrotoxic effects being the 
most important limitation for CNI use.46, 307 Rituximab was also considered by the 
Dutch pediatric nephrologists for the treatment of FRNS and SDNS. The 2012 KDIGO 
Clinical Practice Guideline previously stated that in children with FRNS and SDNS, there 
is low-quality evidence to support the use of MMF, and even very low-quality evidence 
for rituximab.24 Nowadays, both MMF and rituximab are valuable agents in the 
treatment of SDNS.46, 308 Variation was present among our respondents on the 
rituximab regimen used. Similarly, substantial variations in rituximab dose are present 
worldwide, ranging from 375 to 1500 mg/m2 per treatment course.67, 309 Recently, 
Chan et al. reviewed the effect of patient factors, rituximab dose, and use of 
maintenance immunosuppression on treatment outcomes.308 Debate exists on the 
indications for rituximab use. Nowadays, rituximab is often used in patients with FRNS 
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or SDNS that typically tried several non-steroid immunosuppressants. Using rituximab 
as a first-line treatment option could be considered, however long-term safety and 
efficacy results of this approach remain to be established. Strict monitoring is essential, 
especially in young children, to timely identify severe adverse events including 
persistent hypogammaglobulinemia. Finally, large prospective studies are needed to 
identify the exact indications and optimal rituximab regimen in patients with nephrotic 
syndrome.308 After this questionnaire was sent, new evidence regarding the added 
value of levamisole in SSNS became available310, which consequently was not reflected 
in this survey. With continuously developing literature, both the 2010 Dutch practice 
guideline and 2012 KDIGO Clinical Practice Guideline need updating, and indeed a new 
KDIGO guideline is currently under revision. 
For SRNS, variation was present in the definition used, with a wide range in the duration 
of prednisone treatment before a patient is labeled steroid resistant. This variation in 
the definition used is a well-known issue and remains a matter of debate.50 For the 
treatment of SRNS, our respondents mostly chose methylprednisolone pulses in 
combination with CNIs. This is consistent with previous findings on preferred SRNS 
treatment.301-303 In the Cochrane review on treatment of SRNS, CNIs are considered to 
increase the likelihood of complete or partial remission compared with placebo or cy-
clophosphamide.52 The necessity of corticosteroids as an additive to CNI therapy in 
SRNS is unknown. The 2012 KDIGO Clinical Practice Guideline suggests a combination 
of low-dose corticosteroid therapy and CNI therapy with tapering of the dose to the 
lowest level that maintains remission is recommended.24 Similarly, the current 
recommendation of the IPNA includes tapering of prednisolone once the diagnosis of 
SRNS is established with discontinuation of prednisolone therapy after 6 months.50 
Finally, RAAS inhibition with either ACE inhibitors or ARBs were recommended in both 
the 2012 KDIGO Clinical Practice Guideline and 2020 IPNA clinical practice recommen-
dations.50 The use of RAAS inhibition in SRNS varied among our respondents, which 
leaves room for improvement. 
Variation was found in biopsy practice, especially in cases of FRNS and SDNS. Similar to 
our results, Samuel et al. showed that 97% of the physicians would perform a kidney 
biopsy in case of SRNS and almost one-fifth would perform a biopsy with FRNS.301 
According to the 2012 KDIGO Clinical Practice Guideline, a biopsy is indicated in 
children who fail to respond to corticosteroids after one or more remissions, children 
with a high suspicion for a different underlying kidney pathology or children receiving 
CNI with a declining kidney function.24 Respondents who indicated to recommend a 
kidney biopsy in case of FRNS or SDNS were mostly pediatricians. Importantly, most 
pediatricians indicated to consult a pediatric nephrologist in case of FRNS, SDNS, or 
SRNS. In the Netherlands, kidney biopsies are only performed by pediatric nephrologists 
in tertiary care centers. As FRNS and SDNS are not considered a direct indication to 
perform a kidney biopsy, information for pediatricians on the indications to perform a 
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kidney biopsy should be optimized, as this will lead to better expectation management 
of the patients in case of referral to a pediatric nephrologist. 
Substantial variation was found in the use of tapering regimens and additional steroids 
in stress situations to prevent adrenal insufficiency in pediatric nephrotic syndrome 
patients. In the current Dutch practice guideline and 2012 KDIGO Clinical Practice 
Guideline, there is no mention of stress dose steroids. In line with the 2019 guideline 
on steroid therapy of the Pediatric Association of the Netherlands311, no relevant 
literature is available to guide clinicians on this issue. Nevertheless, based on 
physiological mechanisms it is advised to consider a tapering regimen when steroid 
treatment duration exceeds 14 days and growth impairment or cushingoid features 
are present or strong CYP3A4 inhibitors are used. Consequently, the recommendation 
is to perform a low dose ACTH test three months after discontinuation of steroids 
using a low dose ACTH test in patients requiring a tapering schedule.311 Recently, Abu 
Bakar et al. reported the results of a study on adrenal insufficiency in children with 
nephrotic syndrome. Sixty-two % (23/37) of the children showed signs of steroid 
toxicity, whereas only 35% of children (all below 5 years of age) had test results 
consistent with hypothalamic-pituitary-adrenal axis suppression.312 These results 
indicate that, especially in younger children, screening for adrenal insufficiency might 
be useful. Varicella infection may lead to life-threatening disease in children receiving 
immunosuppressive drugs. Large variation was present among respondents in the 
indication and timing of varicella zoster vaccination in patients who were not previously 
exposed to the virus. The 2012 KDIGO guideline recommends to offer varicella 
immunization to children with SSNS who are not receiving immunosuppressive or 
cytotoxic agents other than low-dose daily (<20 mg) or alternate day (<40 mg) 
prednisone.24 Finally, the majority of the respondents indicated not to supply calcium 
and/or vitamin D at the first presentation of nephrotic syndrome. In both the 2012 
KDIGO guideline and the Dutch clinical practice guideline there is no mention of 
vitamin D supplementation. In 2017, Yadav et al., showed a decrease in bone mineral 
density with steroid treatment and a beneficial role of calcium and vitamin D supple-
mentation even during the first episode of nephrotic syndrome.313 Nevertheless, the 
optimal dose, frequency of administration, and duration remain to be elucidated.314 A 
limitation of this study is the response rate of 50%, which may have introduced 
reporting bias. Nearly all pediatric nephrologists completed the survey, whereas for 
the pediatricians this was only 38%, which may be based on the low incidence of 
nephrotic syndrome in childhood.15 Furthermore, our study is based on survey results, 
rather than actual data of clinical practice. 
To conclude, significant practice variation is present in the management of childhood 
nephrotic syndrome in the Netherlands and differences were identified between the 
results of the survey and the Dutch practice guideline and international KDIGO Clinical 
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Practice Guideline. Most variation can be explained by the lack of consensus due to the 
absence of well-performed randomized controlled trials in this patient group. 
Therefore, effort should be made to collaborate in international randomized controlled 
trials to improve evidence based management of children with nephrotic syndrome. 
Moreover, with the recent literature and the subsequent new international guidelines 
and Cochrane reviews, the Dutch guideline needs updating.68 After such an update, it 
is important to promote the adherence to guidelines and thereby reduce practice 
variation. In the Netherlands, the Working Group idiopathic Nephrotic syndrome 
should play a role in the dissemination of the new guideline amongst pediatricians and 
pediatric nephrologists throughout the country.
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Supplemental Table S5.1 Demographics of the respondents
Characteristic Category N (%)a
Gender Male 21 (41%)
Female 30 (59%)
Age <41 years 9 (18%)
41-50 years 22 (44%)
51-60 years 15 (30%)
>60 years 4 (8%)
Profession General pediatrician 13 (26%)
Pediatrician with focus on pediatric nephrology 17 (33%)
Pediatric nephrologist 20 (39%)
Pediatric nephrologist in training 1(2%)
Experienceb 0-5 years 7 (19%)
5-10 years 8 (23%)
10-15 years 7 (19%)
>15 years 14 (39%)
Clinical practice vs 
other responsibilities 
(e.g. research) 
<50% clinical work 2 (4%)
50% clinical work 5 (10%)
>50% clinical work 44 (86%)
Institution Academic hospital 18 (35%)
General hospital 33 (65%)
a Some respondents did not answer all questions, therefore the number (N) does not always add up to N=51
b  Information only available for pediatric nephrologists (in training) and pediatricians with focus on pediatric 
nephrology
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Pharmacology and pharmacogenetics 
of prednisone and prednisolone 
in patients with nephrotic syndrome
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Nephrotic syndrome is one of the most common glomerular disorders in childhood. 
Glucocorticoids have been the cornerstone of the treatment of childhood nephrotic 
syndrome for several decades, as the majority of children achieves complete remission 
after prednisone or prednisolone treatment. Currently, treatment guidelines for the 
first manifestation and relapse of nephrotic syndrome are mostly standardized, while 
large inter-individual variation is present in the clinical course of disease and 
side-effects of glucocorticoid treatment. This review describes the mechanisms of 
glucocorticoid action and clinical PK and PD of prednisone and prednisolone in 
nephrotic syndrome patients. However, these mechanisms do not account for the 
large inter-individual variability in the response to glucocorticoid treatment. Previous 
research has shown that genetic factors can have a major influence on the PK and PD 
profile of the individual patient. Therefore, pharmacogenetics may have a promising 
role in personalized medicine for patients with nephrotic syndrome. Currently, little is 
known about the impact of genetic polymorphisms on glucocorticoid response and 
steroid-related toxicities in children with nephrotic syndrome. Although the evidence 
is limited, the data summarized in this study do suggest a role for pharmacogenetics to 
improve individualization of glucocorticoid therapy. Therefore, studies in larger 
cohorts with nephrotic syndrome patients are necessary to draw final conclusions 
about the influence of genetic polymorphisms on the glucocorticoid response and ste-
roid-related toxicities to ultimately implement pharmacogenetics in clinical practice.
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Introduction
Nephrotic syndrome is one of the most common glomerular disorders in children and 
affects 1-7 per 100,000 children per year (Dutch data: 1.52/100,000) with a male 
predominance (2:1).15 The disease is characterized by the triad of severe proteinuria, 
hypoalbuminemia and edema. Glucocorticoids have been the cornerstone of the 
treatment of childhood nephrotic syndrome for over 60 years, as over 80-90% of the 
patients achieve complete remission with prednisone or prednisolone treatment. 21 
Unfortunately, 80% of these patients will have one or several relapses and will need 
additional courses of glucocorticoid therapy. Furthermore, approximately 10% of 
children with nephrotic syndrome are steroid resistant and do not respond to the 
standard steroid treatment regimen. Treatment guidelines for the first manifestation 
and a relapse of SSNS are mostly standardized and based on practice guidelines rather 
than clinical trials.24 As the optimal glucocorticoid dosing regimens for childhood 
nephrotic syndrome are still under debate and large-scale clinical trials are lacking, 
current clinical practice among physicians is variable315 especially in the treatment of 
subsequent relapses and the choice of second-line immunosuppressive drugs. 
Unfortunately, the variability in the treatment of nephrotic syndrome is mostly based 
on the protocol preference of the physician, rather than the individual characteristics 
of the patient. Therefore, clinical trials are needed to develop international treatment 
guidelines with recommendations for several aspects of the treatment of nephrotic 
syndrome. Recently, a nation-wide study in the Netherlands showed that duration of 
corticosteroids for the initial presentation had no impact on subsequent relapses.63 
Furthermore, a recently published abstract of the PREDNOS study indicated no clinical 
benefit associated with an extended steroid course for the initial presentation in UK 
children.316 Currently, a few clinical trials are underway to further investigate the 
optimal dosing regimens for both the first manifestation as well as relapses of nephrotic 
syndrome.275, 317 
Large inter-individual variation is present in children with nephrotic syndrome 
regarding both the clinical course of disease and the intensity and spectrum of 
side-effects of its treatment. Nephrotic syndrome is characterized by podocyte foot 
processes effacement, however the exact mechanism of disease is still largely unknown 
and often debated. Several etiologies have been investigated over the years and 
different subgroups of the disease are likely to have a different pathogenesis.30, 31 
Damage to the filtration barrier can be caused by genetic defects primarily affecting 
podocytes. Patients with an underlying genetic defect are often primary steroid 
resistant and to date 53 genes associated with SRNS have been identified.41 
Furthermore, a substantial proportion of the patients is likely to have an immune-me-
diated circulating factor disease. These patients are also often steroid resistant, 
however screen negative for the known SRNS genes. The existence of a circulating 
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permeability factor would explain the rapid recurrence of proteinuria after kidney 
transplantation in some patients with nephrotic syndrome.35, 318 Many candidates 
have been identified over the years, however the definitive factor remains to be 
discovered.37 Lastly, involvement of the immune system in the pathogenesis of 
nephrotic syndrome is highly suspected as relapses often occur after the immune 
system is triggered by an infection, allergy or vaccination and glucocorticoid treatment 
is effective in most patients. Nephrotic syndrome has been considered to be a T-cell 
disorder based on several observations, including remission following measles 
infection, the association with Hodgkin disease, and the response to immunosuppres-
sive drugs.31 Furthermore, in the last few years a potential role for B-cells has been 
proposed as well due to the effectiveness of B-cell depletion with rituximab in patients 
with nephrotic syndrome.31, 319 
All in all, most children with nephrotic syndrome have a minimal change disease and 
therefore, the large inter-patient variability cannot fully be attributed to the disease 
histology.102 Previous research has indicated that pharmacogenetics can have an 
influence on both PK and PD of the individual patient.320 Genetic factors influencing 
the individual PK and PD profile may account for 20-95% of the variability in the efficacy 
and side-effects of medication.321 Each of the processes involved in PK and PD can 
potentially be influenced by a clinical significant genetic variation.322 Therefore, pharma - 
cogenetics may have a promising role in personalized medicine. By implementing 
pharma cogenetics in the clinical work-up of the patients, this may ultimately lead to 
individualized drug therapy to maximize drug efficacy and minimize drug toxicity. 
In the era of precision medicine, however, current knowledge on the influence of 
 pharmacogenetics on the steroid response in nephrotic syndrome is limited.323
This review describes the mechanisms of glucocorticoid action and clinical PK and PD of 
prednisone and prednisolone in nephrotic syndrome patients. Furthermore, the current 
data available on pharmacogenetics of prednisone and prednisolone in patients 
with nephrotic syndrome is summarized and areas for future research to improve 
 individualization of glucocorticoid therapy in children with nephrotic syndrome are 
identified. 
Mechanisms of glucocorticoid action 
Glucocorticoids are potent anti-inflammatory and immunosuppressant drugs. The effects 
of glucocorticoids are mediated by both genomic and non-genomic mechanisms. 
Genomic mechanisms implicate the activation or repression of specific genes encoding 
anti- and pro-inflammatory proteins. As a consequence of the time-consuming messenger 
RNA transcription and translation, the genomic glucocorticoid action is characterized 
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by a slow onset of the response. In contrast, non-genomic mechanisms do not influence 
gene expression and have a rapid onset and a short duration of the effect.324 
Genomic mechanisms (Figure 6.1)
Glucocorticoids are, like other steroid hormones, lipophilic molecules that can easily 
diffuse across the cell membrane and bind to the glucocorticoid receptors (GRs) in the 
cytoplasm.325 The inactive GR is bound to a chaperone protein complex to keep the 
Figure 6.1 Molecular mechanisms of glucocorticoid action
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inactive GR in the correct folding for hormone binding and prevent nuclear localization 
of unoccupied GRs.323, 326, 327 When glucocorticoids enter the cell after passive 
diffusion and bind to the GR in the cytoplasm, a glucocorticoid receptor / glucocorticoid 
complex (GR/GC complex) is formed. Subsequently, the chaperone protein complex 
dissociates, allowing the transfer of the GR/GC complex into the nucleus. The mechanism of 
nuclear translocation involves the nuclear import proteins importin-α and importin-13.328 
After entering the nucleus, the activated GR/GC complex binds to the DNA or interacts 
with coactivator complexes. The activated GR/GC complex exerts its anti-inflammatory 
and immunosuppressive effects by increased expression of anti-inflammatory genes 
(transactivation) and decreased expression of pro-inflammatory genes (transrepres-
sion).327, 329 Furthermore, the GR/GC complex can, either directly or indirectly, interact 
with pro-inflammatory transcription factors nuclear factor κB and activator protein 1 
and thus reduce their activity.324, 330 
Non-genomic effects 
The non-genomic mechanisms of glucocorticoid action remain largely undefined. Glu-
cocorticoids affect the physicochemical property of cell membranes, directly or 
through binding to intracellular or membrane bound GRs.331 The effects result in the 
inhibition of inflammatory cell function.332 Another hypothesis is that non-genomic 
effects are mediated after GR/GC binding. When glucocorticoids bind to the GR, the 
aforementioned chaperone proteins are released. The release of signaling molecules 
from the multi-protein complex is also considered to be responsible for rapid 
glucocorticoid effects.333
Pharmacokinetics
PK describe the study of what the body does to a drug. PK involves the processes of 
absorption, metabolism, distribution and excretion, often abbreviated as ADME.
Prednisone and prednisolone
For the treatment of nephrotic syndrome both prednisone and prednisolone are 
frequently used glucocorticoids. Prednisone is a prodrug of prednisolone and is bio - 
activated by the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD)-1. The conversion 
of prednisone into prednisolone occurs rapidly, plasma concentrations of both substances 
reach their peaks at approximately 0.5-3 hours after prednisone administration, both 
in patients with and without nephrotic syndrome.324, 334-337 In addition, interconver-
sion is present between both substances and this varies with time and dose. However, 
prednisolone concentrations are 4- to 10-fold higher than prednisone concentrations. 
In children with nephrotic syndrome, both in the active phase and in remission, similar 
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ratios were found, which indicates that nephrotic syndrome does not influence the 
conversion from prednisone into prednisolone.334-336, 338 
Absorption 
Both prednisone and prednisolone are well absorbed after oral administration. 
A variable systemic bioavailability for prednisone and prednisolone has been reported in 
literature: 84±13 and 99±8percent, respectively.324 The high variability in bio availability 
is most likely mainly based on inter-individual differences rather than the choice of 















Processed on: 16-7-2021 PDF page: 134
134
CHAPTER 6
prednisone or prednisolone.339 In the KDIGO guideline Glomerulonephritis, prednisone 
and prednisolone are considered equivalent and identical dosages are used for the 
standardized treatment regimens for patients with nephrotic syndrome.24 Peak plasma 
concentrations are reached approximately 0.5-3 hours after administration. Food 
intake is generally considered to prolong the time to maximum drug concentration 
(Tmax), but not the extent of drug absorption.340 
Nephrotic syndrome
In patients with nephrotic syndrome a similar bioavailability profile has been described, 
indicating that the nephrotic state does not influence absorption of prednisolone and 
prednisone.338, 341 (Figure 6.2)
Distribution
The Vd of prednisolone and prednisone in adults is 0.64 L/kg and 0.4-1.0 L/kg, 
respectively.342, 343 The total plasma PK of prednisolone and prednisone appear 
non-linear, due to non-linear protein binding. The protein free PK, however, are linear. 
Non-linear protein binding is most evident in the dose range between 5 and 50 mg.336 
Prednisolone binds to the glycoprotein transcortin (i.e. corticosteroid binding globulin) 
and to albumin. Transcortin is a small (50-60kDa), high affinity, low capacity protein 
with normal blood concentrations of 32.0-50.0 mg/l. In contrast, albumin (60 kDa) has 
a low affinity but high capacity.336, 344 Protein binding of prednisolone decreases 
non-linearly from approximately 95% at plasma concentrations of 200 µg/l down to 
60-70% at plasma concentrations of 800 µg/l. Subsequently, a dose-dependent 
increase in the Vd and drug clearance is observed.324 
Nephrotic syndrome 
Patients with nephrotic syndrome have decreased serum albumin and transcortin 
levels in the active phase of disease, leading to a decreased protein binding of 
prednisone and prednisolone.341, 342 When the unbound fraction increases due to less 
protein binding, the drug is eliminated more rapidly and the Vd of total prednisolone 
increases as the displaced drug spreads out. The end result is an initial increase in 
unbound concentration, a decrease in total drug concentration and no change in the 
steady state unbound concentration (Figure 6.3). These findings underline the 
necessity of evaluating unbound concentrations in pharmacological research. Recently, 
Teeninga et al. showed a good correlation between salivary prednisolone levels and 
free serum prednisolone levels in healthy volunteers and pediatric nephrotic syndrome 
patients, indicating the potential use of saliva as a non-invasive and feasible method 
for drug monitoring of prednisolone.345 
Several PK studies performed in both pediatric334, 335, 338, 344 and adult341, 342, 346 
nephrotic syndrome patients have confirmed the increase in unbound fraction, but 
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unchanged unbound steady state concentration of prednisolone. Moreover, PK studies 
performed in children with nephrotic syndrome in both the active phase of disease 
and in remission, showed that free prednisolone concentrations during the active 
phase did not significantly differ from those observed during remission.335 Furthermore, 
PK studies for other highly protein bound drugs showed similar results with an increase 
of total Vd, total clearance and free fraction of the drugs, but unchanged free drug 
concentrations in steady state.347 
Metabolism 
Intracellular metabolism by 11β-HSD controls the availability of prednisolone for 
binding to the glucocorticoid and mineralocorticoid receptors. Two types of 11β-HSD 
are present in the body. 11β-HSD-1 acts primarily as a reductase and converts the 
inactive prednisone into the active prednisolone. 11β-HSD-2 acts primarily as an 
oxidase and converts prednisolone to prednisone, thereby protecting the mineralo-
corticoid receptor from occupation by cortisol and prednisolone.348 The undesired 
mineralocorticoid effects of glucocorticoid treatment will most likely be pronounced 
when the capacity of 11β-HSD-2 is exceeded. Therefore, the mineralocorticoid effects 
of glucocorticoids might depend on the administration scheme. A low glucocorticoid 
dose leading to concentrations just above the protective capacity of 11β-HSD-2 is 
expected to have reduced mineralocorticoid effects when administered as two dose 
fractions, because both concentration peaks would not exceed 11β-HSD-2 capacity. In 
contrast, higher glucocorticoid doses, exceeding the 11β-HSD-2 capacity and even 
leading to saturation of the mineralocorticoid receptor, are expected to have enhanced 
mineralocorticoid effects when administered as two dose fractions, because the total 
time during which mineralocorticoid receptors are occupied would be prolonged. 
Prednisolone and prednisone are primarily cleared from the body by hepatic 
metabolism involving phase I and phase II reactions. The most important enzyme 
system of phase I metabolism is cytochrome P450. However, for the prednisone/
prednisolone metabolism the degree of involvement of specific CYP3A isoenzymes has 
not been fully elucidated yet. Nevertheless, coadministration of the strong CYP3A4 
inhibitor ketoconazole is shown to increase total and unbound prednisolone 
concentrations in plasma by about 50% due to a decreased clearance.349 In line with 
this, previous research has shown coadministration of enzyme inducers to cause an 
increased clearance and decreased half-life of prednisolone.350-352
Furthermore, in vitro data suggest that prednisolone is also a substrate of P-gp. P-gp is 
an ATP-dependent efflux membrane transporter, which is widely distributed 
throughout the body and highly expressed in the small intestine and kidneys. 
Expression of P-gp protein in the intestinal epithelium limits the absorption of drug 
substrates from the gastro-intestinal tract. Therefore, theoretically, coadministration 
of P-gp inhibitors could increase glucocorticoid absorption and oral bioavailability and 
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might affect glucocorticoid distribution.324 A previous study conducted in adult renal 
patients, however, showed a normal metabolism of prednisolone in patients treated 
with cyclosporine, which is a P-gp inhibitor.353
Nephrotic syndrome
For patients with nephrotic syndrome different dosing regimens have been 
investigated. Single daily dosing appears to be as effective as multiple daily dosing in 
maintaining remission in children.354 Serious side effects, including hypertension, 
Cushingoid appearance, and obesity, were less common in patients receiving the single 
daily dose compared to patients receiving divided doses.354 We hypothesize that this 
might be due to continuously exceeding the 11β-HSD-2 capacity in case of multiple 
daily dosing as a consequence of the high doses of steroids given in patients with 
nephrotic syndrome. Whether P-gp inhibitors are able to increase glucocorticoid 
availability in patients with nephrotic syndrome is unknown. In addition, glucocorti-
coids are known to affect the PK of other drugs by enzyme induction as well by inducing 
CYP3A4355 and P-gp356, however the clinical importance of enzyme induction by 
prednisone/prednisolone is largely unknown.324 
Excretion
P-gp is also located in the liver and kidney, resulting in enhanced excretion of drug 
substrates into bile and urine, respectively. In this case, coadministration of P-gp 
inhibitors could potentially result in decreased excretion of prednisone/prednisolone 
and an increased retention time.357 The previously mentioned PK study in renal 
transplant patients, however, also showed a normal metabolic and renal clearance of 
prednisolone in the presence of cyclosporine.353 Elimination half-lives (T1/2) in adults 
are 3.3±1.3h for prednisone and 3.2±1.0h for prednisolone.324 In a PK study performed 
in children lower mean elimination half-lives of 2.2±0.5h were found.337 
Nephrotic syndrome
In the aforementioned study, children with a variety of diseases (e.g. nephrotic 
syndrome, asthma, SLE, congenital virilizing adrenal hyperplasia) were included. 
Children with congenital virilizing adrenal hyperplasia were considered to be 
comparable to normal subjects. No difference regarding elimination half-lives was 
found between this group and the children with nephrotic syndrome.337 Similarly, 
Rocci et al. found no significant difference in half-life between pediatric nephrotic 
syndrome patients in remission and asthmatic controls. However, in the active phase 
of disease, the nephrotic syndrome patients did show increased T1/2 values, which may 
be explained by the larger Vd in active disease.338 In patients with nephrotic syndrome 
total prednisolone clearance increases proportional to the increased unbound fraction 
of prednisolone.338, 342, 346 (Figure 6.3) Renal excretion of unchanged drugs is 
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approximately 2-5% for prednisone and 11-24% for prednisolone after administration 
of either one of the drugs.336 
Summary
In patients with nephrotic syndrome the unbound fraction of prednisolone increases 
due to saturable protein binding. Subsequently, this leads to more rapid elimination 
and an increase in apparent Vd, in the end leading to a decrease in total drug 
concentrations and no change in the steady state unbound (pharmacologically active) 
concentration (Figure 6.3). Therefore, dose adjustment of prednisone/prednisolone is 
not necessary in nephrotic syndrome patients with normal renal clearance.
Pharmacodynamics
PD refers to what the drug does to the body, including the time course and intensity of 
therapeutic and adverse effects.
Therapeutic effects
Clinical efficacy depends on both PK (e.g. what the body does to a drug) and PD (e.g. 
what the drug does to the body) characteristics of a drug. In case of glucocorticoids, 
PD may vary greatly among different glucocorticoids, diseases and individuals. These 
differences may be explained by a variety of factors: different number of GRs per cell, 
a different glucocorticoid binding affinity, GR diversity, regulatory factors that control 
gene translation and protein production, and possibly also by differences in 
non-genomic mechanisms between cell types.358 One way of comparing drug potency 
is by the concentration at which 50% of the maximum effect is achieved (EC50). 
Furthermore, potency is also dependent on the effect monitored. Potential biomarkers 
for glucocorticoids are endogenous cortisol, T-helper and T-suppressor lymphocytes, 
and neutrophil count.359 
Adverse effects
Prednisolone and prednisone therapy have been associated with a broad range of 
toxicities. Adverse effects are more common in patients receiving glucocorticoids in 
high doses or over a long period of time. Potential adverse effects include skin fragility, 
bodyweight gain, increased risk of infections and fractures. Important cardiovascular 
and metabolic effects are hypertension, hyperglycemia and dyslipidemia.352 Whereas 
most anti-inflammatory effects of glucocorticoids are consequences of transrepres-
sion of pro-inflammatory and immune genes, adverse events appear to largely result 
from transactivation that leads to increased expression of regulatory and anti-inflam-
matory proteins.329, 331, 360
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Nephrotic syndrome 
As it stands, it is not completely understood how prednisolone achieves remission of 
nephrotic syndrome. High variability exists between individuals with nephrotic 
syndrome regarding both the efficacy and side-effects of prednisone/prednisolone.16 
Furthermore, the molecular basis for development of clinical resistance to 
glucocorticoid therapy is unclear in patients with nephrotic syndrome. Inter-individual 
differences in glucocorticoid handling and metabolism may partly explain the variability 
in the response to prednisone/prednisolone treatment. However, as previously 
described in the introduction, differences in disease histology, podocytes and 
immunological characteristics of the individual patient may also play a significant role. 
Different hypotheses exist to explain the mechanism of action of prednisone/
prednisolone in patients with nephrotic syndrome. These hypotheses go beyond the 
conventional anti-inflammatory or immunosuppressive actions, as it is unlikely that the 
effect is completely due to conventional anti-inflammatory effects of these drugs, 
since glomerular inflammation is mostly absent in SSNS. 
Previous research has indicated that glomerular podocytes may be a direct target of 
glucocorticoids in patients with nephrotic syndrome as human podocytes express 
GRs.361 The beneficial effect of glucocorticoids might be due to direct protection of 
podocytes from injury and/or promotion of podocyte repair. Xing et al. showed that 
dexamethasone upregulated the expression of nephrin.362 Nephrin is a key component 
of the slit diaphragm, the main site of control of glomerular permeability. This has 
resulted in the hypothesis that glucocorticoids act directly on podocytes via promotion 
of repair with enhanced process formation and upregulation of nephrin. Furthermore, 
podocyte foot processes consist of cortical actin filaments and actin-associated 
proteins, which ensure the dynamic maintenance and reorganization of the 
cytoskeleton. In vitro studies have shown the direct effects of glucocorticoids on 
podocytes by protection of cultured podocytes via actin filament stabilization and 
prevention of apoptosis.363, 364 The effect on apoptosis and upregulation of nephrin 
appeared to be dose-dependent, which might be an explanation for the observed 
differences in clinical response to glucocorticoids.362, 364 Another in vitro study, 
performed by Guess et al., demonstrated functional glucocorticoid signaling by 
multiple glucocorticoid-induced responses, including downregulation of the GR.365 
Gamal et al. reported that glomerular GR expression was significantly higher in minimal 
change early responders in comparison to late responders. Furthermore, a significantly 
lower glomerular GR expression was found in patients with a SRNS compared to early 
responders and late responders. Therefore, evaluation of glomerular GR expression at 
the time of diagnosis can aid in prediction of the response to steroid therapy. This way, 
exposure to ineffective treatment courses may be prevented in children with nephrotic 
syndrome.366 Unfortunately, this technique requires a kidney biopsy and in daily 
clinical practice a kidney biopsy is generally not performed at the time of diagnosis in 
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children with nephrotic syndrome. Therefore, additional approaches are needed to 
predict the response to steroid therapy, of which pharmacogenetics may be a 
promising option.
Pharmacogenetics
It is well known that different patients respond in different ways to the same medication. 
Many non-genetic factors influence the individual differences in drug response, 
including age, sex, disease, organ function, concomitant therapy, drug adherence and 
drug interactions (for a review on such factors, see 324, 352). In addition, genetic factors 
may also have a major influence on the efficacy of a drug and risk of side-effects.322, 367 
Pharmacogenetics is the study of the role of inheritance in inter-individual variation in 
drug response. Genetic factors influencing the patient PK or PD profiles may account 
for 20-95% of variability in the efficacy and side-effects of therapeutic agents.321 For 
example, polymorphisms in the CYP3A5 gene account for 40-50% of the variability in 
tacrolimus dose requirement in Caucasians.90 After administration, the drug is 
absorbed and distributed to the site of action. It interacts with targets (such as 
receptors and enzymes), undergoes metabolism, and is then excreted. Each of these 
processes could potentially involve a clinical significant genetic variation.322 
Understanding the basis of such variations, i.e. pharmacogenetics, is vital to come to 
personalized medicine, which ultimately may lead to individualized drug therapy to 
maximize drug efficacy and minimize drug toxicity. 
 
Clinical practice
In children with nephrotic syndrome large inter-individual variability is present in the 
course of disease, and efficacy and side-effects of glucocorticoids. As the variable 
response to glucocorticoids in patients with nephrotic syndrome cannot completely 
be attributed to the disease histology, it is difficult to predict the response based on 
clinical observations alone. For nephrotic syndrome, research on the impact of genetic 
polymorphisms on steroid response and susceptibility to steroid-related toxicities is 
limited.323 For a few other diseases, however, pharmacogenetics has already been 
implemented in clinical practice.368, 369 Furthermore, in the field of pediatric 
nephrology, new guidelines on tacrolimus dosing recommend involvement of CYP3A5 
genotyping to optimize the immunosuppressive treatment of the individual transplant 
patients.370 
In line with the aforementioned examples, we believe that the involvement of pharma-
cogenetics in the work-up of nephrotic syndrome patients as well might be beneficial, 
preventing exposure to ineffective drug courses and minimizing drug toxicity. As the 
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mechanism of action of glucocorticoids involves numerous receptors, enzymes and 
proteins, a variety of potential targets of genetic polymorphisms may be present. 
Although limited evidence is available, an overview of previously conducted studies on 
pharmacogenetics of prednisone and prednisolone in patients with nephrotic 
syndrome is provided below. Table 6.1 (glucocorticoid targets) and Table 6.2 
(glucocorticoid PK) provide an overview and brief description of the most important 
studies conducted in pediatric patients with nephrotic syndrome in which a positive 
association between the polymorphism and steroid response was described. Below a 




Polymorphisms in the GR gene (NR3C1) are known to be associated with variations in 
the GR function, because they may alter the formation of the GR/GC complex. 
Therefore, the hypothesis is that genetic alterations in the gene encoding for the GR 
receptor, may account for some degree of inter-individual variability in the 
glucocorticoid response and steroid-related toxicity in individuals.390 Three 
polymorphisms are known to be associated with reduced sensitivity in both 
endogenous and exogenous glucocorticoids: TthIIII (rs10052957), ER22/23K (rs6189/
rs6190), and GR-9β (rs6198). In contrast, the polymorphisms N363S (rs6195) and BC1I 
(rs41423247) are associated with an increased sensitivity to glucocorticoids.390, 391 
Increased glucocorticoid sensitivity due to a genetic polymorphism might also be 
associated with increased susceptibility to steroid-related toxicities. Previously, Eipel 
et al. showed that pediatric patients with acute lymphoblastic leukemia carrying the 
N363S polymorphism were more prone to steroid-related toxicities.392, 393 In contrast, 
children with the ER22/23EK polymorphism were less susceptible.392 To our knowledge, 
the role of genetic polymorphisms in the GR gene in susceptibility of steroid-related 
toxicities has only been investigated in patients with nephrotic syndrome in one study. 
Teeninga et al. found no association between the GR-9β polymorphism and side 
effects.371 To date, a few studies investigated the role of NR3C1 polymorphisms on the 
glucocorticoid response in pediatric patients with nephrotic syndrome.371-374, 394, 395 
Four studies found a potential influence of genetic polymorphisms in the GR gene on 
the steroid response in patients with nephrotic syndrome (Table 6.1). 
Glucocorticoid receptor heterocomplex
Components of the glucocorticoid heterocomplex are essential to keep the GR in the 
correct folding for hormone binding and prevent nuclear localization of unoccupied 
GRs. Abnormalities in the chaperones and co-chaperones that make up the 
heterocomplex may contribute to decreased glucocorticoid responsiveness, as the 
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integrity of the GR heterocomplex is required for optimal ligand-binding and 
subsequent activation of the transcriptional response. For several diseases, which are 
treated with glucocorticoids, including nephrotic syndrome, altered levels of chaperone 
protein hsp90 were found in peripheral blood mononuclear cells from individuals with 
a steroid resistant course of disease.396-398 Although limited, some evidence exists 
about the association of polymorphisms in the gene encoding for one of the co- 
chaperones, FKBP5, with steroid resistance in Crohn’s disease.399 Interestingly, this 
could also hold true for nephrotic syndrome patients as well. Recently, one study was 
published on the potential role of FKBP5 polymorphism (rs4713916) in a small group of 
pediatric nephrotic syndrome patients showing a higher frequency in patients with a 
SDNS.375 
Nuclear translocation receptors
Nuclear translocation receptors, known as importins, play a significant role in the 
mechanism of glucocorticoid action. These receptors are responsible for the effective 
transport of the GR/GC complex to the cell nucleus. Importin-13 is a primary regulator 
to facilitate the transfer of the GR/GC complex across the nuclear membrane. In 
children with asthma, polymorphisms encoding the importin-13 gene resulted in 
increased sensitivity for glucocorticoids, which was most likely due to the increased 
availability of glucocorticoids in the nucleus.400 The role of genetic polymorphisms in 
the gene encoding for importin-13 in patients with nephrotic syndrome is unknown.323 
Pro- and anti-inflammatory factors 
To date, the exact underlying pathophysiological mechanisms of nephrotic syndrome 
are still unknown. One of the hypotheses is that nephrotic syndrome is associated with 
an immunoregulatory imbalance between T-helper subtype 1 and T-helper subtype 2 
cells. Cytokines produced by the T-helper cells play a role as mediators of inflammation. 
Several studies have been conducted in patients with various diseases to evaluate the 
association with genetic polymorphisms in the IL-1, IL-4, IL-6, IL-13, and TNF-α genes. 
The evidence for genetic polymorphisms in the cytokines genes in patients with 
nephrotic syndrome is, however, limited. Minimal change nephrotic syndrome is 
associated with atopy and IgE production.401 T-helper subtype 2 cytokines, such as IL-4 
and IL-13 are known to be involved in the development of atopy. Previously genetic 
variations of IL-4 and IL-13 and their receptors have been shown to be associated with 
predisposition to atopy and/or elevated serum IgE levels.402 Several studies have been 
conducted to investigate the role of polymorphisms in the genes coding for IL-4, IL-6 
and IL-13 in pediatric patients with nephrotic syndrome.376-378, 403-405 The IL-4 
polymorphism rs2243250 was associated with nephrotic syndrome and an increased 
risk of steroid resistance.376-378 Furthermore, previous research conducted by Jafar et 
al. and Tripathi et al. indicate that a genetic polymorphism in the IL-6 gene is associated 
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with decreased responsiveness to steroids.377, 378 No significant association was found 
between the IL-13 gene polymorphisms and disease susceptibility or steroid 
responsiveness.373, 403, 405 
An important pro-inflammatory cytokine is macrophage migration inhibitory factor 
(MIF). MIF has the unique ability to override the inhibitory effects of glucocorticoids on 
the immune system. Due to its regulatory properties MIF is considered a critical 
mediator in various immune and inflammatory diseases. The allele MIF-173*C 
(rs755622) is associated with higher serum MIF levels. Several studies have been 
conducted to investigate the potential role of this genetic polymorphism in the gene 
encoding for MIF in patients with nephrotic syndrome.373, 381-383, 406, 407 A meta-analysis 
conducted by Tong et al. showed that gene polymorphism rs755622 plays an important 
role in the risk on glucocorticoid resistance in patients with nephrotic syndrome.408 
The hypothesis is that the G/C substitution at base pair 173 of MIF gene increases the 
MIF level in serum and could therefore cause a pro-inflammatory response, induce 
injury to podocytes and accelerate the progression of glomerulosclerosis.409 TNF-α is 
also an important pro-inflammatory cytokine involved in the inflammatory process. 
Elevation of TNF-α has been found in the plasma and urine of patients with nephrotic 
syndrome.410, 411 Conflicting results have been published for the role polymorphisms 
in the gene encoding for TNF-α in patients with nephrotic syndrome.377, 378, 412, 413 
Lastly, Müller-Berghaus et al. investigated the role of polymorphisms in gene encoding 
for pro-inflammatory mediator IL-12B and found an association of the IL12Bpro-1.1 
genotype with a steroid dependent course of disease.380 
GLCCI1 (glucocorticoid-induced transcript 1) gene
Little is known about the exact function of GLCCI1. GLCCI1 was initially described as a 
thymocyte-specific transcript that is rapidly up-regulated in response to dexamethasone 
treatment.414 In addition, GLCCI1 is expressed in the kidney and in particular in the 
glomeruli. Knockdown of the GLCCI1 gene resulted in disruption of the glomerular 
permeability filter and podocyte foot process effacement. A genome-wide association 
study in patients with asthma showed a significant association between the genetic 
polymorphism rs37972 of the GLCCI1 gene and a decreased response to glucocorticoid 
inhalation therapy.415 In contrast, two studies in pediatric nephrotic syndrome patients 
could not confirm the association between this specific polymorphism and steroid 
responsiveness in patients with nephrotic syndrome.373, 416 
P-gp
P-gp is an efflux pump encoded by the multidrug resistance protein 1 gene (MDR1). 
Glucocorticoids are known substrates for P-gp and may also induce P-gp expression.356, 
417 In the kidney, P-gp is expressed in the brush border membrane of proximal tubular 
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epithelial cells. Increased expression of P-gp results in decreased intracellular drug 
concentrations and may consequently decrease treatment response. Previous research 
has shown higher expression of MDR1 and increased P-gp activity in children with 
SRNS.418, 419 To date, approximately 50 genetic polymorphisms have been reported in 
the MDR1 gene. Among the genetic polymorphisms, C1236T (rs1128503), G2677T/A 
(rs2032582), and C3435T (rs1045642) are the most common variants in the coding 
region of MDR1. The interpretation of the influence of the genetic polymorphisms on 
P-gp expression, however, is unresolved and may vary depending on tissue type, 
pathological status and ethnicity.420 A recent systematic review on pharmacogenetics 
and adverse drug reactions in pediatric oncology patients indicated protective effects 
from two genetic polymorphisms of the MDR1 gene in methotrexate- and vincris-
tine-related neurotoxicity in pediatric acute lymphoblastic leukemia patients.421 In 
nephrotic syndrome patients, however, no studies have been conducted to investigate 
the potential role of genetic polymorphisms in the MDR1 gene in steroid-related 
toxicities. Several studies have been conducted to evaluate the association of P-gp 
polymorphisms with the responsiveness to glucocorticoids in patients with nephrotic 
syndrome. The results of these studies on the significance of the genetic polymorphisms 
are contradictory.373, 384-386, 388, 422-424 A recent meta-analysis concluded that there is 
evidence of an association between rs1128503 and increased risk of steroid resistance 
in children with nephrotic syndrome.425 
Pregnane X receptor
Pregnane X receptor gene (NR1I2) encodes an intracellular receptor that, upon binding 
with glucocorticoids or xenobiotic substances, activates a set of genes involved in the 
metabolism of drugs. Turolo et al. described an association of the presence of a 
pregnane X receptor deletion polymorphism (rs3842689) with steroid resistance. The 
hypothesis is that a reduced expression of pregnane X receptor leads to an underex-
pression of GRs, which may be the explanation for the development of steroid 
resistance.389
Summary
The results of the aforementioned reported papers are generally inconclusive and 
contradictory. However, some genetic polymorphisms appear to be promising in the 
prediction of steroid response or steroid-related toxicities in children with nephrotic 
syndrome. Especially, polymorphisms in the genes encoding for the GR and GR 
heterocomplex seem to have an association with steroid responsiveness. Nevertheless, 
most studies are hampered by small patient cohorts. Therefore, studies in larger 
cohorts with nephrotic syndrome patients are necessary to draw conclusions about 
the influence of genetic polymorphisms on the glucocorticoid response. Furthermore, 
as mentioned above, pharmacogenetics may also play a role in the intensity and 
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spectrum of side-effects. Currently, little is known about the influence of pharmacog-
enetics on steroid-related toxicities in patients with nephrotic syndrome. However, as 
previous research in mostly cancer patients have shown a potential role of genetic 
polymorphisms in the susceptibility on steroid-related toxicities, this area is an 
important opportunity for future research as well.
Conclusion
Glucocorticoids are essential in the treatment of childhood nephrotic syndrome. 
Currently, standardized treatment guidelines with high doses of prednisone or 
prednisolone are proposed world-wide. As current treatment guidelines are largely 
based on empiric recommendations rather than clinical trials, large variability in the 
treatment of nephrotic syndrome is present among physicians, especially regarding 
the treatment of subsequent relapses and the choice of second-line immunosuppres-
sive drugs.315 As large scale clinical trials are lacking, treatment decisions are frequently 
based on either the preference or common practice of the treating physician or 
guidelines of the country, rather than the individual characteristics of the patient. 
Therefore, effort should be made to first provide international guidelines based on 
clinical trials to uniformly treat patients with nephrotic syndrome. Subsequently, effort 
should be made to identify specific markers to individualize treatment, as large in-
ter-individual differences are present in both the clinical course of disease and adverse 
effects of glucocorticoids in children with nephrotic syndrome. Pharmacogenetics has 
a promising role in working towards personalized medicine. Despite the fact that the 
evidence about the role of pharmacogenetics in children with nephrotic syndrome is 
limited, we feel that available data do show a potential role for pharmacogenetics in 
clinical practice to maximize drug efficacy, minimize drug toxicity and avoid exposure 
to ineffective drug courses. Nowadays, the evidence to implement these genetic 
markers in clinical practice is too little and therefore clinical implementation of phar-
macogenetics in nephrotic syndrome patients is not possible yet. Therefore, we feel 
that further research is highly important to identify specific and sensitive markers for 
steroid resistance in patients without genetic podocyte mutations as well as for 
patients more at risk for steroid-related toxicities. As nephrotic syndrome is a rare 
kidney disease in childhood and large patient cohorts are needed to ultimately 
implement pharmacogenetics in the clinical work-up, we believe that this research 
preferably should be conducted in international collaborative studies. 
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Steroid treatment for 
the first episode of childhood 
nephrotic syndrome: 
comparison of the 8 and 12 weeks 
regimen using an individual 
patient data meta-analysis
Anne M. Schijvens, Nynke Teeninga, Eiske M. Dorresteijn, Steven Teerenstra,
Nicholas J. Webb, Michiel F. Schreuder
European Journal of Pediatrics, 2021 Mar 28. 
doi: 10.1007/s00431-021-04035-w. Online ahead of print.
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Steroids are the cornerstone of the treatment of childhood nephrotic syndrome. The 
optimal duration for the first episode remains a matter of debate. The aim of this study 
is to determine whether the 8 weeks ISKDC regimen is equally effective as the 12 
weeks APN regimen. An IPD meta-analysis of randomized controlled trials reporting on 
prednisolone treatment for a first episode of childhood nephrotic syndrome was 
conducted. European trials aimed at investigating the ISKDC and/or APN steroid 
regimen were selected. The lead investigators of the selected trials were requested to 
provide the IPD of the specific treatment groups. Four trials included European cohorts 
using dosing schedules according to the regimens studied. IPD of two trials were 
available. A significant difference was found in time to first relapse after cessation of 
steroid treatment between the 8 and 12 weeks treatment group with a median time to 
relapse of 29 and 63 days, respectively. Moreover, relapse rate ratios during total 
follow-up were 51% higher for the 8 weeks regimen. Finally, younger children have a 
significantly lower time to first relapse and frequently relapsing nephrotic syndrome. 
Conclusions: The results of this IPD meta-analysis suggest that the 8 weeks steroid 
regimen for a first episode of SSNS may not be equally effective as the 12 weeks steroid 
regimen. Moreover, this study highlights the importance of using uniform definitions 
to enable accurate comparison and interpretation of trial results.
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Introduction
Nephrotic syndrome is one of the most common glomerular disorders in childhood 
with a reported incidence of 1-2 per 100,000 children per year.15, 265, 426, 427 For over 
sixty years, steroids have been the cornerstone of the treatment of nephrotic syndrome 
as over 80-90% of patients achieve complete remission after steroid treatment.19, 20 
Current recommendations on the treatment of a first episode of nephrotic syndrome 
are based on empirical experience and small randomized controlled trials. The 2012 
KDIGO Clinical Practice Guideline for Glomerulonephritis recommends that 
corticosteroid therapy should be given for at least 12 weeks.24 Moreover, it is stated 
that daily oral prednisone is given for 4-6 weeks followed by alternate day medication 
for 2-5 months with tapering of the dose. This recommendation leaves room for 
interpretation. In fact, wide variability is present among European centers in the 
treatment of a first episode of nephrotic syndrome.67 Recent, well-conducted trials 
clearly show no benefit of steroid therapy beyond 12 weeks, however are unable to 
provide information on the preference for an 8 or 12 weeks steroid regimen.63-66 
Consequently, the 8 weeks ISKDC protocol and 12 weeks APN protocol are among the 
most frequently used protocols in Europe.67 Recently, a Cochrane review suggested 
little or no difference between the 8 and 12 week steroid regimens.428 However, a 
direct comparison between these commonly used regimens has only been made in 
small cohorts and the results seem contradictory.45, 429-431 The aim of this study is to 
determine whether the 8 weeks steroid regimen for a first episode of nephrotic 
syndrome in European children is equally effective as the 12 weeks steroid regimen 
using an IPD meta-analysis. 
Methods
Protocol and registration
Methods were pre-specified in a protocol that was registered in PROSPERO 
(CRD42020199244).
Paper and patient selection
We conducted an IPD meta-analysis of randomized controlled trials reporting on 
steroid treatment for a first episode of childhood nephrotic syndrome. This IPD 
meta-analysis was reported according to the Preferred Reporting Items for Systematic 
Review and Meta-Analyses of Individual Participant Data (PRISMA-IPD) statement.267 
We identified trials from the Cochrane reviews of Hahn et al.428, 432 Additionally, a 
PubMed search was conducted (March 2nd 2020) to identify additional trial reports. In 
brief, the search strategy included the following terms: (“Nephrotic syndrome”[Mesh] 
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OR nephrotic syndrome [tiab] OR nephrotic OR nephrosis [tiab]) AND (Infan* OR kid OR 
kids OR child OR child* OR children* OR schoolchild* OR schoolchild OR school 
child[tiab] OR school child*[tiab] OR adolescen* OR juvenil* OR youth* OR teen* OR 
under*age* OR pubescen* OR pediatrics[mh] OR pediatric* OR paediatric* OR 
peadiatric*) AND (steroids OR corticosteroids OR prednisolone OR prednisone) AND 
(trial OR clinical trial).  
Eligibility criteria
We selected randomized controlled trials recruiting pediatric nephrotic syndrome 
patients treated according to the ISKDC protocol and/or the APN protocol. From the 
selected trials, only children treated according to the aforementioned protocols were 
included in the analysis. Only European trials were included as ethnicity is considered 
to play a role in susceptibility to the disease as well as in the responsiveness to 
steroids.433, 434 As this resulted in a low number of cohorts that could be included, US 
and Canadian studies were added as well, despite the potential higher impact of 
ethnicity on the outcome. Unfortunately, this did not yield any additional cohorts and 
we therefore returned to our predefined criteria.
Trial selection
Titles and abstracts were reviewed to exclude irrelevant studies and full-text articles 
were evaluated for their eligibility by three members of the study group. The lead 
investigators of the selected trials were requested to provide the IPD. When IPD were 
not available, aggregate results of trials directly comparing the two treatment regimens 
were compared to the results of the IPD meta-analysis.
Data collection
The data requested for each patient included sex, ethnicity, age at diagnosis, treatment 
protocol, weight at presentation, height at presentation, relapse (yes/no), time to 
relapse, FRNS (yes/no), time to FRNS, SDNS (yes/no), time to SDNS, number of relapses 
during 12 months follow-up, number of relapses during 24 months follow-up, and the 
start of immunosuppressive maintenance therapy. We used standard checks to 
identify missing data, assess data validity, and consistency. Sex, ethnicity, and age at 
diagnosis were considered as covariates. Ethnicity was classified as Caucasian, Asian, 
or other. Age at diagnosis was stratified as <4 years and ≥4 years as it is suggested that 
younger children have a higher risk of a complicated disease course.64, 66, 272 Definitions 
of FRNS and SDNS varied significantly among the trials (Supplemental Table S7.1). The 
definitions were adjusted to enable comparison of trial results in this IPD meta-analysis 
(Supplemental Table S7.1). Data were collected in IBM SPSS statistics version 25.
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Study objectives
The objective of this study was to determine whether the ISKDC steroid regimen (4 weeks 
of daily steroids 60 mg/m2, 4 weeks of alternate day steroids 40 mg/m2) for a first 
episode of SSNS in children is equally effective as the steroid regimen proposed by the 
APN (6 weeks of daily steroids 60 mg/m2, 6 weeks of alternate day steroids 40 mg/m2). 
The primary outcome was defined as the time from the final prednisolone dose to the 
first relapse. As the median follow-up duration differed between the trials, the minimum 
follow-up duration across all selected trials was used, which was 24 months. Secondary 
outcomes included the progression to FRNS, SDNS, the number of relapses during 12, 
24 months and final follow-up, and the start of immunosuppressive maintenance therapy. 
In case time to SDNS was not recorded in the trial, progression to SDNS was analyzed 
for the full follow-up duration and time to SDNS was excluded from the analysis. 
Statistical methods
The primary outcome was analyzed using Kaplan-Meier survival curves to visually 
present time to first relapse. We compared the time to events using a log rank test. 
Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a Cox 
proportional hazard model. Time to FRNS was analyzed similarly. All survival analyses 
were carried out using the time after cessation of steroid therapy to avoid bias in favor 
of the extended steroid course group. Categorical outcomes were analyzed using a 
Chi-square test and relative risks (RR) compared to the reference category were 
calculated. For dichotomous outcomes, RRs and 95% CI were used. Poisson regression 
and negative binomial regression in combination with follow-up time as an offset 
variable were used to calculate relapse rate ratios (RRR). An important methodological 
issue in IPD meta-analyses is the choice between the one-stage and two-stage 
approach. As in our analysis only one trial had an arm with the 8 week treatment and 
one (other) trial had an arm with the 12 week treatment, we extracted the IPD of those 
treatment arms and we conducted a two-group comparison. As patients within the 8 
weeks were from one trial and the 12 weeks treatment patients were from another 
trial, it was not possible to estimate trial-effects and we had to consider both groups 
as separate cohorts. Therefore, we compared baseline characteristics to assess 
confounding. Additionally, all analyses were corrected for the covariates gender, age, 
and ethnicity. Finally, there was one trial directly comparing the two treatment 
regimens but with no IPD. The aggregate results of that trial were compared with the 
results of the IPD meta-analysis to assesses consistency. For each outcome, the odds 
ratios (OR) of that trial were compared to the odds ratio obtained in the IPD using a 
logistic regression analysis with the main effects and interaction term for treatment 
regimen (8 versus 12 weeks) and data source (the trial versus the IPD). Time to event 
data could not be compared as ranges or standard deviations were not reported in the 
manuscript. All analyses were carried out using IBM SPSS statistics version 25. 
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Paper and patient selection (Figure 7.1)
The final search yielded 21 non-duplicated studies (Supplemental Table S7.2). Four studies 
were excluded as they only reported the results in abstract form and no full results 
were available [Jayantha UK, 2004, CN-00583710; Pecoraro C, 2005, CN-00644161; 
Satomura K 2001, CN-00447593; Sharma RK 2000, CN-00550434]. Three trials were 
excluded as other steroid regimens or cointerventions were used.279, 435, 436 Finally, 10 
non-European trials were excluded, none of which were US or Canadian studies.64, 65, 
270, 272, 283, 429-431, 437, 438 The remaining four papers were included as they included 
European patient cohorts using the mg/m2 dosing schedule for either 8 weeks or 
12 weeks or both.45, 63, 66, 439 The primary investigators were contacted to share IPD 
and all investigators responded to our request. The trials of Webb et al. and Teeninga 
et al. provided IPD and data from the ‘short treatment arms’ was included in this 
analysis (Figure 7.1).63, 66 The APN studies of 1988 and 199345, 439, had no IPD available 
anymore. As the Ehrich trial provided a direct comparison between the 8 and 12 week 
treatment, it was included in a separate analysis.45 Study characteristics of the included 
trials are shown in Supplemental Table S7.3. 
Participants
In total, 171 patients aged 1.5 – 16 years were included in the IPD meta-analysis. 
As shown in Table 7.1 baseline characteristics did not significantly differ between the 
8 and 12 weeks treatment groups, with the exception of ethnicity. In the original trials, 
children with SRNS were excluded, which was defined as no clinical response after 4 
(Webb) or 6 (Teeninga) weeks of daily prednisolone at 60 mg/m2/day. 
Primary outcome
The proportion of patients having a relapse within 24 months of follow-up was 80% 
and 77% in the 8 weeks and 12 weeks group, respectively (RR=1.03 [0.88-1.22]). The 
median time to relapse of participants experiencing a relapse was 29 days for the 8 
weeks treatment group and 63 days for the 12 weeks treatment group (log rank, 
p=0.04, Table 7.2, Figure 7.2), calculated from the end of the steroid treatment. Cox 
proportional hazards regression analysis suggests children below 4 years of age to 
have a significantly shorter time to first relapse compared to children of 4 years and 
older (HR=0.65 [0.45-0.93], Table 7.3).
Secondary outcomes
The proportion of patients developing FRNS within 24 months of follow-up was similar 
in both groups (Table 7.2). As shown in Table 7.3, multivariable logistic regression 
analysis showed that gender and ethnicity were not significantly associated with the 
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development of FRNS. In contrast, children over the age of 4 had a lower chance on 
developing FRNS (OR=0.50 [0.26-0.95]). Time to FRNS was numerically better but did 
not significantly differ between the 8 weeks and 12 weeks treatment groups (Figure 7.3). 
Cox proportional hazards regression analysis suggests children below 4 years of age to 
have a significantly shorter time to FRNS compared to children above the age of 4 
(Table 7.3). No difference was found regarding the incidence of steroid dependency 
between the 8 weeks and 12 weeks group (RR=0.91 [0.65-1.27], Table 7.3). 
Figure 7.1 The PRISMA IPD Flow diagram
Number of studies for which IPD was
sought n=4 
Number of studies after duplicates
removed n=21
Number of studies screened for
eligibility n=21
Number of studies excluded
- Only reported in abstract form n=4
- Steroid regimen other than ISKDC or APN n=3
- Non-European trial n=10
Number of eligible studies for which IPD was 
not sought n=0
Reasons for not seeking IPD should be reported
Number of studies for which IPD was 
provided n=2
Number of participants for whom data was
provided n=171
Number participants for whom no data was
provided n=216
Reason:
Patients were treated according to another
steroid schedule than requested for this IPDMA. 
Number of studies for which IPD was
not provided n=2
Reason:
No individual patient data available anymore
n=2 (100 participants)  
Number of studies identified through
database searching n=14
Number of studies for which aggregate data
was available/useful n=1 (71 participants) 
IPD










































Number of studies identified from Cochrane
review (Hahn et al. 2015, 2020) n=21 
The PRISMA IPD flow diagram
© Reproduced with permission of the PRISMA IPD Group, which encourages sharing and reuse for non commercial purposes 
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At one year of follow-up counted from the start of treatment, relapse rates were 
significantly lower in the 12 weeks treatment group (1.4 relapses per year) compared 
to the 8 weeks treatment group (2.3 relapses per year) (RRR=0.64 [0.48-0.84], Table 7.4). 
Two years after presentation, the number of relapses were similar in the two treatment 
groups. For the total follow-up duration, relapse rates were 1.2 relapses per year for 
the 8 weeks treatment group, versus 0.8 relapses per year for the 12 weeks group 
(RRR= 0.66 [0.49-0.90], Table 7.4). At one year of follow-up and at last follow-up, 
the incidence rate of relapses in children of 4 years and older was significantly lower 
compared to children below the age of 4 years (Table 7.4). 
Table 7.1 Baseline characteristics of the IPD data
8 week protocol66 12 week protocol63 p-value
Number of patients 109 62
Median (IQR) age at 
presentation (months)






























Median (IQR) height at 
presentation (cm)
104 (92.2 – 122.0) 109.5 (98.8 – 118.3) 0.29
Median (IQR) weight at 
presentation (kg)
19.4 (15.2 – 24.4) 20.2 (17.0 – 25.4) 0.18
Total prednisolone dose 
first treatment (mg/m2)
2240 3360
Median (IQR) follow-up 
duration study participants 
(months)
37 (30-48) 46 (32-60)
IQR, interquartile range
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Table 7.2   Primary and secondary outcomes at 24 months after comparison of 








Relapse 87 (80%) 48 (77%) RR (95% CI)
1.03 (0.88-1.22)
Sustained remission* 21 (19%) 14 (23%) RR (95% CI)
0.85 (0.47-1.56)
SDNS** 48 (44%) 30 (48%) RR (95% CI)
0.91 (0.65-1.27)
FRNS** 52 (48%) 26 (42%) RR (95% CI)
1.14 (0.80-1.62)
Start of immunosuppressive 
maintenance therapy***
61 (56%) 28 (45%) RR (95% CI)
1.24 (0.90-1.71)
RR is reported with the 12 week treatment group as a reference group.
*Sustained remission at total follow-up, see Supplemental Table S7.3 for median (IQR) follow-up duration
**Definition 3 that enables comparison of trial results (Supplemental Table 1)
***For the patients of the Webb trial only the start of second-line immunosuppressive maintenance 
therapy was recorded, whereas for the patients of the Teeninga trial, the start of any additional
immunosuppressive therapy was recorded, including maintenance therapy with steroids
FRNS, frequently relapsing nephrotic syndrome; HR, hazard ratio; IQR, interquartile range; KDIGO, kidney disease 
improving global outcomes; N/A, not available; RR, relative risk; SDNS, steroid dependent nephrotic syndrome.
Figure 7.2 Time to first relapse after cessation of prednisolone therapy
APN, Arbeitsgemeinschaft für Pädiatrische Nephrology; ISKDC, International Study of Kidney Disease in Children.
p 0.04
8 weeks ISKDC protocol
12 weeks APN protocol 
0 6 12 18 24
0 = 56 days after start of therapy 
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Table 7.3   Multivariate logistic regression analysis and cox proportional hazards 
analysis on outcome at 24 months adjusted for treatment, age, gender, 
and ethnicity.



































































CI, confidence interval; HR, hazard ratio; FRNS, frequently relapsing nephrotic syndrome; OR, odds ratio; 
SDNS, steroid dependent nephrotic syndrome.
Figure 7.3 Time to FRNS after cessation of prednisolone therapy
APN, Arbeitsgemeinschaft für Pädiatrische Nephrology; FRNS, frequently relapsing nephrotic syndrome; 
ISKDC, International Study of Kidney Disease in Children.
p 0.14
8 weeks ISKDC protocol
12 weeks APN protocol 
0 6 12 18 24
0 = 56 days after start of therapy 
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Comparison to aggregate trial results
Results of the IPD meta-analysis were compared to the aggregate trial results of the 
Ehrich trial.45 The percentage of patients with sustained remission in the 12 weeks 
treatment group of the Ehrich trial was 49% compared to 23% in the 12 weeks group 
of the IPD meta-analysis (Table 7.5). Percentages of sustained remission in both 8 
weeks treatment groups were comparable. The percentages of patients having a 
relapse within 3 or 6 months after the end of continuous therapy are significantly 
lower in the Ehrich trial (Table 7.5 and Supplemental Table S7.4). Similarly, the 
proportion of patients requiring cytotoxic drug therapy is lower in the Ehrich trial 
(Table 7.5, Supplemental Tables S7.4). The proportion of patients progressing to FRNS 
is similar (44% versus 32% [8 weeks groups] and 16% versus 18% [12 weeks groups]) 
(Table 7.5). 
Table 7.4 Relapse rates 


















































* Counted from the start of treatment
** See Supplemental Table 7.3 for median (IQR) follow-up duration
CI, confidence interval; RR, relapse rate (number of relapses per year); RRR, relapse rate ratio.
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The results of this IPD meta-analysis suggest that the ISKDC steroid regimen using 
8 weeks of steroid treatment for a first episode of SSNS may not be equally effective as 
the 12 weeks APN steroid regimen in terms of time to first relapse and relapse rates at 
12 months and at total follow-up. The proportion of patients developing FRNS or SDNS 
where similar in both treatment groups. Interestingly, children below 4 years of age 
showed a decrease in time to first relapse and time to FRNS, and showed higher relapse 
rates compared to children aged 4 years and older. 
To date, only a few small trials were reported in which the 8 weeks and 12 weeks 
steroid regimens for the first episode of childhood nephrotic syndrome were 
compared.45, 429-431 In line with the results of the IPD meta-analysis, Ehrich et al. 
concluded that the 12 weeks treatment regimen is preferred for the treatment of a 
first episode of nephrotic syndrome.45 Overall, a relatively high percentage (49%) of 
patients in the 12 weeks group having sustained remission after two years was 
reported in the 1993 Ehrich trial, which is not consistent with the results from our 
Table 7.5   Comparison of odds ratios of binary outcome measures from the IPD 
















































*Data used for IPD meta-analysis: progression to FRNS within 24 months of follow-up.
IPD MA, individual patient data meta-analysis; FRNS, frequently relapsing nephrotic syndrome; 
IQR, interquartile range; OR, odds ratio
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analysis and percentages reported in literature.21 Interestingly, in the 8 weeks group of 
the 1993 Ehrich trial, the percentage of patients with sustained remission after two 
years was 19%, whereas in the 1988 Ehrich trial this was 41%.45, 439 Moreover, the 
proportion of patients requiring cytotoxic drug therapy is low compared to patients 
included in the IPD meta-analyses. As many aspects of nephrotic syndrome, such as 
underlying pathology440 and steroid responsiveness441, seem to be changing over 
decades, the apparent difference in outcome may also be based on the different era in 
which the Ehrich study was performed compared with the Teeninga and PREDNOS 
trials. As previously reported in the Cochrane review of Hahn et al.428 blinding was not 
mentioned in the Ehrich trial, which is a major limitation. Norero et al. reported no 
superiority of the 12 weeks treatment in terms of mean relapse rate per patient in 18 
months, number of patients with FRNS, adverse effects, and the number of patients 
with a relapse at 12 and 18 months of follow-up.429 Time to first relapse was not 
reported in this study and patients progressing to SDNS were excluded from the 
analysis. Similarly, Paul et al. indicated that prolongation of prednisolone therapy for 
the initial episode of nephrotic syndrome did not have a beneficial effect on the 
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12 weeks APN treatment was superior to the 8 weeks ISKDC in preventing relapses in 
nephrotic syndrome.430 Of note, the trials of Norero et al., Paul et al., and Moundekhel 
et al. were reported to have high or unclear risks on several bias items.428 Importantly, 
the studies included in this IPD meta-analysis showed a low risk of bias on all bias items 
of the Cochrane review by Hahn et al.428 
The purpose of intensification of steroid therapy in nephrotic syndrome is to alter the 
overall disease course and minimize drug toxicity rather than only delay the first 
relapse. In light of this, time to first relapse should not be the only parameter to select 
the preferred treatment of a first episode of nephrotic syndrome and long-term 
outcome measures should be taken into account. Additionally, our analyses show that 
relapse rates for the total follow-up duration are significantly higher in the 8 weeks 
group compared to the 12 weeks group. Interestingly, in the study of Webb et al. no 
superiority in terms of clinical outcomes of the 16 weeks steroid regimen was found.66 
In contrast, our IPD meta-analysis shows that time to first relapse after cessation of 
prednisolone therapy was significantly increased in the 12 weeks treatment group. We 
hypothesize that the differences in clinical outcomes between the IPD meta-analysis 
and the trial of Webb et al. may be a consequence of longer daily steroid treatment in 
the 12 week steroid regimen (6 weeks of daily steroids) compared to the 16 week 
steroid regimen (4 weeks of daily steroids). In accordance with our results on FRNS, the 
recently published Cochrane review of Hahn et al. concluded little or no difference in 
the number with frequent relapses between the two and ≥ three months regimens 
based on studies at low risk of bias.428 
Post-hoc analyses of previous studies have suggested that an early age at onset is a risk 
marker for a complicated disease course.64, 66 The results of our study confirm this risk 
and suggest that children below 4 years of age show a decrease in time to first relapse 
and time to FRNS, and higher relapse rates, independent from the treatment regimen 
used. Using cut-off values for age at diagnosis of 3, 5, or 6 years similar results can be 
obtained regarding time to FRNS. A subgroup analysis indicated that children below 
the age of 4 treated according to the 12 weeks regimen did not progress less frequently 
to FRNS, however did show a statistically significant increase in time to FRNS. An IPD 
meta-analysis (by Bagga et al. [personal communication]) including patient data from 
several large clinical trials is underway to determine whether initial therapy should be 
prolonged in younger patients with nephrotic syndrome. 
Previously, significant practice variation on the treatment of a first episode of nephrotic 
syndrome has been identified among European centers.67 To answer the question on 
the optimal treatment for a first presentation of nephrotic syndrome in Europe, only 
European trials were included in this IPD meta-analysis. Interestingly, previous studies 
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indicated that Asian children have a higher incidence of nephrotic syndrome with a 
less complicated disease course compared to European children.433, 434 This is likely to 
be associated with differences in genetic factors involved in the pathogenesis of 
nephrotic syndrome or the response to steroids. Multivariate regression analysis 
indicated that ethnicity was not significantly associated with any of our outcomes. As 
a small effect cannot be excluded, we performed a subgroup analysis excluding 
patients with a non-European descent. We found similar results in time to first relapse, 
incidence of SDNS and FRNS, relapse rates at 12 months, 24 months and last follow-up. 
In this analysis, time to FRNS was significantly shorter in the 12 weeks group (HR 0.43 
[0.23-0.78]). 
One of the strengths of our study is that a comparison of the two commonly used 
treatment arms is performed in a large group of patients. The use of IPD offers 
advantages over analyses using aggregate data extracted from publications. Aggregate 
data are often presented non-uniformly across studies and more likely to be reported 
when statistically or clinically significant which may lead to publication bias and 
selective reporting. Individual-level information enables more flexible and robust 
analyses than are possible with aggregate study results.267 The statistical analysis and 
outcome measures are standardized across studies. Finally, baseline factors can be 
adjusted for consistently across studies and IPD meta-analyses may allow detailed 
exploration of interactions between participant characteristics and treatment 
effects.442, 443 Taken together, IPD meta-analyses often provide more detailed and 
reliable results and a greater depth of understanding than is possible from aggregate 
data.444 This IPD meta-analysis also has its limitations. IPD were available for 50% (2/4) 
of the included trials. In randomized controlled trials, randomization causes a fair 
distribution of patient variables among the two treatment groups. As we compared 
two treatment arms from two independent studies, patient variables were not 
randomly distributed. To overcome this potential problem, baseline characteristics 
were compared between both groups and all analyses were adjusted for the covariates 
to control confounding. The cumulative amount of steroids used during follow-up was 
not available, nor could we compare data on adverse events and time to SDNS. Finally, 
we chose to only include European trials in the IPD meta-analysis to prevent 
interference from ethnicity on outcomes as we aimed to answer the question on the 
optimal treatment regimen for European children with nephrotic syndrome. This 
however, hampers the generalizability of the results and therefore the results should 
be interpreted with caution for patients with a non-European descent. 
In conclusion, the results of this IPD meta-analysis suggest that the 8 weeks steroid 
regimen for a first episode of SSNS is not equally effective as the 12 weeks steroid 
regimen. Although less steroids for the first nephrotic syndrome episode would be 
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beneficial in terms of steroid toxicity in the short term, these results suggest patients 
treated with a 12 week steroid regimen may have a lower number of relapses during 
follow-up. Nevertheless, as the number of patients developing FRNS or SDNS were 
similar in the two treatment groups, the final conclusion on the preferred treatment 
for a first episode of childhood nephrotic syndrome remains to be elucidated. To 
further minimize steroid toxicity alternative strategies may be considered including 
dose reduction306 or addition of second line immunosuppressive drugs for a first 
manifestation of nephrotic syndrome.276, 280 
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Supplemental material 
Table of contents
1 Supplemental Table 1 Definitions used for FRNS and SDNS
2 Supplemental Table 2 Identified trials on steroid treatment of first presentation 
of nephrotic syndrome in children
3 Supplemental Table 3 Study characteristics of the included trials
4 Supplemental Table 4 Comparison of 8 and 12 weeks treatment groups of IPD  
meta-analysis and Ehrich trial
Supplemental Table S7.1 Definitions used for FRNS and SDNS
Definitions
1 KDIGO FRNS Two or more relapses in the first 6 months of initial 
response, or four or more relapses in any 12-month 
period
SDNS Two or more consecutive relapses during corticosteroid 
therapy, of within 14 days of ceasing therapy
2 Webb trial FRNS Two or more relapses in the first 6 months following 
presentation or four or more relapses in any 12 month 
period 
Teeninga trial FRNS A. Two or more relapses within 6 months after 
completing initial treatment
B. Four relapses within any period of 12 months, 
including relapses during initial treatment
(C. FRNS based on a clinical decision that included 
additional treatment: prednisolone maintenance 
therapy (>three months) or other immunosuppressive 
agents)
Webb trial SDNS Relapse while receiving corticosteroid treatment or 
within 14 days of stopping the drug
Teeninga trial SDNS Two or more consecutive relapses either during or 
within 14 days of completion of steroid therapy
3 To enable 
comparison of 
trial results
FRNS Two or more relapses in the first 6 months following 
presentation or four or more relapses in any 12 month 
period
SDNS Relapse while receiving corticosteroid treatment or 
within 14 days of stopping the drug
FRNS, frequently relapsing nephrotic syndrome; SDNS, steroid dependent nephrotic syndrome.
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REducing STEroids in 
Relapsing Nephrotic syndrome: 
the RESTERN study – protocol of 
a national, double-blind, randomised, 
placebo controlled, noninferiority 
intervention study
Anne M. Schijvens, Eiske M. Dorresteijn, C J. Roeleveld, Rob ter Heine,
Joanna A. van Wijk, Antonia H. Bouts, Mandy G. Keijzer-Veen,
Lambertus P. van den Heuvel, Michiel F. Schreuder
BMJ Open 2017 Sep 27;7(9):e01848. 
doi: 10.1136/bmjopen-2017-018148.
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Oral corticosteroids are the first-line treatment for idiopathic childhood nephrotic 
syndrome. Most children experience several relapses, needing repeated courses of 
corticosteroid therapy. This exposes them to side effects and long-term complications. 
For most patients, long-term prognosis is for complete resolution of the disease over 
time and maintenance of normal kidney function. Therefore, it is vital to focus on 
minimizing adverse events of the disease and its therapy. Unfortunately, no randomized 
controlled trials are available to determine the optimal corticosteroid treatment of an 
infrequent relapse of nephrotic syndrome. Recent studies show that treatment 
schedules for the first episode can safely be shortened to two months. The hypothesis 
of the RESTERN study is that a 4-week reduction of alternate day steroids after inducing 
remission is effective and safe, reduces steroid exposure by 35% on average, and is 
therefore preferable.
Methods and analysis
The RESTERN study is a nation-wide, double-blind, randomized, placebo controlled, 
noninferiority intervention study. Children aged 1-18 years with a relapse of SSNS are 
eligible for this study. Study subjects (n=144) will be randomly assigned to either 
current standard therapy in the Netherlands or a reduced prednisolone schedule. The 
primary outcome of the RESTERN study is the time to first relapse after the final 
prednisolone dose. The secondary outcomes are the number or relapses, progression 
to FRNS or SDNS and the cumulative dosage of prednisolone during the study period. 
Ethics and dissemination
This noninferiority trial will be performed in accordance with the Declaration of 
Helsinki and has been approved by the medical ethical committee of Arnhem-Nijme-
gen and the Dutch Competent Authority (Central Committee on Research Involving 
Human Subjects, CCMO). After completion of this study, results will be published in 
national and international peer-reviewed scientific journals. Papers will be published 
according to CCMO guidelines. The final report will be made available to trial 
participants.
Registration details
Trial registration number NTR5670, EudraCT number 2016-002430-76.
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Nephrotic syndrome is characterized by the triad of severe proteinuria, hypoalbuminemia, 
and edema. It is one of the most common glomerular diseases in children with an 
incidence of 1-7 per 100,000 children per year (Dutch data: 1.52/100,000) and a 
prevalence of 16 per 100,000 children.15, 265, 426 Most children have minimal change 
nephrotic syndrome and will have favorable prognosis with complete resolution of the 
disease over time and maintenance of normal kidney function.102 
For over 60 years corticosteroids have been the first-line treatment for idiopathic 
nephrotic syndrome in children as over 80-90% of patients achieve complete remission 
after prednisolone treatment.20, 21 Yet, over 80% of the patients experience one or more 
relapses and around 50% suffer from frequent relapses, thereby needing additional 
courses of corticosteroid therapy.63 This exposes them to the side effects and 
long-term complications of corticosteroid therapy, such as growth retardation (8-16%), 
osteopenia (13-63%), mood disorders, and cataract (6-20%).47, 59-61 The currently used 
treatment regimens for a nephrotic syndrome relapse are mostly based on practice 
guidelines of the ISKDC44 and the APN.446 In the Netherlands, the standard treatment 
schedule consists of 60 mg/m2 prednisolone daily until complete remission is achieved 
for 3 days, followed by 40 mg/m2 prednisolone on alternate days for 4-6 weeks.68, 447
Several trials have been conducted to study the duration of the initial corticosteroid 
treatment regimen, as Hodson et al. suggested that a prolonged period of prednisolone 
might reduce chances of subsequent relapses.448 A previous nation-wide study in 
the Netherlands addressed the issue of duration of corticosteroids for the initial 
presentation, and showed that the duration had no impact on subsequent relapses.63 
A few recent, well-conducted trials suggest that it may be safe to reduce the duration 
and thereby cumulative dose of corticosteroid therapy for the initial episode of 
nephrotic syndrome from six to two or three months.64, 65, 432, 449, 450 With recent 
studies showing no benefit for longer duration of initial prednisolone treatment, one 
may conclude that we still don’t know the optimal treatment duration of relapses. 
In addition, as stated in the KDIGO clinical practice guideline glomerulonephritis, 
“there are no randomized controlled trials examining relapse regimens with cortico-
steroids in infrequent relapsing nephrotic syndrome”.24 With the current evidence 
against longer steroid therapy for the initial treatment, the time is now to determine 
whether this holds true for treatment of relapses as well in both children with and 
without maintenance immunosuppressive therapy. The aim of the RESTERN study 
(REducing STEroids in Relapsing Nephrotic syndrome) is to assess the safety and 
effectiveness of a reduced alternate day steroid schedule for treatment of a nephrotic 
syndrome relapse in comparison with the current standard therapy. 
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Methods and analysis 
Trial design and setting
The RESTERN study is designed as a nation-wide, double-blind, randomized, placebo 
controlled, noninferiority intervention study with two treatment arms. The study is 
performed and coordinated by a single center (Radboudumc Amalia Children’s 
Hospital) where the research team is instituted, with inclusion of patients throughout 
the Netherlands from all secondary and tertiary hospitals.
Eligibility criteria
Children aged over 1 and less than 18 years with SSNS will be assessed for possible 
inclusion in the study. A detailed description of the in- and exclusion criteria is shown 
in Table 8.1. 
Study objectives
The primary objective of this study is to investigate the effectiveness of a reduced 
steroid schedule for the treatment of a relapse in children with SSNS. Secondary 
objectives are:
- To study the influence of maintenance immunosuppressive therapy on the effectiveness 
of a reduced steroid schedule for the treatment of a relapse in children with SSNS. 
Maintenance immunosuppressive therapies include levamisole, cyclosporine, tacrolimus, 
MMF and mycophenolate sodium, and alternate day prednisolone with a maximum 
of 4 mg/m2;
- To investigate the occurrence of relapses, frequency of relapses and progression to 
SDNS and FRNS in children with nephrotic syndrome under the standard treatment 
regimen; 
- To study the influence of maintenance immunosuppressive therapy on the occurrence 
of subsequent relapses, frequency of subsequent relapses and progression to SDNS 
and FRNS under the standard regimen, and;
- To study the effectiveness of a reduced steroid schedule for the treatment of a 
relapse and occurrence and frequency of subsequent relapses in children with SDNS. 
Interventions
Eligible patients will be randomized between standard prednisolone treatment and 
a reduced treatment schedule. At the start of a relapse, participants are treated 
according to the current standard therapy, consisting of daily oral prednisolone 
(60 mg/m2). After three days of remission, defined as three consecutive days of absent 
proteinuria based on urine dipstick analysis, standard care dictates that prednisolone 
is changed to an alternate day dosing of 40 mg/m2 with a maximum of 40 mg. After two 
weeks of alternate day prednisolone, participants are randomized between the two 
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treatment arms. The standard treatment group will receive an additional 4 weeks of 
alternate day oral prednisolone (40 mg/m2, with a maximum of 40 mg) and the placebo 
group will receive 4 weeks of alternate day oral placebo (Figure 8.1). Prednisolone (5 
mg/ml) or placebo will be provided as an oral solution (see paragraph “Investigational 
medicinal product”). 
Table 8.1  In- and exclusion criteria
Inclusion criteria
• Age over 1 and less than 18 years
• SSNS
• At least one episode of nephrotic syndrome in the preceding 24 months that was 
treated with prednisolone
• The last prednisolone use (at a dose over 10 mg/m2 on alternate days) for the treatment 
of a previous episode was at least 4 weeks ago
• Subjects without maintenance immunosuppressive therapy
• Subjects with maintenance immunosuppressive therapy
▪ Long-term immunosuppressive therapies: levamisole, cyclosporine, tacrolimus, MMF 
(Cellcept®), mycophenolate sodium (Myfortic®), prednisolone max. 4 mg/m2 on 
alternate days
▪ Cyclophosphamide (oral of intravenous), at least three months post completion of 
therapy
▪ A single dose or course of intravenous rituximab, at least three months post 
completion of therapy
• Signed informed consent from the parent or legal representative and/or the patient, 
depending on the age of the patient
Exclusion criteria
• Steroid resistant nephrotic syndrome 
• Receiving, or within 3 months after receiving, cyclophosphamide or rituximab
• Daily prednisolone maintenance therapy at any dose
• Alternate day prednisolone maintenance therapy at a dose over 4 mg/m2
• Documented or suspected significant non-compliance
• Pregnancy
• Stimulant drug use
• Comorbidity
- Kidney transplant recipient
- Any disease that requires the variation in oral prednisolone to be at the discretion of 
the treating physician(s)
• Concomitant use of moderate and strong CYP3A inducers
• Concomitant use of moderate and strong CYP3A inhibitors, other than cyclosporine 
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Children will be withdrawn if they are unable to take the study medication and will be 
treated according to the standard treatment regimen (oral prednisolone 40 mg/m2 on 
alternate days). Maintenance immunosuppressive therapy, including levamisole, 
cyclosporine, tacrolimus, MMF and mycophenolate sodium, is continued throughout 
the treatment period. Alternate day prednisolone maintenance therapy with a 
maximum of 4 mg/m2, is discontinued during the non-randomized treatment and 
restarted after randomisation, administered at the same day as the study medication. 
Antihypertensive agents, antiproteinuric agents, and/or diuretics may be continued at 
the discretion of the treating physician. All children will be followed for two years and 
subsequent nephrotic syndrome relapses will be treated according to the current 
standard treatment protocol in the Netherlands.
Investigational medicinal product
A prednisolone or placebo solution (5 mg/ml) will be produced compliant with current 
Good Manufacturing Practice at the department of pharmacy of our institute. 
The standardized formulation of the oral solution is based on the Dutch Pharmacists 
Formulary. The investigational medicinal product is an aqueous solution preserved 
with methylparaben, buffered at a pH of 7.1 with a phosphate buffer and contains 
sorbitol and banana essence to mask the bitter taste of prednisolone sodiumphosphate. 
For the placebo, prednisolone sodiumphosphate is left out of the product. A pilot 
palatability study of the investigational medicinal product showed no relevant visual 
or taste differences of the drug or placebo. Drug dispensing and accountability is 
performed on individual basis from the central pharmacy.
Outcomes
The primary outcome of the RESTERN study is the time to first relapse. This is defined 
as the time (in days) from the final prednisolone dose until the first day of treatment of 
the next relapse. 
Secondary outcomes include the following: 
1.  The number of relapses per patient after the final prednisolone dose, censored at 
12 and 24 months of follow-up;
2.  Progression to FRNS, defined as four or more relapses in any 12-month period 
(KDIGO criteria), censored at 24 months of follow-up;
3.  Progression to SDNS syndrome, defined as two consecutive relapses during 
corticosteroid therapy, or within 14 days of ceasing therapy (KDIGO criteria), 
censored at 24 months of follow-up;
4.  Cumulative dosage of prednisolone (mg/m2) during study period, censored at 12 
and 24 months of follow-up.
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Participant timeline (Figure 8.1)
During the period of daily prednisolone, participants determine the timing of remission 
by daily urine dipstick analysis. In order to objectively establish remission of nephrotic 
syndrome, participants are requested to deliver a urine sample to the local hospital 
within 5 days of attaining remission to confirm the absence of proteinuria. During the 
two weeks of alternate day prednisolone and the subsequent 4 weeks of study 
medication, participants are requested to check their urine for proteinuria at least 
weekly. In addition, patients are requested to fill out digital questionnaires at different 
time points (Figure 8.1). As shown in Table 8.2, follow-up information will be collected 
at 1 and 2 years after randomisation and when a relapse occurs. 
Sample size
The sample size calculation is based on the noninferiority design and calculated for 
the primary outcome: time to first relapse after the final prednisolone dose. Based 
on previous data, average time to relapse in the first year is approximately 185 days 
with a standard deviation of 120 days.63 Using the power calculation for a non -
inferiority trial with a continuous primary outcome, a power of 80% and a non- 
inferiority limit of 50 days, 72 patients per group are required. Using a Cox Proportional 
Hazard time-to-relapse analysis (survival analysis), similar numbers can be calculated. 
Figure 8.1 Participant timeline
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Urine dipstick analysis 
Urinalysis for proteinuria, 
within 5 days after remission
1 Daily study log Contact with investigator
Additional time points: Additional time points: 
Digital questionnaires
• 1 year after study medication
• 2 years after study medication
• relapse nephrotic syndrome
• 1 year after study medication
• 2 years after study medication
• relapse nephrotic syndrome
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With an estimated prevalence of nephrotic syndrome of 15 in every 100,000 children, 
a population most at risk between the ages of 2 and 12 years, about 270 children 
may be at risk of developing a nephrotic syndrome relapse each year. The necessary 
inclusion rate is therefore approximately 50%. Subjects will be replaced after with- 
drawal. Based on withdrawal rates of a previous nephrotic syndrome clinical trial in 
The Netherlands a maximum of 23 subjects (=16%) will be replaced.63 The reason for 
withdrawal will be recorded in the medical status report and the trial master file.
Recruitment
Study subjects will be notified about the existence of the RESTERN study via their 
treating physician, the patient associations and/or the study website (www.restern.nl). 
Written informed consent for participation will be obtained from the parents or legal 
representative(s) and/or the patient, depending on the age of the patient. 
Randomisation and blinding
Participants will be randomly allocated in a 1:1 ratio to receive either prednisolone or 
placebo. The randomisation will be performed by the pharmacy of our institute using 
the data management system Castor Electronic Data Capture with stratification for 
treatment with immunosuppressive maintenance therapy. Castor uses a variable block 
algorithm with random blocks of 4, 6, or 8. The randomisation list remains preserved 
by the pharmacy and will not be accessible to the investigators until the end of the 
follow-up of the last patient. An unblinding procedure at the hospital pharmacy 
department will be available at all times. The true group allocation will be unmasked 
only if necessary and after the database is locked. 
Table 8.2  Study questionnaires
Questionnaire Information Time points
Questionnaire 1 General information, medical 
history, relapse information
At the start of alternate day 
prednisolone
Questionnaire 2 Information study medication 
period
One week after initiation of study 
medication
Questionnaire 3 Information after study 
medication period
After the final dose of study 
medication
Questionnaire 4 Information subsequent 
relapses
At the time of a new relapse
Questionnaire 5 Follow-up 1 year One year after randomisation
Questionnaire 6 Follow-up 2 years Two years after randomisation
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Participants are requested to maintain a digital study log in which results from dipstick 
analysis, medication and special remarks are gathered. In addition, participants receive 
digital questionnaires about their medical history, previous relapses and the current 
nephrotic syndrome relapse. Moreover, the digital questionnaires include questions 
about side effects and steroid toxicity at different time points, e.g. during the period of 
daily prednisolone, alternate day prednisolone and study medication. First, patients 
are asked if the different side effects were present during the specific time period. 
Second, the level of inconvenience is assessed (ranging from not at all inconvenient to 
very inconvenient). Local pediatricians and pediatric nephrologists will be requested to 
provide patient information at different time points. Patients randomized who did not 
take their allocated treatment will be considered as having deviated from the protocol. 
If a patient or their representative withdraws consent for data collection, only data up 
to the point of withdrawal will be used in the analysis.
Data management
The study will use the Good Clinical Practice compliant, web-based application Castor 
Electronic Data Capture to record data. Data will be entered in the case report form in 
Castor by the coordinating investigators at the Radboudumc. The digital questionnaires 
will automatically be uploaded in the data management system. 
Statistical analysis
Statistical analysis will be conducted using IBM SPSS Statistics. A p-value <0.05 will be 
considered statistically significant. The main analysis will consist of an intention-to-treat 
analysis. Participants who are lost to follow-up or in whom trial medication is stopped 
prematurely will be analyzed according to their allocated groups. In addition, as inten-
tion-to-treat analysis may increase the risk of type 1 errors in a non-inferiority trial, a 
per-protocol analysis will also be conducted.451 Missing baseline and outcome data 
will not be imputed. When a patient is lost to follow-up or has withdrawn consent, all 
available data up until withdrawal of consent or loss to follow-up will be used. Discrete 
variables will be summarized by frequencies and percentages. Continuously distributed 
variables will be summarized using either mean and standard deviation (SD) for data 
with normal distribution, or median and interquartile range (IQR) for non-normally 
distributed data. Further details regarding statistical analysis of the primary and 
secondary outcomes can be found in the statistical analysis plan.452 
Monitoring
As the standard treatment group will receive the current standard therapy for a 
nephrotic syndrome relapse in the Netherlands, no specific safety surveillance is 
needed for this group. The placebo arm provides the participants with a reduced 
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prednisolone exposure, which is therefore unlikely to result in any adverse events. 
However, the main concern in this study is that the reduced treatment schedule may 
result in an earlier relapse, which is the primary endpoint of the study. An external data 
safety and monitoring board will be convened to monitor safety outcomes and to 
provide the principal investigator with recommendations regarding reconsideration of 
the trial. The data safety and monitoring board will consist of two members: a 
methodologist and a pediatric nephrologist with experience in clinical trials, both 
independent of the trial. Interim analysis performed by the data safety and monitoring 
board, will take place three months after the first 40 participants have received study 
medication. Aim is to check for a significant difference in relapse rate between the two 
groups. Further details about the interim analysis can be found in the statistical analysis 
plan. An independent research coordinator will monitor the study to verify that the 
rights and well-being of human subjects are protected, the reported trial data are 
accurate, complete, and verifiable from source documents and the conduct of the trial 
is in compliance with the currently approved protocol and Good Clinical Practice. The 
coordinating investigators will report the serious adverse events and will submit an 
annual safety report to the medical ethical committee and Competent Authority. 
Ethics and dissemination
Ethics approval
The RESTERN study has been approved by the medical ethical committee of Arn-
hem-Nijmegen and the Dutch Competent Authority (CCMO). The registration number 
of the RESTERN study is NL8185.091.16. The project will be conducted in line with the 
declaration of Helsinki. In addition, all researchers will follow the guidelines for Good 
Clinical Practice and trial outcomes will be reported in line with the Consolidated 
Standards of Reporting Trials (CONSORT) guidelines.453 Any substantial amendments 
or modifications of the protocol will be presented to the medical ethical committee 
and, when approved, be notified to the Competent Authority compliant with EU 
regulations. 
Consent
Written informed consent for participation will be obtained from the parents or legal 
representatives and/or the patient, depending on the age of the patient. Patients will 
be informed that withdrawal from the study is possible at any time at their own 
discretion without necessarily giving reasons. The ‘Code of conduct involving minors’ 
will be used as guideline to respond appropriately to resistance of subjects to study 
procedures as established by the Paediatric Association Of The Netherlands.
562850-L-bw-Schijvens





All patients have their own unique patient identification number as allocated by the 
hospital administration. Source data will be stored confidentially in the hospital 
information system under the subject’s identification number. Participants will also 
receive an identification code, all final study data will be kept under this identification 
number. The investigators safeguard the key to the code. Handling of personal data 
will comply with the Dutch Personal Data Protection Act. Data will be stored until 
fifteen years after publication. 
Dissemination policy
The trial is registered on the Dutch Trial Registry, trial number NTR5670, prior to the 
start of inclusion. After completion of this study, results will be published in national 
and international peer-reviewed scientific journals. Papers will be published according 
to CCMO guidelines. The final report will be made available to trial participants. 
Discussion
The RESTERN study aims to demonstrate that relapses of nephrotic syndrome in 
children can be treated effectively and safely by a reduced duration of alternate day 
prednisolone. Using a nation wide, double-blind, randomised, placebo controlled, 
noninferiority study, the hypothesis will be tested. 
Currently, corticosteroid treatment duration in children with infrequent relapses of 
SSNS is based on empirical recommendations from the ISKDC and APN. The RESTERN 
study is the first randomised placebo controlled clinical trial to investigate a reduced 
corticosteroid schedule for the treatment of relapsing nephrotic syndrome in 
childhood. So far, most studies have been conducted to investigate the initial treatment 
schedule. Recently, it has been shown that a reduction in prednisolone duration for 
the treatment of a first presentation of nephrotic syndrome in children, with or without 
increased cumulative dosage, is clinically safe and results in similar treatment 
outcomes, while potentially reducing side effects.64, 65, 432, 449 For FRNS an abstract 
from a single randomized controlled trial suggests that children with relapsing SSNS 
relapse less frequently if treated with tapering doses of prednisolone for seven months
compared to the standard treatment of two months. Unfortunately, these results have 
never been published, which makes it impossible to examine them closely and evaluate 
for any bias.432(Jayantha UK, 2004, CN-00583710)
In this study a treatment duration of 6 weeks alternate day prednisolone after inducing 
remission for the standard therapy group was chosen as this is the current standard 
therapy in the Netherlands for the treatment of a nephrotic syndrome relapse. As the 
KDIGO recommendation of at least 4 weeks alternate day steroid treatment is based 
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on a rather small study454, the Dutch guidelines traditionally follow the 6 week 
alternate day steroid schedule described by the APN. However, a potential limitation of 
this study could be that some clinicians already reduced the alternate day treatment 
schedule from 6 to 4 weeks after inducing remission based on the notion of this in the 
KDIGO guideline.24 Our choice of 6 weeks alternate day prednisolone may therefore 
discourage eligible patients to participate in our study as this may increase the 
prednisolone duration for some patients. The use of different treatment protocols in 
the Netherlands underlines the need for our randomised controlled trial to determine 
the optimal dosing regimen for a nephrotic syndrome relapse. In case noninferiority is 
shown, our results are also transferrable to the KDIGO recommendation of at least 
four weeks of alternate day steroid treatment. However, in case inferiority is shown, 
additional research is needed.
The results of the RESTERN study may provide evidence to adapt current recommen-
dations for national and possibly international guidelines to treat children with 
relapsing nephrotic syndrome. If corticosteroid exposure could be reduced to treat 
relapses of nephrotic syndrome, this would reduce the toxicity of prednisolone and 
thereby decrease the side effects and long-term complications associated with 
corticosteroid therapy in children with relapsing nephrotic syndrome. 
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Trial status - February 2021
Ethical approval
The protocol of the RESTERN study has been approved by the medical ethical 
committee of Arnhem-Nijmegen and the Dutch Competent Authority in November 
2016. Several amendments were made to the protocol during the conduct of the study 
which were approved by the Competent Authorities and medical ethical committees.
Substantial amendments
Add-on study 1: Psychological questionnaires 
Behavioral problems, quality of life aspects, and parental stress related to childhood 
relapsing nephrotic syndrome are assessed using questionnaires on different 
timepoints during the conduct of de trial. The following questionnaires are used:
1.  The PedsQL is an instrument designed to measure quality of life in children aged 
2-18 years. The instrument measures physical, emotional, social and school 
functioning. It has been evaluated in healthy children and in multiple pediatric 
chronic conditions.
2.  The strength and difficulties questionnaire is a brief behavioral five factor 
instrument developed to assess emotional and behavioral problems in children 
aged 3-16 years. The instrument evaluates hyperactivity/inattention, conduct 
problems, emotional problems, peer related problems and prosocial behavior. 
3.  The Pediatric Inventory for Parents, is a psychometrically valid assessment tool 
measuring parenting stress specific to caring for children with a chronic condition.
Add-on study 2: Prednisolone and prednisone monitoring in saliva 
Monitoring prednisolone concentrations could aid in providing more tailored 
treatment regimens and minimize steroid toxicity. Saliva samples are collected at 
home with Salivette cotton swabs. Sampling is performed at different time-points: 
pre-dose and at 2,4,6 and 8 hours post-ingestion. Parents are instructed to report the 
time of intake and sampling (hours and minutes). In addition, patients are requested to 
not brush their teeth within 30 minutes before sampling, to avoid contamination of 
saliva samples with blood from the oral mucosa. Sampling will take place at the active 
phase of disease (3-5 days after the start of daily prednisolone treatment) and after 
remission is achieved (one week after the start of alternate day prednisolone). To split 
and limit the burden for parents and patients, this add-on study is conducted during 
one of the relapses that occur after the relapse for which the patient was included in 
the RESTERN study.
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Changes in in- and exclusion criteria
1.  At least 1 episode of nephrotic syndrome in the preceding 24 months that  
was treated with prednisolone (removed)
This criterium was initially formulated to exclude patients who will only relapse once or 
twice during childhood and are therefore not able to achieve the primary endpoint 
(time to first relapse). After screening 75 patients we concluded that the aforementioned 
category was basically not present in the study population, however due to this 
criterium we had to exclude a substantial number of patients who are withdrawn from 
maintenance therapy after two years. Therefore, this inclusion criterium was removed. 
2.  Receiving, or within 3 months after receiving, cyclophosphamide or rituximab 
(removed)
This criterium was initially included due to the potential effect of cyclophosphamide 
and rituximab on biobank material. As the biobank was not included in the trial 
anymore, this exclusion criterium was removed.
Changes in study medication
1. Change in standard treatment arm 
After remission is achieved with daily prednisolone for a nephrotic syndrome relapse, 
the standard duration of alternate day steroids is 4 to 6 weeks. In the Netherlands and 
Belgium most clinicians treat the patients with 6 weeks of alternate day steroids. 
In Germany, it is common practice to treat patients with 4 weeks of alternate day 
steroids after remission. Therefore, the standard treatment arm was changed from 
6 weeks of alternate day steroids, to 4-6 weeks of alternate day steroids. This did not 
change the number of patients to be included in the study. 
2. Change in drug formulation for Belgium and Germany
In the Netherlands the drug formulation for the trial is a prednisolone and placebo 
5 mg/ml suspension. Shortly after the trial was approved by the competent authority 
and ethics committees in Belgium, the supplier of the prednisolone for the drug 
suspension terminated supply. An alternative supplier did not possess all documentation 
required by Belgian and German law to be used for the study drug manufacturing. 
No alternative supplier with a Certificate of Suitability (CEP) was available, therefore 
the study drug suspension was ultimately switched towards tablets in Belgium and 
Germany.
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Addition of centers in Belgium and Germany
Trial status
The RESTERN trial is currently in the recruiting phase. The first patient was included in 
December 2016. Currently, 4 years after the start of inclusion, 57 patients are included 
of whom 30 patients received study medication (25 Dutch patients, 3 German patients 
and 2 patients from Belgium). The remaining 27 patients signed up during remission 
and will receive study medication in case of a relapse of nephrotic syndrome. We 
initially planned to include all 144 patients in the Netherlands within 18 months, 
however the inclusion numbers were significantly lower than anticipated. Various 
causes for these significantly lower inclusion rates were identified and actions were 
taken (Table 8.4).
Table 8.3 Centers in Belgium and Germany
Country Center Approval status Patient inclusion
Belgium University Hospital 
of Ghent
Start preparations May 2017
Competent authority March 
2018




Start preparations May 2017
Competent authority March 
2018
Ethics committee June 2018
June 2019
Germany University Hospital 
of Cologne
Start preparations September 
2017
Competent authority July 2019

















Start preparations September 
2020
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Table 8.4   (Potential) obstacles and actions in the design and conduct  
of the RESTERN trial
Number of patients eligible for the study
(Potential) problem Action taken 
Less patients experiencing relapses than 
expected, insufficient patient numbers in 
the Netherlands
Expansion of the trial to Belgium and 
Germany
Longer period of remission due to start of 
immunosuppressive maintenance therapy 
in a large part of SSNS patients
Removal of inclusion criterium 
At least 1 episode of nephrotic syndrome in 
the preceding 24 months that was treated 
with prednisolone 
More patients than expected had daily 
prednisolone maintenance therapy
None, these patients were not eligible for 
the study as this would interfere too much 
with the outcomes of the study. 
Cooperation of study participants and physicians
(Potential) problem Action taken 
Insufficient awareness of the study in 
patients, pediatricians and pediatric 
nephrologists
Newsletters, presentations at national 
and international congresses, updates in 
the national working group of nephrotic 
syndrome (twice a year), presentation at 
national patient day, trial website www.
restern.nl with information on the website 
available in Dutch, German and English. 
The start of another nephrotic syndrome 
trial in the Netherlands may have been 
confusing for pediatricians and pediatric 
nephrologists in the Netherlands and 
Belgium
Newsletters are sent in collaboration with 
coordinating investigator of LEARNS trial, in 
which both studies are explained and clear 
inclusion criteria and contact information 
are provided
Time and effort for international colleagues 
to adjust all documents for submission at 
competent authority and ethics committee
Fees to compensate time for the 
submission process
Patient inclusion in Germany Inclusion fee for pediatric nephrologists 
Study protocol
(Potential) problem Action taken 
The standard treatment for a nephrotic 
syndrome relapse was 6 weeks of alternate 
day steroids after remission was achieved. 
After the study was initiated it became clear 
that a significant part of pediatricians and 
pediatric nephrologists in the Netherlands 
treats relapses of nephrotic syndrome 
with 4 weeks of alternate day steroids. In 
Germany the latter is common practice. 
The standard treatment arm was changed 
from 6 weeks of alternate day steroids, to 
4-6 weeks of alternate day steroids. This did 
not change the number of patients to be 
included in the study.
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Table 8.4   Continued
Study protocol
(Potential) problem Action taken 
Suitability of medicinal product in both 
Belgium and Germany
Different dosing forms for Belgium and 
Germany (capsules, tablets) were explored 
together with our hospital pharmacists
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The quest for optimal 
control of relapses in children 
with nephrotic syndrome
Anne M. Schijvens, Rasmus Ehren, Lutz T. Weber, Michiel F. Schreuder
Kidney International 2019 Mar;95(3):717. 
doi: 10.1016/j.kint.2019.01.002.
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CONTROL OF RELAPSES IN NEPHROTIC SYNDROME
To the editor: In their recent randomized controlled study, Sinha et al.455 compared 
MMF with levamisole in children with FRNS or SDNS. As evidence to guide the choice 
for the best steroid-sparing agent is limited in this patient group, we would like to 
compliment and thank the authors for conducting this head-to-head trial. The authors 
conclude that MMF is not superior to levamisole in patients with FRNS or SDNS. 
However, we believe that this result should be interpreted with caution. As Sinha et al. 
state correctly, the administered dose in this study (750-1000 mg/m2 daily) is 
significantly lower than the dose commonly used (1200 mg/m2 daily),24 and 
mycophenolic acid exposure is well known to influence its steroid sparing capacity 
(Table 9.1). Gellermann et al. previously conducted a head-to-head trial comparing 
MMF (1000-1200 mg/m2) and cyclosporine in children with FRNS.456 Using a post hoc 
analysis they were able to show a difference between patients with low and adequate 
MPA exposure; the latter was accomplished in less than 50% of the patients. Similarly, 
Hackl et al. showed that higher mycophenolic acid exposure was associated with 
improved therapeutic efficacy.457 Using therapeutic drug monitoring to obtain 
adequate mycophenolic acid exposure could therefore lead to significantly lower 
relapse rates. To conclude, we believe an additional randomized controlled trial with 
proven adequate mycophenolic acid exposure is needed to draw a final conclusion 
about the comparability of MMF and levamisole as steroid sparing agent in patients 
with FRNS or SDNS. 
Table 9.1 Influence of mycophenolic acid exposure on relapse rate
Mean relapse rate
Sinha et al. 2018 – MMF group 1.05 relapse/year
Gellermann et al. 2013 – MMF group 0.75 relapse/year
Gellermann et al. 2013 – low MPA exposure
(MPA-AUC0-12 < 50 µg*h/ml)
1.40 relapse/year
Gellermann et al. 2013 – high MPA exposure
(MPA-AUC0-12 > 50 µg*h/ml)
0.27 relapse/year
Hackl et al. 2016 – low MPA exposure
(MPA-AUC0-12 < 45 µg*h/ml)
1.06 relapse/year
Hackl et al. 2016 – high MPA exposure
(MPA-AUC0-12 > 45 µg*h/ml)
0.17 relapse/year
AUC, area under the curve; MMF, mycophenolate mofetil; MPA, mycophenolic acid.
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Pharmacokinetics in children 
with chronic kidney disease
Anne M. Schijvens, Saskia N. de Wildt, Michiel F. Schreuder
Pediatric Nephrology 2020 Jul;35(7):1153-1172. 
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In children, the main causes of CKD are congenital diseases and glomerular disorders. 
CKD is associated with multiple physiological changes and may therefore influence 
various PK parameters. A well-known consequence of CKD on PK is a reduction in renal 
clearance due to a decrease in the GFR. The impact of renal impairment on PK is, 
however, not limited to a decreased elimination of drugs excreted by the kidney. In 
fact, renal dysfunction may lead to modifications in absorption, distribution, transport 
and metabolism as well. Currently, insufficient evidence is available to guide dosing 
decisions on many commonly used drugs. Moreover, the impact of maturation on drug 
disposition and action should be taken into account when selecting and dosing drugs 
in the pediatric population. Clinicians should take PK changes into consideration when 
selecting and dosing drugs in pediatric CKD patients in order to avoid toxicity and 
increase efficiency of drugs in this population. The aim of this review is to summarize 
known PK changes in relation to CKD and to extrapolate available knowledge to the 
pediatric CKD population to provide guidance for clinical practice.
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CKD is a general term for multiple, heterogeneous disorders causing irreversible kidney 
damage, which is a major public health problem worldwide.458 The overall prevalence 
in children ranges from 55-75 per million.4, 5 The causes of CKD in children are very 
different from adults. In fact, in adults diabetic nephropathy and hypertension are the 
main causes of CKD, whereas CKD in children is often caused by congenital diseases 
and glomerular disorders.4, 5 
The kidneys play an important role in handling of drugs, most importantly in excretion. 
A well-known consequence of CKD on PK is a reduction in renal clearance due to a 
decrease in the GFR. The impact of renal impairment on the PK of drugs is, however, 
not limited to a decreased elimination of drugs excreted by the kidneys. PK describes 
the individual steps that determine drug disposition in the body, namely absorption 
from an extravascular site of administration, distribution to various tissues, and 
elimination from the body based on metabolism and excretion (Figure 10.1). In fact, 
CKD is associated with multiple physiological changes and may therefore influence 
extrarenal PK processes, which may increase the risk of toxicity.70, 74, 75 Consequently, 
patients with impaired kidney function are more at risk of altered drug exposure or 
toxic effects than individuals with normal kidney function.76
Drug dosage adjustment guidelines, based on the assumption that systemic clearance 
primarily reflects renal clearance and is proportional to kidney function, are commonly 
used. However, response to drug therapy is often less predictable, which is illustrated 
by the fact that the frequency of adverse drug reactions and other medication related 
problems is higher in patients with kidney disease than in those with normal kidney 
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function.459, 460 Despite numerous published guidelines regarding drug dosing for 
patients with reduced kidney function, there is insufficient evidence to guide decisions 
on many commonly used drugs.461 Moreover, the impact of maturation on drug 
disposition and action should be taken into account when dosing drugs in children. 
Evidence on the impact of growth and development on absorption, distribution, 
metabolism and excretion (ADME) of drugs has increased significantly over the years.11 
However, the exact interplay between age and disease on PK, PD, and dose requirements 
remains poorly understood.11, 71 Furthermore, the majority of drugs prescribed in 
children are off-label462, 463, which limits the evidence on drug dosing in pediatric CKD 
patients even further. Clinicians should take PK changes into consideration when 
selecting and dosing drugs in children with CKD in order to avoid toxicity and to 
increase efficiency of drugs in this population. Unfortunately, very little information is 
available on PK changes in pediatric CKD patients. Therefore, data from animal studies, 
non CKD children, and clinical studies in adult CKD patients are used to get an 
appreciation of the possible impact of these conditions on the PK in pediatric patients. 
The aim of this review is to summarize known PK changes in relation to CKD with 
respect to absorption, distribution, metabolism and excretion and extrapolate 
available data to the pediatric CKD population to provide knowledge for clinicians 
prescribing drugs in this vulnerable population. 
Absorption
Absorption describes the extent to which an intact drug is absorbed after oral 
administration from the gut lumen into the portal circulation. Several factors are 
known to have an impact on absorption, such as dissolution of the drug, the gastric 
emptying rate, gastric pH, intestinal motility, drug interactions, and passage through 
the gut wall.464 Some of these factors may vary with growth and development. 
Ultimately, this may result in changes in the drug absorptive capacity at different ages 
in the individual pediatric patient.11 Maturational changes in the gastrointestinal tract 
were reviewed by Neal-Kluever et al.465 and Mooij et al.466 The absorption and bio-
availability of drugs is highly variable in patients with CKD, in whom several pathophys-
iological changes in the gastrointestinal tract have been identified that may impact 
drug absorption.75 Thus far, only little research has been conducted to investigate the 
influence of CKD on drug absorption in children. 
Gastric emptying
Impact of age in non CKD children
Bonner et al. investigated the impact of age and other covariates on the rate of gastric 
emptying by analyzing published data on approximately 1500 individuals ranging from 
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premature neonates to adults. A model-based meta-analysis indicated that age itself is 
not a covariate of gastric emptying.467 Similarly, Billeaud et al. showed that in children 
between 0 and 1 year old, gastric emptying did not vary with age.468 On the contrary, 
Anderson et al. reported slow absorption of acetaminophen in neonates, with a 
significant increase in the first days of life, suggesting fast maturation of gastric 
emptying in early life.469 Furthermore, gastric emptying appears to be slower in 
preterm neonates compared to term neonates.470
Adult CKD patients
Patients with CKD may suffer from delayed gastric emptying for which several patient 
characteristics and external factors can be identified, including peritonitis, peritoneal 
dialysis, and pharmacotherapy (e.g. aluminium containing antacids, opioids).74, 471 
Results on gastric emptying in adult CKD patients are conflicting ranging from no 
obvious impairment to a significant delay in over 30% of the population.472-474 
Ultimately, decreased gastric emptying in CKD patients affects the time to reach the 
maximum drug concentrations and peak plasma drug concentration, but is not 
expected to have an impact on bioavailability.475, 476 
Pediatric CKD patients
Ravelli et al. investigated gastrointestinal function in 12 pediatric CKD patients and 
found both delayed (n=5) as well as accelerated (n=2) gastric emptying.477 Furthermore, 
Ruley et al. showed that gastroesophageal reflux, as a manifestation of gastrointestinal 
dysmotility, was present in 73% of the pediatric CKD patients.478 
Gastric pH
Impact of age in non CKD children
Changes in the gastric pH may influence the bioavailability of many drugs. In children, 
gastric pH is neutral at birth due to fetal ingestion of alkaline amniotic fluid.479 In the 
first few hours after birth, after amnion fluids are removed from the stomach, a rapid 
decrease in pH is noticed, most likely explained by gastric secretion.479 Generally, as 
reviewed by Mooij et al. mean gastric pH remains around 2 or 3 in children of all 
ages.466 Gastric pH rises after feeding, however as pH rapidly decreases again and 
most children receive intermittent feeding, the effect on absorption of acid-labile 
drugs is limited.480 On the contrary, one may hypothesize that in children with very 
frequent or continuous milk-based feeding regimens acid-labile drugs may be absorbed 
more efficiently due to a persistent higher gastric pH. 
Adult CKD patients
CKD patients often have an increased gastric pH, which may have several causes. For 
instance, patients with renal dysfunction have increased blood urea nitrogen. Excess 
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salivary urea is converted to ammonia by gastric urease enzymes, resulting in increased 
gastric pH.481, 482 Furthermore, patients are often treated with antacids, H2-receptor 
antagonists, or proton-pump inhibitors that alter gastric pH.483 The resulting increase 
in gastric pH may affect the ionization and dissolution of drugs that are soluble in acidic 
environments, like furosemide or iron therapy, and reduce their bioavailability by 
approximately 20% and 50%, respectively.484, 485 
Pediatric CKD patients
Currently, studies on gastric pH in children with CKD are limited. However, feedings 
problems, anorexia and recurrent vomiting are prevalent problems in pediatric CKD 
patients.486, 487 Ravelli et al. investigated the percentage of time spent with an in-
traoesophageal pH below 4 and found significantly higher mean values in pediatric 
CKD patients compared to age matched controls. Concomitant drug use was, 
unfortunately, not reported in these patients.477 
Formation of insoluble salts or metal ion chelates
Some of the drugs administered in patients with CKD may alter the absorption of other 
drugs. The ingestion of cation-containing antacids (e.g. sevelamer hydrochloride, 
lanthanum carbonate) and minerals (e.g. calcium, magnesium) may reduce drug 
absorption because of chelation with co-administered medications, resulting in the 
formation of insoluble salts or metal ion chelates.475, 488 For example, bioavailability of 
oral ciprofloxacin was significantly decreased when co-administered with sevelamer 
hydrochloride or calcium acetate by 48% and 51%, respectively, due to formation of 
chelate complexes.488, 489 
Intestinal transport and metabolism
After ingestion, the drug reaches the lumen of the gut, where it may either passively 
diffuse or be actively transported by uptake transporters across the apical membrane 
into the enterocyte. Once inside the enterocyte, drugs can be actively excreted by 
transporters or metabolized by intestinal enzymes.490 The most important drug 
metabolizing enzyme family is the CYP family, with the CYP3A4 isoenzyme as most 
prevalent drug-metabolizing enzyme. The CYP3A subfamily is present in the intestine, 
more specifically in the villi, in abundance and contributes to the first-pass metabolism 
of several CYP3A4 substrates such as midazolam, cyclosporine, and tacrolimus.491-494 
In addition to the intestine, other organs, including the liver contain a diversity of drug 
metabolizing enzymes as well.492, 493 More detailed information regarding drug 
metabolizing enzymes is given in the metabolism section of this review. Drug 
transporters are transmembrane proteins facilitating the passage of both drugs and 
other xenobiotics across biological barriers.495 Transporters are characterized as 
either influx transporters, which facilitate transport into the cell, or efflux transporters, 
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facilitating the transport out of the cell. The presence of transporters is not limited to 
the gut.496 In fact, multiple uptake and efflux transporters are expressed in the 
membranes of the intestines, liver and kidneys (for a review on these transporters, see 
497, 498). An example of an important drug efflux transporter in the gastrointestinal 
tract and hepatobiliary system is P-gp. P-gp is an ATP-dependent efflux pump expressed 
on the apical membrane of tissues, which are often exposed to high concentrations of 
xenobiotics. The function of P-gp is to protect the body against the toxic compounds 
by transporting those out of the cell and the body via the intestinal lumen, bile, or 
urine.499, 500 Conversely, organic anion-transporting polypeptides (OATP) are a group 
of uptake transporters expressed on the basolateral surface of membranes with a 
similar tissue distribution of P-gp.495 OATP mediates the transport of mainly organic 
anions across the cell membrane into the cell. 
Impact of age in non CKD children
In general, little is known about transporter gene expression in children. Furthermore, 
evidence on the ontogeny of the different influx and efflux transporters in children is 
limited.11, 501 The ontogeny of expression of P-gp was investigated in 59 normal 
duodenal biopsies of children aged 1 month to 17 years. Fakhoury et al. found P-gp 
mRNA expression levels to be highly variable and unrelated to age.502 In addition, 
Mooij et al. observed stable intestinal P-gp mRNA expression from neonatal to adult 
age, confirming the aforementioned finding.503 In contrast, multidrug resistance- 
associated protein 2 (MRP2), another intestinal efflux transporter, showed a different 
pattern, with similar mRNA expression levels in neonates and adults, but significantly 
decreased levels in children age 1-12 months.503 Furthermore, intestinal OATP2B1 
messenger RNA expression levels were higher in neonates compared to adults. In 
children with an age range of 1-12 months, messenger RNA expression levels reached 
adult values.503 To our knowledge, no in vivo studies have been conducted to 
investigate activity of intestinal drug transporters in pediatric patients. Drug 
metabolizing activity may change significantly from fetal to adolescent age. Data 
regarding the expression of CYP3A enzymes in the gut wall in children are contradictory, 
ranging from an increase with age to the opposite pattern of a decrease with age. 
Johnson et al., investigated enterocytic CYP3A expression in duodenal biopsies in 
fetuses and children (age range 2 weeks – 17 years) and found a significant increase in 
CYP3A4 expression and activity with age.504 In contrast, another study showed high 
CYP3A4 messenger RNA expression levels in the first year of life, followed by a decrease 
with age.502 Using a physiological population PK modeling approach, Brussee et al. 
simulated intestinal CYP3A4 activity per gram of organ to remain relatively constant 
throughout childhood, indicating that organ growth appears the most important 
contributing factor to the increase in intrinsic CYP3A clearance in the gut wall.505 Using 
a similar approach, low CYP3A activity in the gut wall was found in preterm neonates, 
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yielding a low first-pass effect and higher bioavailability in this patient group compared 
to adults.506 The ontogeny of other intestinal drug-metabolizing enzymes is still largely 
unknown. 
Animal studies
CKD may increase bioavailability of drug substrates due to downregulation of transporters 
and enzymes in the enterocytes. A decrease in intestinal drug efflux activity may lead 
to increased bioavailability and increased systemic exposure of various drugs, such as 
CNIs.70 Evidence supporting this phenomenon is mostly based on animal studies using 
CKD models.507, 508 Leblond et al. showed that CKD in rats is associated with a decrease 
in intestinal CYP1A1 and CYP3A2 activity509, whereas intestinal CYP3A function was 
investigated in several clinical studies by using phenotyping probes and appeared not 
to be substantially altered in patients with end stage renal disease (ESRD).510-512 Veau 
et al. found a reduction in intestinal drug elimination in CKD rats due to a significant 
decrease in P-gp transport activity without a decrease in protein expression.508 
Moreover, Naud et al. showed a significant reduction in both transport activity as well 
as protein expression of intestinal P-gp in CKD rats.507
Pediatric CKD patients
A frequently observed interaction in pediatric nephrology is the effect of diarrhea on 
tacrolimus levels in kidney transplant recipients. Tacrolimus is extensively metabolized 
by CYP3A4 and is a substrate for P-gp. Oral bioavailability of the drug is low, due to 
metabolism in the small intestine by CYP3A4 and active secretion into the gut lumen 
by P-gp.513 The concentration of CYP3A4 enzymes decreases from the duodenum to 
the colon. In case of severe diarrhea, the gastrointestinal transit time is decreased. This 
could be an explanation for an increased oral tacrolimus bioavailability as the drug is 
shunted to the colon with lower intestinal metabolism.514 Furthermore, the epithelial 
cells of the intestine may be damaged during the course of diarrhea. This may reduce 
the enzymatic activity of CYP3A4 and/or P-gp in the enterocytes and will subsequently 
lead to increased levels of tacrolimus (Figure 10.2).515, 516 Taken together, CKD induced 
reduction in intestinal metabolism and P-gp-mediated drug transport might result in 
increased oral bioavailability of certain drugs. Therefore a decrease in dose may be 
necessary for drugs that are substrates for P-gp and/or CYP3A4.70, 517
Bowel wall edema 
Gastro-intestinal edema has also been identified as a potential cause of altered drug 
absorption, particularly in CKD patients with concomitant cirrhosis or congestive heart 
failure.74, 518 Bowel wall edema increases intestinal permeability and may therefore 
impair the intestinal barrier function in CKD patients.518
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After absorption, drugs distribute to target tissues and sites of elimination in the 
systemic circulation. The Vd represents the parameter relating the concentration of a 
drug in the plasma to the total amount of the drug in the body. Several physiologic 
variables may affect the Vd, including physicochemical properties of the drug (e.g. size, 
charge, acid dissociation constant, water solubility, lipid solubility), plasma protein 
binding, tissue binding, and total-body water. With the exception of the physicochem-
ical properties of the drug, these variables may be affected in children with CKD.75 
Unfortunately, no clinical data are available in pediatric kidney transplant patients. 
Figure 10.2 Impact of CKD and diarrhea on tacrolimus bioavailability














Processed on: 16-7-2021 PDF page: 206
206
CHAPTER 10
Therefore, age related changes in non CKD children and clinical data in adult CKD 
patients are summarized below. 
Protein binding
Many drugs are extensively bound to plasma proteins, and the Vd is highly dependent 
on the protein binding of the drug. Protein binding limits drug distribution as only the 
unbound concentration of the drug is able to cross cellular membranes and distribute 
outside the vascular space and is therefore pharmacologically active.490 The major 
drug binding proteins in plasma are albumin and alpha1-acid glycoprotein (AAG). Acidic 
drugs are bound to albumin, whereas alkaline drugs primarily bind to AAG. AAG is an 
acute phase protein with one binding site for alkaline drugs. 
Impact of age in non CKD children
Children generally have lower concentrations of the important binding proteins, which 
is most pronounced in newborns and young infants.519 Furthermore, in newborns, 
fetal albumin (with a reduced binding affinity for weak acids) and endogenous 
substances, such as bilirubin, are present. This contributes to higher free fractions of 
highly protein bound drugs, due to the capacity of these substances to displace a drug 
from the albumin binding sites.520 Clinical implications are especially present for highly 
protein-bound drugs with a narrow therapeutic index, such as vancomycin.521
Adult CKD patients
AAG is reported to be increased up to three times in CKD patients and patients on 
dialysis as a result of chronic inflammation.483, 522, 523 In line with this, an increased 
plasma binding of alkaline drugs, such as propranolol and cimetidine, has been 
demonstrated in vitro.524 In vivo AAG binding, however, generally appears to be 
unaffected in patients with CKD.483, 524-526 Plasma protein binding of acidic drugs, such 
as penicillin, cephalosporins, furosemide and phenytoin, is often decreased in vivo in 
CKD patients.483, 526 This decrease has been suggested to be due to proteinuria or 
malnutrition related low plasma albumin, conformational change of the albumin 
binding sites due to uremia, or the accumulation of competitive inflammatory factors, 
protein-bound uremic toxins and/or drug metabolites competing with the acidic drugs 
for protein binding sites.527, 528 The last factor appears, however, to be most 
important.529 A decrease in protein binding leads to an increase in the unbound 
fraction of the drug. Generally, this has no significant clinical implications as the 
unbound drug is readily available for elimination and distribution in tissues, leading to 
increased clearance and Vd. (Figure 10.3) The overall effect is a new steady state 
situation in which the concentration of unbound drug and therefore pharmacological 
effect is unaffected.530 This phenomenon can be illustrated by the distribution of 
phenytoin in CKD patients. Phenytoin is highly protein bound (90%) in healthy and 
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around 80% in CKD patients, but the pharmacologically active, unbound concentration 
in plasma is unaffected.531 The decreased total plasma concentration could be 
misinterpreted as a need for dose correction, subsequently, the increase in dose may 
produce toxicity with no increased effectiveness. 524 Ideally, free concentrations 
should therefore be monitored for highly protein bound drugs with narrow therapeutic 
indices in CKD patients.
Tissue binding
Vd may also be affected by altered tissue binding, e.g. in patients with ESRD. The Vd of 
digoxin can be reduced by 50% due to decreased tissue binding.73, 532, 533 Potentially 
due to a reduction in tissue levels of Na/K-ATPase, the major tissue-binding site for 
digoxin.534 The reduction in Vd may result in increased serum concentrations if the 
loading dose is not reduced. However, the pharmacological effect of digoxin correlates 
with the amount of drug in the myocardium and Jusko et al. reported the myocardi-
um-to-serum concentration ratio of digoxin to decrease in parallel with renal 
clearance.532 Therefore, a decrease in loading dose may not be necessary. Moreover, 
as toxic effects also rely on the presence of tissue binding sites, increased serum 
concentrations may not lead to toxic effects.535 
Fluid retention 
CKD may cause severe changes in body composition. Furthermore, body composition 
changes with age and may affect the physiological spaces into which a drug will 
distribute.71 An already physiological large total body water compartment in a neonate, 
combined with a higher total body water due to CKD could result in a significantly 
increased Vd.462 Excessive fluid retention, manifesting as increased extracellular fluid 
such as edema or ascites, is expected to increase the Vd of hydrophilic drugs. An 
increase in extracellular fluid volume will have the greatest effect on hydrophilic drugs 
with low to moderate Vd (i.e., <0.7 L/kg), such as aminoglycosides and cephalospo-
rines, resulting in lower plasma and tissue concentrations.517 However, as aminoglyco-
sides and cephalosporines are largely excreted unchanged in the urine, a decrease in 
kidney function also causes a prolonged half-life and will lead to increased drug 
concentrations. 
Metabolism
Nonrenal clearance includes all routes of drug elimination, including metabolism, 
except for renal excretion of unchanged drugs. In fact, only few drugs are excreted 
unchanged by the kidney. Metabolism is the major mechanism for elimination of drugs 
from the body.536 Drug metabolism is classified as either a phase I or a phase II reaction. 
562850-L-bw-Schijvens




The major enzymes responsible for phase I metabolism are the CYP enzymes.537 The 
most abundant CYP enzyme, CYP3A is responsible for the metabolism of many 
drugs.538 The most important groups of drug metabolizing enzymes in phase II 
metabolism are the superfamily of uridine 5’-diphospho-glucuronosyltransferases 
(UDP-glucuronosyltransferases, UGT). For comprehensive information regarding CYP 
substrates, inhibitors, and inducers see Flockhart table (Flockhart DA. Drug Interactions: 
Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 
(2007). “https://drug-interactions.medicine.iu.edu”). 
Hepatic metabolism
CKD may have various effects on the metabolism of drugs. Decreased protein 
expression, messenger RNA expression, and/or activity of several nonrenal clearance 
pathways have been reported in experimental animal models of CKD.539, 540 Decreased 
functional expression of hepatic drug metabolizing enzymes could lead to a reduction 
in hepatic clearance of relevant substrates. Thus far, the exact mechanism by which 
CKD may affect PK of non-renally eliminated drugs is not entirely understood. However, 
the most important hypothesis is direct inhibition of nonrenal clearance pathways by 
accumulated uremic toxins. Due to kidney failure, molecular breakdown products, 
which are normally eliminated by the kidneys, now accumulate in the body. These 
molecular breakdown products include urea, inflammatory cytokines, and indoxyl 
sulfate, also known as uremic toxins.541, 542 Uremic toxins cause downregulation of 
gene expression mediated by proinflammatory cytokines and directly inhibit the 
activity of CYP enzymes and drug transporters.
Impact of age in non CKD children
Maturational changes are well known to occur in the drug metabolizing enzymes and 
have a clear impact on drug disposition in children.543 Age dependent changes are 
enzyme and organ specific. For instance, hepatic CYP3A7 is present at birth and 
almost disappears after infancy.544 In contrast, CYP3A4 appears in the first week of 
life and reaches 30-40% of adult activity after one month.544 CYP3A4 reaches an adult 
level of activity at the end of childhood, while CYP3A5 activity appears stable, 
but with large genetic variation.538, 543 While the ontogeny of hepatic phase I metabolism 
is increasingly known, our knowledge on phase II metabolism lags behind.545 A well- 
known example of UGT maturational changes, is the development of the potentially 
lethal grey baby syndrome in neonates receiving chloramphenicol, which is a 
consequence of accumulation in the body due to immature glucuronidation by 
UGT2B7.546, 547 Similarly, neonatal glucuronidation of morphine (a UGT2B7 substrate) 
is decreased in newborns compared with adolescents.548, 549 For additional reviews on 
metabolism including ontogeny of drug metabolizing enzymes and age related changes 
in metabolism of drugs, please see550, 551.
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The expression and activity of CYP3A in CKD patients has been studied in several 
experimental models and clinical studies.540, 552 Leblond et al. showed a significant 
decrease in total liver CYP activity (mainly in CYP2C11, CYP3A1, and CYP3A2) secondary 
to reduced gene expression in rats with CKD.553, 554 Furthermore, phase II drug 
metabolizing enzymes may also be affected by CKD. For example, Simard et al. showed 
a decrease in N-acetyltransferases (Nat)1 and Nat2 protein and Nat2 activity secondary 
to a decrease in gene expression in CKD rats causing a decrease in drug acetylation.555
Adult CKD patients
Yoshida et al. investigated the effect of CKD on the PK of in vivo model drugs of 
CYP3A4/5 in humans and found a modest but variable effect.539 The effect of CKD on 
the expression of CYP3A, however, might be a reflection of changes in transporter 
function rather than a change in enzyme activity itself. This hypothesis is supported by 
the fact that the PK of midazolam, a CYP3A substrate neither a P-gp nor an OATP 
substrate, is not altered in CKD patients.512 In contrast, in vivo CYP2B6, CYP2C19, 
CYP2D6 and CYP2E1 decreased in parallel with the degree of CKD.539, 556 Furthermore, 
changes to CYP1A2, CYP2C9, CYP2C8 due to CKD appear limited.557, 558 Osborne et al. 
showed a significant increase in the area under the curve of morphine in CKD patients 
compared to control subjects, which suggests reduced UGT2B7 activity, but a role of 
the organic cation transporter (OCT1) transporter cannot be excluded.559 
Excretion
Biliary excretion
Biliary excretion eliminates substances from the body when the secreted drug is not 
reabsorbed from the intestine (enterohepatic cycle). Little is known on the 
developmental changes in biliary excretion in children.560 Alterations in various biliary 
efflux transporters have been found in experimental models of CKD. An increase in the 
expression of hepatic efflux transporters, including P-gp, was reported resulting in an 
increase in biliary excretion.561 In contrast, the protein expression of uptake transporter 
OATP2 was found to be decreased in animal studies, causing a reduction in biliary and 
metabolic clearance.561 This was confirmed in vivo by Nolin et al.512 
Renal excretion
Only few drugs are excreted almost entirely unchanged by the kidney, for instance 
aminoglycosides and penicillins.562, 563 Renal drug clearance is the net result of three 
processes: filtration at the glomerulus, active secretion and reabsorption by the 
proximal tubule, and passive reabsorption in the kidney tubules. According to the
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‘Intact Nephron Hypothesis’ all segments of the nephron are equally affected by the 
development of any type of renal disease.526, 564 This suggests that, regardless of the 
intrarenal pathways of excretion, the loss of excretory function in the diseased kidney 
can be quantified by GFR. However, depending on the cause of renal dysfunction, the 
normal histology of the glomeruli and the tubules may be differentially affected.565
Glomerular filtration
As blood passes through the glomerulus (±1000 ml/min in an average adult), about 
20% of the plasma is filtered into the renal tubule (GFR 120 ml/min). Furthermore, the 
unbound drug in plasma water is filtered as well, whereas drugs bound to plasma 
proteins are not filtered. Glomerular filtration depends on kidney blood flow, which 
can decrease when a reduced cardiac output or volume depletion is present.70 GFR is 
often used as an indicator of overall kidney function. 
Impact of age in non CKD children
At the transition from fetal to extrauterine life, the glomerular filtration needs to 
develop. By 36 weeks of gestation, nephrogenesis is complete.566 After birth, nephrons 
are slowly recruited as reviewed by Filler et al.567 In term neonates GFR is just 2-4 ml/
min/1.73m2, it doubles by 1-2 week(s) of age, reaching adult values at approximately 
12-24 months of age.568, 569 Furthermore, GFR continues to increase after reaching 
adult values until prepubescent age, resulting in a higher clearance compared to 
adults.570, 571 The development of GFR is slowed in preterm born neonates, even 
though normal values are reached in the end.568 Maturation of the glomerular filtration 
and the different patterns depending on perinatal circumstances on this maturation 
have a major impact on renal drug clearance.
Adult CKD patients
Endogenous creatinine clearance is frequently used as a measure for GFR. However, a 
discrepancy may be present between endogenous creatinine clearance and GFR, 
which is most pronounced in subjects with low GFR. This is due to an increasing tubular 
secretion of creatinine with increasing serum creatinine.572, 573 In that case, creatinine 
clearance overestimates GFR. Moreover, muscle mass is typically decreased in patients 
with severe renal dysfunction, leading to a reduced production rate.573 Furthermore, 
tubular secretion of creatinine can be inhibited by various drugs. Examples of drugs 
that inhibit creatinine secretion include: triamterene, spironolactone, amiloride, and 
trimethoprim.574-576 In general, the GFR is decreased in CKD patients. According to the 
‘Intact Nephron Hypothesis’ all segments of the nephron are equally affected by the 
development of any type of renal disease.526, 564 This suggests that, regardless of the 
intrarenal pathways of excretion, the loss of excretory function in the diseased kidney 
can be quantified by GFR. However, depending on the cause of renal dysfunction, the 
normal histology of the glomeruli and the tubules may be differentially affected.565 
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In CKD patients not only the drug itself may accumulate; accumulation of drug 
metabolites that are primarily excreted by the kidneys may also be an issue.577, 578 Due 
to a decrease in GFR, patients will be exposed to prolonged drug effects or even 
toxicity if the metabolites are pharmacologically active, especially if a large percentage 
of the active metabolite is excreted unchanged by the kidney under normal 
circumstances. A well-known example of this phenomenon is the administration of 
morphine in CKD patients. Renal excretion of morphine itself only accounts for 
approximately 4% of its overall elimination. However, patients with renal dysfunction 
may show typical signs of morphine intoxication when given standard doses of 
morphine. Studies have shown that the major morphine metabolites, which are 
normally excreted by the kidney, extensively accumulate in patients with renal 
dysfunction.579, 580 Thus, despite the fact that the kidneys are only marginally involved 
in the elimination of morphine, patients with CKD can still show signs of morphine 
intoxication due to accumulation of active metabolites. Moreover, uremic toxins can 
compete with acidic drugs for active secretion by the kidney.581
Active tubular secretion
In the proximal tubule several transporters are present to facilitate both tubular 
secretion and tubular reabsorption of drugs, exogenous, and endogenous substances. 
Transporters are localized at the basolateral and apical membrane of the proximal 
tubular epithelial cells.582 For some compounds active secretion is significant, and 
therefore, the renal clearance exceeds the GFR. This is the case with creatinine, but 
this can also occur with drugs, such as metformin and amoxicillin.583, 584 
Impact of age in non CKD children
As reviewed by Brouwer et al. little evidence is available on the ontogeny of drug 
transporter expression in the human developing kidney. However, from both animal 
and human studies one may conclude that renal transporters appear to mature at 
different rates.560 Para-aminohippurate (PAH) clearance, a substrate of OAT1, was low 
at birth, with an increase in the first weeks of neonatal life, reaching adult levels around 
one year of age.585-587 Similarly, Momper et al. reanalyzed previously published data 
on the maximum tubular secretory capacity of PAH from 119 neonates, infants, and 
children. The maximum tubular secretory capacity of PAH was low in the immediate 
postnatal period, increased markedly after birth, and reached 50% of the adult value 
at 8 years of age.588 While PAH clearance may reflect OAT1 maturation, it cannot be 
excluded that these findings can also be explained by maturation in renal blood flow, 
as PAH is also a marker of renal blood flow. Digoxin is excreted by glomerular filtration 
and extensively secreted in the proximal tubule by P-gp. Pinto et al. investigated 
age-dependent expression of renal P-gp in mice and its correlation with changes in the 
clearance rate of digoxin. A significant correlation between P-gp expression and 
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digoxin clearance values was found.589 In line with these results, young children need 
significantly higher doses of digoxin per kg body weight than adults. This cannot be 
explained by GFR changes alone and may indicate higher renal P-gp expression in 
young children than adults.
Animal studies
Komazawa et al. investigated transport activity of renal transporters in CKD rats and 
showed a decrease in tubular function in line with a decrease in glomerular filtration. 
Expression levels of Oat1, Oat3, Oct1, and Oct2 were found to be decreased in CKD 
rats. In contrast, levels of P-gp were significantly increased.590 Similarly, Naud et al. 
also examined the effects of CKD on the expression and activity of the major renal drug 
transporters in rats. A significant correlation was found between the clearance of 
creatinine and the protein expression of transporters. In contrast to Komazawa et al., 
P-gp was found to be significantly reduced. 591
Adult CKD patients
Contrary to the Intact Nephron Hypothesis, it has been shown that, depending on the 
underlying cause of CKD, active secretion can increase relative to glomerular clearance 
and does not necessarily show a decline in parallel with the decline in glomerular 
filtration.565, 592 For instance, in patients suffering from glomerulonephritis, drug 
clearance may be maintained relative to the reduced GFR by preservation of active 
tubular secretion.593 Hsueh et al. reviewed clinical studies regarding the inhibition of 
OAT1 and OAT3 in CKD patients and their data suggest that uremic solutes contribute 
to the decline in renal drug clearance in CKD patients by inhibition of OAT1 and 
OAT3.594 One may hypothesize that reduction in uptake transporters due to uremic 
toxins may lead to increased circulating drug levels in human as well.
Tubular reabsorption
Most of the 120 ml/min of plasma water filtered at the glomerulus is reabsorbed 
during its passage through the renal tubule and in the end only about 1-2 ml/min 
appears as urine. Reabsorption of water occurs along the entire nephron, yet, the 
majority is reabsorbed in the proximal tubule.595 As plasma water is reabsorbed, a 
concentration gradient appears between drug in the tubules and unbound drug in the 
blood. For the majority of drugs and drug metabolites, tubular reabsorption takes 
place by passive diffusion. If the drug is able to pass through the membranes of the 
tubular cell, it moves down this concentration gradient and is reabsorbed from the 
tubular fluid black into the blood. Many vital endogenous compounds, including 
vitamins, electrolytes, and amino acids are actively reabsorbed via transporters.595 
Several transporters, such as OAT4, urate transporter 1 (URAT1), peptide transporter 2 
(PEPT2), organic cation and carnitine transporters OCTN1, OCTN2 reabsorb selected 
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compounds.582 In line with the maturation of transporters involved in tubular 
secretion, little data are available regarding the ontogeny of transporters involved in 
tubular reabsorption, as reviewed by Brouwer et al.560
Renal metabolism
As CYP enzyme activity in the human kidney homogenate is about 14-18% of hepatic 
enzyme activity, renal impairment could affect renal drug metabolism.596, 597 
Impact of age in non CKD children
The administration of ifosfamide for the treatment of solid tumors in children may 
illustrate the ontogeny of renal metabolism. Ifosfamide is metabolized into the toxic 
metabolite chloroacetyldehyde.598 Aleksa et al. investigated the expression of CYP3A 
expression in pigs, showing low levels in early life, followed by a significant increase in 
both CYP3A expression and ifosfamide metabolism with age followed by a decrease to 
adult levels.599 Subsequently, ontogeny in renal CYP3A enzyme activity may explain 
why younger children (median age 2.2 years) treated with ifosfamide experience more 
severe nephrotoxicity compared to older children.600
Adult CKD patients
The active form of vitamin D, calcitriol (1,25 dihydroxycholecalciferol vitamin D3), is 
taken by patients with CKD to increase calcium absorption and prevent bone disease. 
Metabolic activation of vitamin D (from diet or synthesized in the skin) to calcitriol 
requires hydroxylation of 25-hydroxycholecalciferol at the 1alpha-position in the 
kidney.601 Therefore, in patients with CKD, it may be better to administer vitamin D in 
the form of calcitriol or 1α-hydroxycholecalciferol.74
Drug dosing
As summarized in this review, several PK parameters may be altered in CKD patients. 
The bioavailability of certain drugs may be decreased due to increased gastric pH and 
formation of insoluble salts, necessitating a dose increase. In contrast, for other drugs, 
bioavailability may be increased due to downregulation of transporters and enzymes 
in enterocytes, and a lower dose should be administered. Alterations in protein and 
tissue binding and body composition, may impact the Vd, requiring an increase or 
decrease in dose. Furthermore, CKD may have various effects on drug metabolizing 
enzymes and transporters. A well-known effect of CKD is a decreased GFR. However, 
depending on the cause of renal dysfunction, tubular secretion can be affected to a 
different extent. Individual patient and drug characteristics should be taken into 
account when proposing an alternative, individual dosing regimen. In children, 
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developmental changes cause variations in absorption, distribution, metabolism, and 
excretion over time. All changes should be taken into account when selecting and 
dosing drugs in children. 
Taken together, it is difficult to develop generic drug dosing guidelines for pediatric 
CKD patients due to a large variability in PK changes in CKD and maturational changes 
in children. Both sub- or supratherapeutic dosing can occur when the appropriate dose 
adjustments are not made in (pediatric) patients with kidney disease. Subtherapeutic 
dosing increases the risk of treatment failure, supratherapeutic dosing increases the 
risk of toxicity. A practical approach to adjusting drug doses in CKD is to assume that 
renal drug clearance will decrease in proportion to GFR, and that nonrenal clearance is 
unchanged, which is also known as the Dettli method.602, 603 However, this would 
ignore the role of other processes involved in PK, including the alteration of the 
functional expression of numerous drug metabolizing enzymes and drug transporters, 
and tubular function.75 In children, PK may be different from adult healthy and CKD 
patients due to growth and development and the underlying changes in the processes 
involved in absorption, distribution, metabolism, and excretion. Linear extrapolation 
of doses from adults will lead to under- or overdosing, dependent on the age of the 
child and the relevant disposition pathways of the drug. In pediatrics, dose adjustments 
are undertaken to obtain adequate exposure and PD effects. Still to date, for half of all 
drugs, high quality data are lacking to support the optimal effective and safe drug dose 
in children, as reflected by this percentage of drugs being prescribed off-label to 
children.604 In a project by the Dutch Pediatric Formulary we found that evidence to 
support dosing guidelines in pediatric patients with CKD, remains especially limited 
(unpublished data). Consequently, current dosing guidance in pediatric patients with 
CKD in the Dutch Pediatric Formulary and other dosing guidelines, such as the online 
Pediatric Drug Handbook, is derived from adult data and often excludes young infants 
and neonates.605, 606
Nevertheless, although drug-specific data are lacking in this vulnerable population, a 
few basic principles can be kept in mind to guide dosing adjustments in children with 
CKD. The important principles to consider include the therapeutic index of the drug, 
the presence of active metabolites that are eliminated by the kidneys, and the extent 
of reduction in kidney function. In Table 10.1, dosing advice for pediatric CKD patients 
is given for a few drugs, based on the PK processes affected (ADME). This table includes 
both commonly prescribed drugs as well as drugs that are illustrative of one of the 
specific PK processes.
Basic principles of dose adjustments in CKD
Drug exposure relates to the maximum plasma concentration and/or the AUC. In 
general, supra-therapeutic exposures increase the risk of dose-related adverse drug 
reactions, and subtherapeutic exposure the risk of ineffective therapy. As infections 
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Table 10.1   Dosing advices for pediatric CKD patients for 18 different drugs,  
based on the PK processes affected
Drug Vd (L/kg) PPB
(%)
Mode of elimination Effect CKD
Absorption
Propranolol 4 80-95 Considerable first pass effect 
in the liver, almost completely 
excreted in the urine as active 





Amitriptyline 6-36 96 Extensive first pass 
metabolism, almost 





Ciprofloxacin 2.5 20-40 10-20% metabolized, mostly 
excreted in urine 40-70% 
unchanged
Chelate formation
50% of oral dose is bound when 
given together with currently 
used phosphate binders.
Decreased renal clearance. 
Variable increase in elimination 
of the drug via the transluminal 
route across the bowel mucosa. 
Furosemide 0.07-0.2 91-99% 20% converted to metabolites. 
Mostly excreted in the urine, 
largely unchanged. Excreted 
by tubular secretion. 
Reduced bioavailability due 
to increased gastric pH. 




Oxazepam 0.6-1.6 85-97 Metabolism by conjugation. 
Mostly excreted in the urine 
as inactive metabolites, <1% 
excreted unchanged.
Decreased protein binding, 
increased Vd
Phenytoin 0.52-1.19 90 Extensive biotransformation 
in the liver, mostly excreted in 
the bile.
Decreased protein binding
Pravastatin 0.5 50 Biotransformation in the liver, 
mostly excreted in the feces.
Increase in Vd, due to fluid 
retention
Metabolism
Captopril 2 25-30 40% hepatic metabolism, 65% 








T ½ N (h) T ½ ESRD
(h)
Required dosing GFR 
<30 ml/min/1.73m2
Required dosing GFR 
<15 ml/min/1.73m2
Ref
2-6 unchanged Start with small dose,  
titrate to response*
Start with small dose,  
titrate to response*
607, 608
9-25 unchanged Reduce dose or increase  
dosing interval*
Reduce dose or increase 
dosing interval*
607, 608
3-5 8 Alter dosing regimen of  
separate drugs
50-100% of normal dose / 
increase dose interval
Alter dosing regimen of 
separate drugs
50% of normal dose / 
increase dose interval 
605-608
0.5-2 9.7 Normal dose, increased  
doses may be required* 
Normal dose, increased  
doses may be required*
605, 607, 608
3-21 25-90 Normal dose Start at low dose, increase 
according to response* 
607, 608
7-42 unchanged Normal dose, request free 
phenytoin concentrations  
after 4-5 days




1.5-2 unchanged Starting dose 10mg Starting dose 10 mg 606, 607
2.3 21 Start low, titrate to response.
75% of normal dose
Start low, titrate to response.
50% of normal dose
605, 607, 608 
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Table 10.1   Continued
Drug Vd (L/kg) PPB
(%)
Mode of elimination Effect CKD
Metabolism
Repaglinide 0.4 >98 Hepatic CYP3A4 metabolism 
to inactive metabolites, 
excretion via bile. 
Decreased clearance
Reboxetine 26-63L 97 Hepatic CYP3A4 metabolism 
to inactive metabolites, 




Insulin 0.15l/kg 5 Hepatic and renal metabolism, 
1-1.5% unchanged excretion 
in urine
Decreased clearance
Vitamin D - - Renal metabolism No conversion to active form
Excretion
Benzyl-penicillin 0.5-0.6 60 Almost completely excreted 
unchanged in urine.
Decreased clearance
Aciclovir 0.7 9-33 Predominantly excreted in 
urine, >80% unchanged
Decreased clearance
Fluconazole 0.65-0.7 11-12 >90% excreted in the urine, 
80% unchanged.
Decreased clearance
Morphine 3-5 20-35% Hepatic conjugation, 10% 
excreted unchanged in urine
Decreased clearance 




Vancomycin 0.47-1.1 10-50 80-90% excreted unchanged 
in urine
Decreased clearance
Amikacin 0.22-0.29 <20 94-98% excreted unchanged 
in urine
Decreased clearance
Gentamicin 0.3 0-30 90% excreted unchanged in 
urine
Decreased clearance
Tobramycin 0.25 <5 90% excreted unchanged in 
urine
Decreased clearance
*No exact dose recommendations or contradictory dose recommendations are available in the literature. 
CKD, chronic kidney disease; ESRD, end stage renal disease; GFR, glomerular filtration rate; h, hours; N, 
normal; ND, no data; PPB, plasma protein binding; Ref, references; T½, half-life; Vd, volume of distribution.
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T ½ N (h) T ½ ESRD
(h)
Required dosing GFR 
<30 ml/min/1.73m2
Required dosing GFR 
<15 ml/min/1.73m2
Ref
1 2 Start low, titrate to response* Start low, titrate to response* 607, 608
13 26 50% of initial dose,  
adjust according to response
50% of initial dose,  
adjust according to response
607, 608
2-5 13 Variable, based on glucose levels. Variable, based on glucose 
levels.
608
- - Use active form Use active form 607
0.5 10 50%, dose interval 12h 25-50%, dose interval 12-16h 607, 608
2.9 19.5 100% dose, dose interval 24h 50% dose, dose interval 24h 605-608
30 98 50% of normal dose,  
dose interval 24h
50% of normal dose, dose 










Small doses, extended dosing 
intervals, titrate to response. 
75% of normal dose.
Consider switch to alternative 
drug (e.g. piritramide)
Small doses, extended dosing 
intervals, titrate to response.
50% of normal dose.
Consider switch to alternative 
drug (e.g. piritramide)
605-608
6 120-216 100% of normal dose, increase 
dose interval to 48-72h 
100% of normal dose, increase 
dose interval to 1 week
605-608
2-3 17-150 Dose reduction and increase 
dose interval based on drug 
levels*
Dose reduction and increase 
dose interval based on drug 
levels*
605-608
2-3 20 Dose reduction based on drug 
levels, increase dose interval to 
48 hours*
Dose reduction and increase 
dose interval based on drug 
levels*
605-608
2-3 5-70 Dose reduction based on drug 
levels*
Dose reduction and increase 
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are common in patients with CKD, basic knowledge on the PD properties of antibiotics 
is necessary to optimize treatment as was recently reviewed by Momper et al.609 For 
antibiotics, three PK-PD targets describe features of the concentration-time profile 
that maximize antibiotic efficacy (Figure 10.4):
1.  The ratio of maximum free drug plasma concentration to minimum inhibitory 
concentration (MIC) (aminoglycosides)
2.  The ratio of AUC to MIC (vancomycin)
3.  The proportion of time that the plasma concentration exceeds the MIC (β lactam 
antibiotics)
For each individual drug the PK-PD target should be taken into account when 
prescribing the dosing regimen. Dose adjustments for primarily hepatically metabolized 
drugs should be carefully considered as well, as their pharmacologically active and/or 
toxic metabolites can be excreted by the kidney, e.g. morphine, MMF.610, 611 The 
minimum change in kidney function that requires a change in dose, is not well defined.70 
In general, dose adjustment is unlikely to be required when <30% of the dose is 
excreted by the kidney.70,612 However, in drugs with a small therapeutic index, this 
statement should be reconsidered.
Loading dose
Some drugs and clinical situations, for instance antibiotics in patients with a severe 
infection, require rapid therapeutic concentrations. The time to reach steady state is 
determined by the half-life (T1/2) and it takes 3-5 half-life periods to reach steady state. 
Half-life is a PK parameter determined by both clearance (CL) and Vd (T1/2 = 0.693 * Vd/
CL). When T1/2 is prolonged, the time to reach steady state increases proportionally. 
Hence, for some drugs a loading dose is necessary to decrease the time needed to 
reach the plateau drug concentration. The loading dose to achieve a target 
concentration is determined by the Vd (loading dose = target concentration * Vd). 
However, when CKD coincides with an altered Vd of a drug, the loading dose must be 
modified.581 
Maintenance dose
The maintenance dose is aimed at maintaining the desired steady-state drug 
concentrations. The maintenance dose is determined by the drug concentration at 
steady state (Css) and the CL of the drug from the body (maintenance dose = Css * CL). 
For intermittent dosing the desired dosing interval should be taken into account as 
well. A decrease in drug clearance with kidney disease necessitates, therefore, a 
decrease in either maintenance dose, an increase in the dosing interval, or both.483 
The dosing frequency depends on the toxicity profile of the drug. An important 
question to consider is whether the effects of the drug relate to the peak or to average 
exposure of the drug. A relatively long dosing interval will require a relatively high 
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maximum concentration to maintain an acceptable mean drug concentration or AUC. 
Therefore, in most instances, a reduction in dose rather than an increase in dosing 
interval is appropriate, with the exception of drugs where high peak serum 
concentrations are beneficial such as gentamicin and tobramycin. 
Research priorities
As stated in the KDIGO guideline on CKD evaluation and management, national and 
international research groups should ensure adequate representation of adult CKD 
patients in clinical trials to improve the understanding of PK and PD parameters in this 
population.1 Moreover, drug research involving pediatric indications and drug dosing 
optimization in pediatric clinical practice is challenging. Limited observational data can 
be used to create dosing advices for specific drugs and patient categories, as we 
previously demonstrated.613 Furthermore, physiologically-based pharmacokinetic 
(PBPK) modeling can be used to predict the PK behavior of drugs in humans using 
preclinical data.614 For the pediatric (CKD) population, we believe that PK studies and 
PBPK modeling should be used to incorporate pediatric developmental physiology and 
disease to predict drug exposure in vulnerable patient groups. Currently, several 
initiatives are started to determine the population PK of for instance, antibiotics 
Figure 10.4 Concentration-time profile of antibiotics
1. Peak/MIC: The ratio of maximum free drug plasma concentration to the MIC
2. AUC/MIC: The ratio of the total exposure of the drug to the MIC
3. Time/MIC: The proportion of time that the plasma concentration exceeds the MIC
AUC, area under the concentration time curve; Cmax, maximum concentration; MIC, minimum inhibitory 
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(NCT03248349, NCT02539407) and antiretroviral drugs (NCT03194165) in the pediatric 
(non-CKD) population.
Conclusion
CKD is a heterogeneous condition, which is a major public health problem worldwide. 
In patients with CKD the PK of several drugs can be significantly altered. For pediatric 
CKD patients the impact of maturation on drug disposition and action should be taken 
into account as well. As shown in this review, the effects may be variable and are not 
limited to renal drug clearance. In fact, CKD may also have a major influence on drug 
absorption, distribution, and drug metabolism in the liver, gut and kidneys. 
Inappropriate dose adjustments may lead to sub- or supratherapeutic concentrations 
predisposing the patient to either therapeutic failure or adverse drug reactions. As 
general guidelines in pediatric CKD patients are lacking, prescribing an appropriate 
dose requires knowledge on specific PK alterations in this study population. Finally, we 
believe that all available data should be used to extrapolate dosing advices in the adult 
population to the pediatric CKD population.
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Tacrolimus is an important immunosuppressive agent with high intra- and interindivid-
ual PK variability and a narrow therapeutic index. As tacrolimus extensively accumulates 
in erythrocytes, hematocrit is a key factor in the interpretation of tacrolimus whole 
blood concentrations. However, as hematocrit values in pediatric kidney transplant 
patients are highly variable after kidney transplantation, translating whole blood 
concentration targets without taking hematocrit into consideration, is theoretically 
incorrect. The aim of this study is to evaluate the potential impact of hematocrit 
correction on tacrolimus target exposure in pediatric kidney transplant patients. 
Methods
Data were obtained from 36 pediatric kidney transplant patients. 255 tacrolimus 
whole blood samples were available, together responsible for 36 AUCs and trough 
concentrations. First, hematocrit-corrected concentrations were derived using a 
formula describing the relationship between whole blood concentrations, hematocrit, 
and plasma concentrations. Subsequently, target exposure was evaluated using the 
converted plasma target concentrations. Ultimately, differences in interpretation of 
target exposure were identified and evaluated. 
Results
In total, 92% of our patients had a lower hematocrit (median 0.29) than the reference 
value of adult kidney transplant patients. A different evaluation of target exposure for 
either trough level, AUC or both, was defined in 42% of our patients, when applying 
hematocrit corrected concentrations.
Conclusion
A critical role for hematocrit in TDM of tacrolimus in pediatric kidney transplant 
patients is suggested in this study. Therefore, we believe that hematocrit correction 
could be a step towards improvement of tacrolimus dose individualization. 
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HEMATOCRIT CORRECTION AND TACROLIMUS
Introduction
CNIs are the cornerstone of immunosuppressive therapy after kidney transplantation. 
Tacrolimus was introduced in the 1990s as an alternative to cyclosporine and is now 
widely used to prevent rejection after solid-organ transplantation in both adult and 
pediatric transplant recipients.77 At the time of discharge after transplantation, 
approximately 70% of pediatric kidney transplant patients are treated with tacrolimus.7 
Tacrolimus is characterized by a narrow therapeutic index: high concentrations are 
associated with toxicity, malignancy and infection, while low concentrations are 
associated with an increased risk of acute rejection.80, 81 Furthermore, the intra- and 
interindividual PK variability is high.77, 615 Previously, body weight86, 87, 616, CYP3A5 
polymorphisms83, 86, 87, 616, age83, 84 and hematocrit level86, 616 were found to have 
significant effects on PK variability in pediatric kidney transplant patients, especially in 
the early phase after transplantation. Due to the large PK variability, individualizing 
tacrolimus dosing regimens by performing TDM to optimize the therapeutic effect and 
minimize adverse effects is essential and currently the standard of care. 
For pediatric kidney transplant patients, little is known about the optimal targets for 
tacrolimus exposure. Furthermore, both whole blood trough concentrations and AUCs 
are used to adjust the tacrolimus dosing regimen of the individual patient. As it stands, 
it is unknown what is the best PK parameter to predict treatment outcome and the 
relationship between blood trough concentrations and AUCs in pediatric patients remains a 
matter of debate.84 As reference values for target exposure based on clinical trials in 
pediatric patients are lacking, adult targets are currently used.80, 95, 96 Yet, large differences 
exist between the pediatric and adult population in terms of PK and physiology.97 
Hematocrit is a confounder for interpretation of tacrolimus exposure in whole blood. 
Several population PK studies have indeed identified hematocrit as a key factor for 
interpretation of tacrolimus whole blood concentrations in both the adult and pediatric 
population.78, 86, 617 A low hematocrit results in lower whole blood exposure and can 
then be incorrectly interpreted as an increased apparent clearance of tacrolimus from 
whole blood, while the plasma concentrations and clearance remain unchanged.86, 616 
Currently, tacrolimus is generally measured as total concentrations in whole blood, 
whereas only the unbound concentration in plasma is pharmacologically active as it is 
available for cellular diffusion and distribution.618 Measurement of plasma or unbound 
tacrolimus concentrations might therefore be a better reflection of the pharmaco-
logically active drug, which is technically challenging and often unavailable in clinical 
practice.80, 619 Tacrolimus extensively accumulates in erythrocytes, and the concentration 
in whole blood is the weighted average concentration of the plasma and erythrocyte 
fractions. Consequently, a change in hematocrit will affect the whole blood 
concentration, without affecting the pharmacologically active unbound plasma 
concentration.618, 620, 621 
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Hematocrit values tend to change significantly in the first months after transplanta-
tion.617, 622 Changes in hematocrit values can occur in both ways: most patients will 
have an increase in hematocrit as erythropoietin levels increase rapidly after a 
successful kidney transplantation. However, a decrease is also possible both early after 
transplantation based on blood loss due to the surgery or dilution due to intensive 
fluid control, and after discharge as a side effect of the frequently used concomitant 
immunosuppressive agent mycophenolic acid. As tacrolimus trough concentrations 
and AUCs are currently measured in whole blood, this may lead to incorrect dose 
adjustments and inadequate tacrolimus exposure.623 
The aim of our study was to evaluate the potential impact of hematocrit correction on 
tacrolimus target exposure in pediatric kidney transplant patients.
Materials and Methods
Study design 
To evaluate the impact of hematocrit correction on tacrolimus dose individualization 
in pediatric kidney transplant patients, we performed a retrospective cohort study at 
our tertiary referral center (Radboudumc Amalia Children’s Hospital, Nijmegen) in the 
Netherlands. 
Setting and subjects
Pediatric kidney transplant patients (aged 1-18 years) undergoing TDM for tacrolimus 
between 2012 and 2017, were included when an AUC0-12h or AUC0-8h was available. A 
subset of our study population has previously been described by Martial et al.624 
Patients were excluded in case a hematocrit value was not available within 2 days of 
sampling. Sampling for the AUCs was typically performed at the following time-points: 
pre-dose and 1, 2, 3, 4, 8, and 12 hours after tacrolimus intake. All patients received 
oral capsules (Prograft, Astellas Pharma) or a suspension (as extemporaneous 
preparation). Tacrolimus doses were adjusted based on TDM to achieve the whole 
blood target exposure that depends on the time post-transplantation and the immu-
nosuppressive regimen of choice, as shown Table 11.1 and Table 11.2.80, 95, 96, 625, 626 
In our hospital two treatment regimens with tacrolimus are commonly used: a prednis-
olone-free immunosuppressive regimen (according to the TWIST protocol) or a triple 
therapy including prednisolone and MMF.80, 627 As food may decrease the rate and 
extent of tacrolimus absorption, patients were instructed to always take the medication 
in an identical manner (either with or without food). The ethics committee of the 
Radboudumc waived the need for ethical approval according to the Dutch Law on 
Human Research, as only patient chart data were collected. 
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Step 1: Derivation of hematocrit-corrected target exposure
As tacrolimus dose individualization in children is guided by measurement of whole 
blood concentrations, we derived the associated plasma trough concentrations and 
plasma AUCs to use as hematocrit-corrected target exposure.80 Whole blood 
concentrations (Cwb) can be calculated from plasma concentrations, using the fraction 
of hematocrit (fHCT) for weighting with the following equation (equation 1), in which 
Bmax is the maximum binding concentration of 418 μg/L and KD is the dissociation 
constant of 3.8 μg/L:78
Table 11.1 Target whole blood concentrations and predicted plasma 



























0-4 weeks 10-20 0.27-0.58 8.6-17.2 7.2-14.5
4 weeks-6 months 5-15 0.13-0.42 4.3-12.9 3.6-10.8
6-12 months 5-10 0.13-0.27 4.3-8.6 3.6-7.2
>12 months 4-8 0.10-0.21 3.4-6.9 2.9-5.8





0-4 weeks 10-15 0.27-0.42 8.6-12.9 7.2-10.8
4 weeks-6 months 7-12 0.19-0.33 6.0-10.3 5.1-8.7
6-12 months 5-10 0.13-0.27 4.3-8.6 3.6-7.2
>12 months 4-8 0.10-0.21 3.4-6.9 2.9-5.8
aTargets according to our local hospital protocol which is based on the following references:80, 95, 625, 626
AUC, area under the concentration time curve; C0, trough concentration; wb, whole blood.
Table 11.2 Target whole blood AUCs and predicted plasma AUCs
Time post-
transplantation
Target wb  
AUC0-12h (range)a
Target plasma  
AUC0-12h (range)
Target AUC0-12h 0-6 weeks 210 h*µg/l (168-252) 6.9 h*µg/l (5.4-8.4)
>6 weeks 125 h*µg/l (100-150) 4.0 h*µg/l (3.1-4.8)
aTargets according to our local hospital protocol which is based on the following references: 80, 87
AUC, area under the concentration time curve; wb, whole blood.
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Equation 1 can be rearranged to calculate the plasma concentrations if the whole 
blood concentration and fraction hematocrit are known, with the following equation 
(equation 2):
For calculation of the plasma target concentrations we assumed a fHCT of 0.35 L/L in 
the adult population, based on hematocrit values found in previous studies conducted 
in adult kidney transplant recipients.617, 628-630 
Converted plasma target trough concentrations
Subsequently, whole blood target trough concentrations were converted to plasma 
target trough concentrations using the aforementioned equation 2. The target ranges 
for converted plasma trough concentrations and whole blood trough concentrations 
with different hematocrit values are shown in Table 11.1. To further illustrate the 
influence of hematocrit, a nomograph (Figure 11.1) is created using equation 2, 
in which the relationship between whole blood tacrolimus concentrations and plasma 
tacrolimus concentrations for different hematocrit levels is shown. 
Converted plasma target AUCs 
Whole blood target AUCs cannot be directly converted to plasma target AUCs, due to 
the non-linear binding of tacrolimus and thus a varying blood-to-plasma ratio during a 
dosing interval. Therefore, the individual whole blood concentrations on which the 
target AUCs are based should be converted to plasma concentrations and subsequently 
the plasma target AUC can be calculated. In literature, however, these individual whole 
blood concentrations for the AUC targets are not available. Therefore, we simulated 
the steady-state whole blood PK of tacrolimus in 1000 virtual adult patients, based on 
a previously validated population PK model for tacrolimus with the software package 
NONMEM V7.4.1.631 For calculation of the AUCs, we integrated the predicted whole 
blood concentrations and plasma concentrations versus time during a 12-hour dosing 
interval for all 1000 individuals. A power trend line fitted our data best (R squared 
coefficient of 0.93, Supplemental Figure S11.1). Subsequently, plasma target AUCs 
were calculated using the corresponding formula y=0.0218x1.0772, where y and x 
represent the plasma target AUC and whole blood target AUC, respectively. The target 
ranges for whole blood AUCs and converted plasma AUCs are shown in Table 11.2.
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Step 2: Derivation of hematocrit-corrected trough concentrations and 
AUCs of the patients
Whole blood trough concentrations of the patients were converted to plasma trough 
concentrations using the aforementioned equation 2. Whole blood AUCs were 
converted to plasma AUCs by converting the individual concentrations of different 
time points on which the total AUC0-12h was based. 
Step 3: Evaluation of target exposure 
Subsequently, whole blood AUCs and trough concentrations of the patients as well as 
predicted plasma AUCs and trough concentrations of the patients were compared with 
the corresponding target concentrations. 
Step 4: Evaluation of differences in interpretation of target exposure
Finally, to evaluate the impact of hematocrit correction in TDM of tacrolimus, 
differences in the interpretation of target exposure were identified by comparing the 
evaluation of target exposure for whole blood concentrations with and without 
hematocrit correction. 
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A validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
bioanalytical assay was used to determine tacrolimus whole blood concentrations. The 
range of the assay was 1–300 μg/l. Intra-assay precision and accuracy was 3.4%, 2.2%, 
3.0% and 102%, 94%, and 94%, respectively, at 3.04, 6.23, and 13.0 μg/l (n = 6), 
respectively.624, 632 Furthermore, the following baseline characteristics were collected 
from the electronic patient records: age at kidney transplantation, gender, ethnicity, 
time post transplantation, donor type (living or deceased), height, and body weight. In 
addition, several laboratory data were collected: hematocrit, blood hemoglobin, 
serum creatinine, and serum urea. The estimated GFR was calculated with the adapted 
Schwartz formula (K * height (cm)/ serum creatinine (µmol/l)) with a k-value of 36.5.633 
Variables missing on the day of sampling were obtained by selecting the value closest 
to this date with a maximum for hematocrit of 2 days. 
Data analysis
Baseline variables were summarized using median and IQR. Whole blood trough 
concentrations were evaluated using the target concentrations according to our local 
hospital protocol. As shown in Table 11.1, target concentrations vary with time after 
transplantation and concomitant immunosuppressive medication.80, 95, 625, 626 
Furthermore, the whole blood AUCs were compared to the AUC0-12h target range of 
210 ±20% µg*h/L up to 6 weeks post transplantation and 125 ±20% µg*h/L upon 6 
weeks post-transplantation (Table 11.2).80, 96 The AUCs0-12h were calculated using the 
linear-log trapezoidal method. To adequately compare the individual AUCs to the 
target AUC, the estimated AUC0-8h was extrapolated to an AUC0-12h. 
Results
Study population
A total of 37 children (age range 1.8-17.1 years) were eligible for inclusion in this study. 
One patient was excluded because the closest hematocrit value was 18 days before 
sampling. Data on a total of 255 tacrolimus whole blood concentrations were available, 
together providing 36 AUCs. Patient characteristics are presented in Table 11.3. The 
AUCs and trough levels were measured at any time post transplantation, predominantly 
in the first two weeks after transplantation. Of note, 33 of the 36 patients (92%) had a 
lower hematocrit value (median 0.29) than the reference hematocrit value of adult 
kidney transplant patients of 0.35 L/L on which the current recommendations of the 
dosing guidelines are based.
562850-L-bw-Schijvens
Processed on: 16-7-2021 PDF page: 233
233
11
HEMATOCRIT CORRECTION AND TACROLIMUS
Step 1 and 2
For every individual patient, a whole blood AUC0-12h (range 62-354 h*µg/L) and whole 
blood trough concentration (range 2.0-25.7 µg/L) were converted to the corresponding 
plasma AUC0-12h (range 2.0-16.0 h*µg/L) and plasma trough concentration (range 
0.06-1.02 µg/L). Figure 11.2 shows the target AUCs and target trough concentrations, 
whole blood and predicted plasma AUC0-12h, and whole blood and predicted plasma 
trough concentration of the individual patient. 
Step 3
Furthermore, Figure 11.2 shows the evaluation of the AUCs and trough concentrations 
of the patients when compared to the corresponding target whole blood and predicted 
plasma ranges. Of the whole blood AUCs, 69% (25/36) were outside the target range, 
Table 11.3 Patient characteristics
n (%) Median IQR
Number of study participants 36











Height (cm) 124.4 95.0-160.9
Total body weight (kg) 23.1 15.7-46.2
Laboratory measurements
Hematocrit (l/l) 0.29 0.26-0.31
Blood hemoglobin (mmol/l) 6.2 5.5-6.7
Serum creatinine (µmol/l) 55 37-103
Serum urea (mmol/l) 6.4 5.1-10.4
eGFR (ml/min/1.73m2) 85 52-123
eGFR, estimated glomerular filtration rate
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compared to 58% (21/36) of the whole blood trough concentrations. For the predicted 
plasma AUCs and trough concentrations similar numbers were found (69% and 61%, 
respectively). 
Step 4
Using the hematocrit corrected target levels, a different evaluation for target exposure 
for either the trough level, AUC or both, was defined in a total of 42% (15/36) of our 
pediatric kidney transplant patients. In Table 11.4 the number of whole blood and 
Figure 11.2   Whole blood and predicted plasma AUCs0-12h and trough 


































Whole blood and predicted trough concentrations
- Immunosuppressive regimen including prednisolone -
Target range whole blood and plasma trough concentrations
No difference in evaluation
Different evaluation of whole blood and plasma concentrations
b
a
AUC , area under the concentration time curve;  C0, trough concentration.
a The hematocrit-corrected plasma trough concentration is above the corresponding target range, the whole blood
trough concentration was below the corresponding target range. Therefore, the evaluation of target exposure is different.
b The blood samples of this patient where taken >6 weeks after transplantation, therefore other reference values
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predicted plasma values in and out of range are shown. For the AUCs a different 
evaluation of target exposure was found in 22% (8/36) of the cases. For the trough 
concentrations a different evaluation was shown in 33% (12/36) of the patients. 
Discussion
Tacrolimus is a key immunosuppressive agent in the majority of pediatric kidney 
transplant patients. This study shows the importance of hematocrit correction in 
tacrolimus target evaluation in this population. Using hematocrit corrected target 
concentrations, a different interpretation of tacrolimus exposure was found in 42% of 
our patients. As tacrolimus has a narrow therapeutic index, indicating that small 
variations in drug exposure can have a relevant impact on graft survival and toxicity, 
the results of this study suggest that using hematocrit corrected targets could prevent 
incorrect dose adjustments of tacrolimus based on whole blood concentrations. As 
the majority of our patients had a lower hematocrit value than the reference value of 
adult kidney transplant patients of 0.35L/L, which causes an underestimation of the 
pharmacologically active concentration, especially toxicity may be prevented. 
Currently, therapeutic target ranges for tacrolimus exposure in pediatric kidney 
transplant patients are based on empirical observations in adult transplant patients, as 
reference values based on clinical trials in pediatric patients are lacking.80, 96 Especially 
at the time of a kidney transplantation, hematocrit values are generally low and tend 
to change significantly in the first months after transplantation. This underlines the 
need to take this into account in the TDM of kidney transplant patients.617, 622 
Moreover, this study shows that hematocrit levels are significantly decreased in our 
population and effort should be made to adequately correct hematocrit in these 
patients. 
The importance of hematocrit correction in adult kidney transplant patients has been 
highlighted previously.617, 629, 634 Størset et al. developed a population PK model for 
Table 11.4   Number of whole blood and predicted plasma AUCs and trough 









plasma - in range 7 4 9 5
plasma – out of range 4 21 6 16
Total 11 25 15 21
AUC, area under the concentration time curve; C0, trough concentration; wb, whole blood.
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tacrolimus dosing in kidney transplant patients and recommend to standardize 
tacrolimus whole blood concentrations to a hematocrit of 45% to reflect the unbound 
(active) drug more closely, showing that hematocrit is a confounder and not a covariate 
for tacrolimus PK.617, 629 Furthermore, a pharmacokinetic study conducted by 
De Jonge et al. indicated that hematocrit explained 4-14% of variability in tacrolimus 
PK parameters.634 
The challenge for clinicians to attain the optimal target exposure in the individual 
patient after kidney transplantation has previously been described by Ekberg et al. and 
Størset et al, who found 50% and 42% respectively, of tacrolimus trough concentrations 
outside the target range during the first 6-8 weeks post-transplantation.617, 635 Our 
data show even higher percentages of AUCs and trough concentrations outside the 
proposed target range, underlining the large inter-individual variability and challenge 
for clinicians to attain the optimal target concentration. 
To our knowledge, this is the first study investigating the role of hematocrit in the 
interpretation of tacrolimus whole blood exposure in pediatric kidney transplant 
patients in clinical practice. As the optimal strategy for TDM is still under debate, both 
AUC and trough concentrations are currently used in the clinical setting. Reported 
correlations between tacrolimus AUC and trough concentration are variable, indicating 
that trough concentrations alone may be a poor predictor of exposure.636 A PK study 
previously conducted in a small subset of our study population, recommends the use 
of AUC as driver for dose adaptations rather than trough concentrations in very young 
pediatric kidney transplant patients.624 One of the strengths of this study is that both 
AUC and trough concentrations were evaluated to make the results as broadly 
applicable as possible. Unfortunately, there is no consensus among transplant centers 
on the optimal tacrolimus target exposure.77 The target concentrations in our center 
are based on European consensus guidelines, however as target concentrations vary 
among centers, the predicted plasma target concentrations should be adjusted 
according to local clinical practice.80 
An important limitation of our study is its retrospective design, which may cause 
information bias. Although the observed whole blood concentrations were evaluated 
retrospectively, the exact time of dose administration was known in 35/36 of our 
patients. For one patient the approximate time of dose administration was recorded in 
the medical file. As all patients were admitted to the hospital during the time of 
sampling and medication was administered by the nursing staff, we believe that the 
adherence to the medication is good and therefore full compliance was presumed. 
Due to the retrospective design of this study laboratory values of 15 patients were 
unavailable on the day of sampling, therefore, these variables were imputed by 
choosing value closest to the day of sampling with a maximum of 2 days for hematocrit. 
This, however, is a limitation of our study and ideally all paired samples are needed. In 
this study, values for the binding capacity (Bmax) and affinity constant (KD) were 
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obtained from a previously conducted study in adult liver transplant patients.78 In 
addition, Zahir et al. found similar values for Bmax and KD in 40 liver transplant recipients 
using the same equation.637 Recently, Størset et al. also used equation 2 to estimate 
the PK disposition parameters to develop a theory-based population PK model of 
tacrolimus in adult kidney transplant patients.629 As our study involves pediatric kidney 
transplant patients, these values should ideally be obtained from this specific 
population by determination of the blood:plasma ratios of tacrolimus concentrations 
in pediatric kidney transplant recipients using the equation previously described by 
Piekoszewski et al. and Jusko et al.78, 638
As previously mentioned, the confounding effect of hematocrit variability can have a 
significant impact on the evaluation of tacrolimus whole blood concentrations as 
tacrolimus is highly bound to erythrocytes. As 99% of tacrolimus in plasma is bound to 
proteins, mainly albumin and α-1-acid glycoprotein, this could hold true for variations 
in albumin concentrations as well.77 Although previous research showed no influence 
of albumin on whole blood tacrolimus concentrations in adult kidney transplant 
patients, this should be evaluated in pediatric kidney transplant patients as well.617 
The influence of albumin was not evaluated in the current study, because on the day 
of sampling albumin concentrations were available for only 8 of our patients. 
Furthermore, due to low patient numbers and tight monitoring, ‘hard’ clinical endpoints 
(e.g. toxicity, rejection or infection) could not be identified in our study population.
For pediatric kidney transplant recipients, long-term graft survival is especially 
important. Clinical trials in pediatric kidney transplant patients to obtain the optimal 
target exposure are however scarce.80 As it is difficult to conduct clinical trials with 
‘hard’ clinical endpoints in small patient groups, we feel that all available information 
should be used to optimize therapeutic drug monitoring in pediatric patients. Although 
technically challenging, measuring both total and unbound tacrolimus concentrations 
in plasma of pediatric kidney transplant patients would be an important opportunity 
for future research. Nonetheless, as tacrolimus is known to show high affinity to 
erythrocytes, we advocate a critical role for hematocrit correction in TDM of tacrolimus 
in pediatric kidney transplant patients. We consider the current study a proof-of- 
concept that hematocrit correction may be of added value in dose individualization of 
tacrolimus, especially in the pediatric population. In future studies, therefore, effort 
should be made to characterize Bmax and KD in pediatric kidney transplant patients and 
to prospectively investigate the impact of hematocrit correction on clinical endpoints.
562850-L-bw-Schijvens





Processed on: 16-7-2021 PDF page: 239
239
11
HEMATOCRIT CORRECTION AND TACROLIMUS
562850-L-bw-Schijvens
Processed on: 16-7-2021 PDF page: 240
562850-L-bw-Schijvens
Processed on: 16-7-2021 PDF page: 241
CHAPTER 12
Low bioavailability of oral 
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The CNI tacrolimus is considered a cornerstone of immunosuppressive treatment 
to prevent rejection in both adult and pediatric kidney transplant recipients. In the 
Netherlands, immediate release tacrolimus is commercially available in 0.5, 1, and 
5 mg capsules and 0.2 mg granules. In pediatrics, liquid formulations are essential for 
administration of drugs. As granules for oral suspension are considered inappropriate 
due to the large number of sachets required and liquid formulations are not commercially 
available, hospitals often rely on an extemporaneously prepared formulation. A lower, 
and age-dependent, bioavailability for oral liquid formulations in children compared to 
the original formulation in adults, is a well-known issue for various drugs.639 Labberton 
et al. have shown the stability of the extemporaneous preparation using tacrolimus 
monohydrate.640 The relative bioavailability of this tacrolimus oral suspension is, 
however, unknown for pediatric kidney transplant patients. 
We aimed to compare relative bioavailability of tacrolimus oral suspension versus oral 
capsules (Prograft, Astellas Pharma) in this retrospective cohort study, using TDM data 
from pediatric kidney transplant patients from the Radboudumc Amalia Children’s Hospital 
between 2012 and 2018. The tacrolimus oral suspension was manufactured at the A15 
pharmacy (Gorinchem, The Netherlands), as described by Labberton et al.640 
PK data, collected for purposes of TDM, were analyzed by means of nonlinear 
mixed-effects modelling. A mechanistic population PK model was developed, where 
PK was allometrically scaled to fat-free mass (see Online Supplemental material). This 
approach allowed us to account for age related differences (weight) and hematocrit a 
priori. After development of the base model, we investigated the presence of the liquid 
oral formulation as a binary covariate on absorption rate and bioavailability relative to 
the solid oral formulation.
Rich PK data from 38 kidney transplant patients (39% female) between 1.5 and 
17 years old were available (median age 8.5 years), with 274 time-concentration data 
in total responsible for 38 AUCs and trough levels, predominantly measured in the first 
2 weeks after transplantation (median 11 days, interquartile range 9-13 days). As all 
patients were hospitalized at the time of sampling, patient compliance was excellent. 
Oral suspension was administered to 34% of the patients (median age 4.5 years) 
versus oral capsules to 66% of the patients (median age 11.9 years). Genotyping was 
performed in 22/38 patients; 90% of the patients were non-expressors (CYP3A5*3/*3) 
and 10% showed heterozygous CYP3A5 expression (CYP3A5*1/*3). Using a forward 
inclusion, backward elimination approach, we found that the mean absorption time of 
tacrolimus was significantly decreased from 1.06 hours (relative standard error of the 
estimate [RSE] 23%) to 0.17 hours (RSE 56%) in patients taking the oral suspension. 
Furthermore, we found that the relative bioavailability of the oral suspension was 
53.7% (RSE 23%) compared to that of the solid oral formulation. To illustrate the effect 
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of the formulation on the PK of tacrolimus, we simulated the steady-state PK of 
tacrolimus in whole blood for a typical 10-year-old boy weighing 30kg, measuring 
1.30m with a hematocrit of 0.35 taking a dose of 5 mg twice daily (Figure 12.1).
In agreement with expectations, the oral suspension showed a reduced absorption 
time. In line with our findings, Reding et al. showed a lower absolute bioavailability of 
an oral suspension based on the contents of the 5 mg tacrolimus capsules compared 
to oral capsules (12.9% vs 25%, respectively) in pediatric liver transplant patients.641 
The lower bioavailability observed for the oral suspension used in our clinic may be 
caused by incomplete dissolution in the gut lumen or impaired absorption. First, it is 
known that the formulation and production process may influence the dissolution of 
tacrolimus. In this case, the capsules contain a small amount of lecithin, which may 
affect both dissolution (e.g. by its micelle forming capability) and absorption (as 
absorption enhancer). However, taken into consideration the small amount of lecithin 
used, it is unlikely that this contributes significantly to the observed difference between 
both formulations. In addition, sweeteners (sucrose crystalline) used in the oral 
suspension may decrease intestinal transit time due to their osmotic effect.639 Second, 
administration of tacrolimus with food is known to significantly decrease the rate and 
extent of absorption.642 In our population the administration with food is largely 
unknown. However, we believe it is unlikely that patients on the oral suspension more 
Figure 12.1   Simulated pharmacokinetic profile of oral solid and liquid tacrolimus 
formulation in one virtual patient
Predicted steady state concentrations after administration of 5 mg tacrolimus oral solid and liquid formulation 
in a virtual 10 year-old patient weighing 30kg, measuring 1.30m with a hematocrit value of 0.35 taking a dose 
of 5mg twice daily. Cwb, whole blood concentration.
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frequently take their medication with food compared to patients taking capsules. A 
large proportion of our population has nasogastric feeding tubes (4/25 children using 
oral capsules and 11/13 children using the oral suspension). Tacrolimus is known to 
stick to PVC tubes, however in our population only silicone tubes are used. Furthermore, 
Undre et al. recently showed that nasogastric administration of tacrolimus does not 
substantially affect the absorption and distribution of tacrolimus when compared to 
intact capsules.643 Therefore, we believe that the presence of nasogastric tubes in our 
population does not explain the difference in relative bioavailability between the liquid 
and solid formulation. Due to the retrospective design of the study, it was not possible 
to correct for differences in nutrition, gastro-intestinal motility, and tube feedings. 
Third, tacrolimus is a CYP3A and P-gp substrate. No strong/moderate CYP3A or P-gp 
inhibitors or inducers were administered in our population. As patients taking the 
liquid formulation are generally younger than those taking oral capsules, an age-related 
effect may also be hypothesized. The observed lower bioavailability for the tacrolimus 
oral suspension could have resulted from an increased first-pass effect. Data regarding 
the expression of CYP3A enzymes in the gut wall in children, responsible for the 
first-pass effect, are contradictory, ranging from an increase with age to the opposite 
pattern of a decrease with age.502, 504 Hepatic CYP3A4 is very low at birth, reaches 
30-40% of the adult values at one month of age, and may slightly exceed adult values 
during infancy.538 In our population two CYP3A5 intermediate expressors were 
present, both were taking capsules. This, together with the large wild type expression 
in our population, makes variation in CYP3A5 genotype as an explanation for the 
decreased bioavailability highly unlikely.
We believe that clinicians should be aware of differences in bioavailability between 
oral suspension and capsules: a higher dose of oral suspension with this formulation 
compared to capsules seems advisable.
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PART I Diagnosis and classification of nephrotic syndrome
Diagnosis of nephrotic syndrome
In the Netherlands, approximately 55-60 children are diagnosed with nephrotic 
syndrome each year.15 Patients typically present at the general practitioner’s office 
with periorbital edema, mostly noticeable in the morning. As nephrotic syndrome is a 
rare manifestation in childhood, general practitioners are likely to encounter the 
disease only once or twice during their careers. Consequently, these symptoms are 
initially often attributed to allergy, partly due to frequently coexisting atopic 
constitution.18, 644, 645 This causes a delay in accurate diagnosis, referral to a 
pediatrician or pediatric nephrologist, and initiation of adequate therapy.644 Minor 
additional evaluation, using a simple, non-invasive urine dipstick for detecting 
proteinuria can quickly lead to the diagnosis of nephrotic syndrome. Urine dipsticks 
are already used by general practitioners for cardiovascular risk assessment and 
therefore readily available in clinical practice. As nephrotic syndrome is an important 
cause of generalized edema in children646 and serious complications and prolonged 
discomfort may be prevented by rapid diagnosis, the use of the non-expensive dipstick 
with rapid results is highly advisable. As the doctor’s delay is frequently reported as an 
important issue by parents of children with nephrotic syndrome, we consulted a 
general practitioner and discussed the optimal way to address this issue to the general 
practitioners in the Netherlands. This resulted in the clinical lecture presented in 
Chapter 2 in which the use of dipstick analysis in pediatric patients with periorbital 
edema is emphasized. To ultimately implement the use of dipstick analysis in the 
general practitioner’s office, we believe that this recommendation should be included 
in a general practitioner’s guideline (NHG standaard) on the evaluation of edema in 
children. After referral to the pediatrician or pediatric nephrologist, nephrotic 
syndrome is diagnosed by the triad edema, hypoalbuminemia (<25g/l) and proteinuria 
(≥200mg protein per mmol creatinine).24 Previously, kidney biopsies were standard of 
care in the diagnosis of childhood nephrotic syndrome. Nowadays, kidney biopsies are 
not routinely performed in children presenting with nephrotic syndrome, as most 
children show an excellent response to steroid therapy and this cannot be predicted 
on the basis of biopsy results.19, 20 Kidney biopsies are now reserved for identifying 
pathology in pediatric patients with an atypical clinical presentation or response.24 
Genetic analysis is generally performed in children who do not respond to an initial 4 
or 6 week course of steroids.50, 647 To date, at least 60 genes have been linked to 
SRNS.38, 39, 41 Interestingly, variants in nuclear genes encoding mitochondrial proteins 
involved in the CoQ10 biosynthesis pathway account for about 1% of genetic SRNS 
cases.40 In the past few years three patients have been identified with a primary CoQ10 
deficiency in our clinic. In Chapter 3 we included a case description of these patients 
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and performed a review on mitochondrial diseases and the kidney with a special focus 
on CoQ10 deficiency.43 Primary CoQ10 deficiency is a unique mitochondrial disease, in 
which nephrotic syndrome may be the only manifestation at presentation. Several 
genes are involved in the CoQ10 biosynthesis and mutations in five of them are 
associated with glomerular involvement (PDSS1, PDSS2, COQ2, COQ6, and COQ8B/
ADCK4). Early recognition of defects in the CoQ10 biosynthesis is important as patients 
with primary CoQ10 deficiency may be responsive to treatment with oral CoQ10 
 supplementation. Moreover, treatment should be initiated as early as possible as oral 
supplementation of CoQ10 can limit disease progression, prevent neurological 
deterioration, and improve clinical symptoms.122 We identified all reported patients 
(until February 2020) with a primary CoQ10 deficiency and kidney involvement. 
Interestingly, wide variation was present in the age of onset, extrarenal symptoms, 
response to CoQ10 supplementation, and prognosis. Only one patient with a PDSS1 
mutation and glomerular involvement was reported in literature. Patients with a PDSS2 
mutation generally presented at young age (median age at onset 6 months), rapidly 
progressed to kidney failure, and showed severe extrarenal involvement. Patients with 
a mutation in the COQ2 gene often presented with SRNS within the first 2 years of life. 
Most of the children with a COQ6 mutation presented with SRNS and sensorineural 
deafness, generally at older ages than patients with a COQ2 mutation. Finally, the 
majority of patients with a primary CoQ10 deficiency reported in literature have a 
mutation in the COQ8B/ADCK4 gene. Symptoms typically present in puberty and 
patients seem to have a less severe clinical entity. The response to CoQ10 supplemen-
tation was difficult to deduct from the published cases due to the variation in dose and 
the unknown timing of supplementation. Nevertheless, various clinical reports have 
shown the ability of CoQ10 supplementation to block progression of the disease. In 
literature, high doses of CoQ10 (>30 mg/kg) are recommended as inadequate dosage 
and duration have often affected adequate uptake of exogenous CoQ10 and only few 
mild side effects have been reported.648 The diagnostic process for mitochondrial 
diseases is undergoing a transition, moving away from a histological and biochemical 
approach to a primarily genetic approach.649 We recommend to perform genetic 
diagnostics (targeted whole exome sequencing) in children with nephrotic syndrome 
presenting in adolescence or at young age (<3 years) and in patients with nephrotic 
syndrome at any age with extrarenal symptoms. Results of standard genetic testing 
are available in our center after approximately three months. Nowadays, rapid whole 
exome sequencing is available and able to provide results in two weeks. As CoQ10 sup-
plementation should be started as early as possible, using rapid whole exome 
sequencing should be considered in this patient group. If rapid whole exome 
sequencing is not available and standard genetic testing is performed, starting CoQ10 
supplementation prior to the results of genetic diagnostics should be considered. 
Moreover, in all remaining pediatric patients presenting with nephrotic syndrome we 
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recommend performing metabolic testing including blood lactate and alanine levels 
(which may be a marker for impaired energy production in skeletal muscle and 
long-standing pyruvate accumulation, respectively). If lactate and alanine levels are 
within the normal range (lactate ≤ 2.1 mmol/l and alanine ≤450 µmol/l), we recommend 
to await steroid responsiveness for 4 weeks, after which rapid genetic diagnostics 
should be performed in case of unresponsiveness to steroids.
Future perspectives
As proposed above, diagnostic testing in patients with nephrotic syndrome may 
include both genetic, metabolic, and biochemical testing. Identification of a genetic 
cause in children with SRNS is important for genetic counselling, to avoid ineffective 
and potentially harmful therapies, and to start early suitable treatment.647 Additionally, 
in patients with CoQ10 deficiency a genetic diagnosis is relevant to provide insight in 
the etiology of the disease, which is important for the prognosis regarding development 
and severity of extrarenal symptoms and deterioration of kidney function. Next 
generation sequencing has facilitated molecular diagnosis in terms of speed, efficiency, 
and diagnostic yield.200 Nevertheless, negative findings in COQ genes do not completely 
discard the possibility of a CoQ10 deficiency as it is likely that genes remain to be 
identified as some genes of the biosynthesis pathway of CoQ10 are still unknown. 
Biochemical diagnostics (i.e. assessment of CoQ10 levels) may play an important role in 
the diagnosis and follow-up of patients with CoQ10 deficiency who are treated with 
CoQ10 supplementation if the results are rapidly available and reflective of CoQ10 
levels in tissues. 221 Nevertheless, the optimal biological specimen for identification of 
CoQ10 levels remains to be elucidated.224 Measurement of CoQ10 in skeletal muscle is 
considered the gold standard for the diagnosis of CoQ10 deficiency, still this approach 
is invasive and therefore far from ideal for the pediatric population.200, 219, 221 The 
assessment of CoQ10 levels in skin fibroblasts is less invasive, however still too invasive 
for daily clinical care and diagnostic pitfalls have been demonstrated.650 CoQ10 levels 
can be measured in plasma and leukocytes as well, yet CoQ10 levels in plasma appear 
to be highly dependent on dietary intake and are therefore not reflective of the levels 
in tissues, and CoQ10 levels in leukocytes do not always seem to correlate with the 
severity of the disease.43, 223, 227 Finally, promising results have been published on the 
determination of CoQ10 levels in buccal mucosa cells and urine, however the exact 
correlation of the CoQ10 levels between these specimens and tissue and skeletal 
muscle CoQ10 levels remains to be elucidated.200, 203, 222, 226, 651 
In future studies, effort should be made to identify additional genes involved in the 
CoQ10 biosynthesis and to determine the best, non-invasive biological specimen for 
measurement of CoQ10 levels that could enhance rapid diagnosis and enable adequate 
follow-up of patients with a primary CoQ10 deficiency. Moreover, future studies should 
focus on treatment strategies for patients with CoQ10 deficiency, including the exact 
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timing and duration of the start of therapy, the optimal dose, and optimal drug 
formulation. 
Classification of nephrotic syndrome
After diagnosis, nephrotic syndrome may be classified in various ways. Historically, the 
classification of nephrotic syndrome was based on results from kidney biopsy with 
most children showing minimal changes or FSGS.102 Debate exists as to whether FSGS 
and minimal change disease are the same disease with different severities, or separate 
entities.652 Nevertheless, as kidney biopsies are not routinely performed anymore, this 
classification may be considered outdated for pediatric nephrotic syndrome patients. 
Moreover, nephrotic syndrome may be classified as primary or secondary nephrotic 
syndrome. Primary nephrotic syndrome can be further classified based upon response 
to steroid therapy, which is widely used as classification system nowadays (Figure 
13.1). The majority of patients achieve complete remission after steroid therapy and 
are indicated as SSNS patients. Despite the initial response, over 80% of children 
experience one or several relapses.21 A significant proportion of patients progresses to 
a steroid dependent or frequently relapsing course of disease, which is often an 
indication for additional immunosuppressive treatment.21, 266 Patients who do not 
achieve remission after several weeks of steroid treatment are considered steroid 
resistant.17 Interestingly, we found significant variation in the definitions used for the 
different courses of the disease in pediatric nephrotic syndrome patients. This has 
hampered uniformity of clinical care and research. The use of non-uniform definitions 
and clinical outcomes is not limited to nephrotic syndrome. Several studies have 
highlighted the importance of reporting uniform outcomes in trials involving children 
with CKD.653, 654 Importantly, in 2020 a consensus report was published on the use of 
uniform definitions and classification of acute kidney diseases and disorders and AKI.3 
In Chapter 4 we emphasize that uniformity in definitions for childhood nephrotic 
syndrome is important to allow comparison of data across different centers, 
harmonization of research protocols, and implementation of clinical practice 
guidelines.655 Most children have primary nephrotic syndrome and different 
histological variants have been described including minimal change nephrotic 
syndrome, focal segmental glomerulosclerosis, and membranous nephropathy. 
Membranous nephropathy is one of the most common causes of primary nephrotic 
syndrome adults, however it contributes to less than 5% of cases in children.16, 102 
Furthermore, it is important to consider and rule out secondary causes of nephrotic 
syndrome. Secondary causes of nephrotic syndrome may include infections (hepatitis 
B, hepatitis C, HIV/AIDS, toxoplasmosis), systemic diseases (diabetes, lupus, He-
noch-Schönlein purpura, IgA nephropathy, amyloidosis, sickle cell disease or post-in-
fectious glomerulonephritis), or drug induced nephrotic syndrome. Moreover, 
nephrotic syndrome is a recognized manifestation of neoplastic diseases.656, 657 
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Currently, different classification systems are used to define nephrotic syndrome. 
As described in Chapter 4 classification based on steroid responses poses difficulties 
as well. The current approach results in relatively broad groups of patients that tend to 
be treated as a single entity, whereas significant variation may be present in the 
underlying pathogenesis of the disease and the response to treatment. To work 
towards a more tailored approach in the treatment of nephrotic syndrome, a new 
classification system could be helpful. Recently, Saleem proposed a new classification 
for children with nephrotic syndrome based on disease mechanisms and outcomes 
(Figure 13.1).38 The ultimate goal of molecular stratification is to identify therapeutic 
agents that target specific molecular pathways with minimal adverse effects.38 This 
classification implements our new understanding of underlying molecular mechanisms 
and includes genetic nephrotic syndrome, immune-based nephrotic syndrome, and 
circulating factor disease. 
PART II Optimization of pharmacotherapy in pediatric nephrology patients
Nephrotic syndrome 
Steroids have been the cornerstone of the treatment of nephrotic syndrome for over 
sixty years.658 Current recommendations on the steroid treatment of nephrotic 
syndrome are based on empirical experience and small randomized clinical trials.44, 45, 
446 The current recommendation in the 2012 KDIGO Clinical Practice Guideline for Glo-
merulonephritis is to initiate steroid therapy for at least 12 weeks for a first episode of 
nephrotic syndrome in children. Moreover, the guideline states that daily oral 
prednisone is given for 4-6 weeks followed by alternate day medication for 2-5 months 
with tapering of the dose.24 This recommendation leaves room for interpretation. In 
Chapter 5 we describe the substantial variation found in steroid tapering after 
alternate day dosing among pediatricians and pediatric nephrologists in the 
Netherlands.659 In total, 51 physicians (pediatric nephrologists and pediatricians) 
completed our survey on the management of nephrotic syndrome. Additionally, wide 
variation was found in the choice of steroid sparing agents, biopsy practice, the use of 
steroid coverage during stress, the definition of SRNS, and supportive treatment. As 
expected, practice variation is not only present in the Netherlands, but appears to be 
a global problem due to the lack of clear recommendations in international guidelines.67, 
301 Notably, treatment of the first episode of nephrotic syndrome is often debated. 
The 8 weeks ISKDC protocol and 12 weeks APN protocol are among the most frequently 
used protocols in Europe.67 Using an IPD meta-analysis, we found that children treated 
with a 12 week steroid regimen for a first episode of nephrotic syndrome may have a 
less complicated disease course (Chapter 7). The time to first relapse after cessation of 
prednisolone therapy was significantly shorter for the 8 weeks steroid regimen in 
comparison to the 12 weeks steroid regimen. Relapse rates were significantly higher in 
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the 8 weeks group at one year and at final follow-up. Moreover, the results of our 
study confirm the risk that an early age of onset of nephrotic syndrome is a risk marker 
for a complicated disease course and show that children below 4 years of age show a 
decrease in time to relapse and time to FRNS and higher relapse rates. An IPD 
meta-analysis (by Bagga et al., in which we are involved) including patient data from 
several large clinical trials from the Netherlands63, UK66, India64 and Japan65, is 
underway to determine whether initial therapy should be prolonged in younger 
patients with nephrotic syndrome. In total, approximately 800 children with a first 
episode of nephrotic syndrome are included in this analysis to determine whether 
prolonged therapy (16 to 24 weeks) is more effective than conventional therapy (8 to 
12 weeks) at various age thresholds. 
The optimal treatment for a relapse of nephrotic syndrome is often debated as well, 
partly due to the paucity of well-designed randomized controlled trials addressing this 
issue.660 The RESTERN study (Chapter 8) was designed to study the effectiveness and 
efficacy of a reduced steroid regimen for a relapse of nephrotic syndrome.275 The 
hypothesis of the RESTERN study is that relapses of nephrotic syndrome in children can 
be treated adequately with a reduced duration of alternate day prednisolone (2 weeks 
instead of the currently used 4-6 weeks) after a similar induction of remission. Recently, 
the results of the first randomized controlled trial investigating a short steroid regimen 
for an infrequent relapse of nephrotic syndrome were published. This single-center, 
open-label, randomized controlled trial from India examined the efficacy of 
prednisolone as a short regimen (40 mg/m2 on alternate days for 2 weeks) compared 
with the standard regimen (40 mg/m2 on alternate days for 4 weeks) for children who 
achieved remission. The short steroid regimen resulted in a similar proportion of 
patients developing FRNS or SDNS. Noninferiority of the short regimen could not be 
established as the trial was underpowered.661 Similarly, the RESTERN randomized 
controlled trial aims to assess the efficacy of a short steroid regimen in patients with a 
relapse of nephrotic syndrome, however includes any relapse subsequent to the initial 
episode. Moreover, patients on immunosuppression are included in the RESTERN 
study as well. Finally, as mentioned in the publication of Kainth et al: ‘If the study 
(RESTERN study) succeeds to show noninferiority of the abbreviated regimen, in 
conjunction with the results from our study, a change in the current treatment of 
relapse in nephrotic syndrome can be expected.’661 The RESTERN trial was initially 
designed as a national trial, however, due to low inclusion numbers in the Netherlands, 
the trial was expanded to two centers in Belgium en several centers in Germany. 
Despite the urgent need for this study, several challenges were faced during the set-up 
and conduct of this randomized controlled trial. After first approval of the study in 
Belgium and Germany by the ethics committees and competent authorities, it took 
approximately a year before patient inclusion was started due to several medication 
related problems. The supplier of the prednisolone for the drug suspension terminated 
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supply and alternative suppliers did not possess all documentation required by the 
Belgian and German law to be used for the study drug manufacturing. Ultimately, the 
study drug was switched towards another formulation. Thereafter, significant delays 
were caused by the COVID-19 pandemic. Taken together, despite the urgent need to 
answer the question on optimal steroid treatment for relapses of nephrotic syndrome 
from both a physician’s and patients perspective, conducting a randomized controlled 
trial in a small pediatric subspecialty is challenging and hampered by the small number 
of patients available and lack of research infrastructure.662 As mentioned above, the 
RESTERN study is still in the recruiting phase. Obtaining approval of the different 
competent authorities and ethical committees was especially time consuming. As of 
December 2021, the European Clinical Trial Regulation is expected to apply. The aim of 
this regulation is to simplify and accelerate clinical trials within the European Union in 
order to make new treatment options available sooner. Study protocols and other 
study-related documents will be submitted centrally and electronically in the European 
Union, which will significantly accelerate the start of clinical trials in different European 
countries. Recently, Turner et al. described two European initiatives including the 
conect4children (c4c) consortium that facilitates the design and implementation of 
clinical trials in children.663 The c4c consortium is working to create the infrastructure, 
processes and relationships that will allow the network to optimize the delivery of 
clinical trials in children. Ultimately, this network will improve the quality of pediatric 
research in Europe and for researchers, it is highly important to join such initiatives.
Future perspectives 
Most children with nephrotic syndrome experience one or several relapses and are 
thereby in need of additional courses of steroids, causing (severe) steroid toxicity. 
Recently, Oh et al. assessed the occurrence of steroid-associated adverse events in 
patients with nephrotic syndrome.664 Establishing the most effective and least toxic 
therapeutic regimen for treating nephrotic syndrome in children is highly important 
from both a physician’s as well as patients perspective665 and the main reason for the 
conduct of the RESTERN trial. Recently, results of the PROPINE randomized controlled 
trial were published. Patients were randomized to receive, from day 5 after remission, 
either 18 doses of 40 mg/m2 of prednisone on alternate days (i.e. 5 weeks), or the 
same cumulative dose tapered over double the time. The results of this trial suggest 
that prolonged tapering of prednisone treatment for relapses of SSNS is not beneficial 
in terms of six-month relapse rate.69 Additionally, alternative strategies may be 
considered for steroid minimization, including dose reduction and identification of the 
lowest necessary dose to achieve remission.660 A prospective randomized pilot study 
investigated the efficacy of different doses in achieving remission of nephrotic 
syndrome relapses in a small cohort of 30 patients with SSNS. The results suggest that 
a lower dose (1-1.5 mg/kg/day) may be as safe and effective as the standard dose 
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(2 mg/kg/day [similar to 60 mg/m2]).306 Finally, the addition of a second-line immuno-
suppressive drug might aid in reducing steroid toxicity and aiming for sustained 
remission. Clinical trials are underway to investigate steroid schedules for a first 
manifestation of nephrotic syndrome combined with a second-line immunosuppres-
sant such as MMF or levamisole.276, 280 A similar approach could be considered in case 
of an early or infrequent relapse. Taken together, future studies could focus on a 
combination of a reduction in dose and a reduction in duration to further minimize 
steroid toxicity. Moreover, the addition of a second-line immunosuppressive or immu-
nomodulatory agent in the early course of the disease should be further investigated. 
For patients with SRNS, SDNS, and FRNS several immunomodulatory and/or immuno-
suppressive drugs are available, including cyclophosphamide, cyclosporine, tacrolimus, 
levamisole, MMF, and rituximab. Recently, it was concluded that comparative studies 
of CNIs, MMF, levamisole and alkylating agents demonstrated little or no differences in 
efficacy for children with SSNS. However, due to insufficient power, clinically important 
differences in treatment effects could not be excluded.46 We propose to conduct IPD 
meta-analyses on the non-steroid treatment in patients with FRNS/SDNS and SRNS. 
The use of IPD offers advantages over analyses using aggregate data. Individual level 
information enables more flexible and robust analyses that are possible with aggregate 
study results. 267, 442 As treatment effects and adverse effects seem to differ significantly 
among pediatric patients with nephrotic syndrome, the next step would be to aim for 
individualized treatment. Currently, steroid treatment strategies involve a one dose fits 
all approach. Monitoring prednisolone concentrations could aid in providing more 
tailored treatment regimens. For other immunosuppressive drugs, such as tacrolimus 
and MMF, it is already common practice to perform TDM and subsequently adjust 
dosages. Several studies have shown wide interpatient variability in prednisolone PK 
parameters, and prednisolone has been associated with severe side effects, potentially 
supporting a role for TDM.666-668 Nevertheless, drug monitoring of prednisolone and 
prednisone is not routinely done due to the need of multiple blood sampling and 
practical difficulties as only the unbound fraction of prednisolone is pharmacologically 
active.339 One way to overcome the problem of invasive and time consuming drug 
monitoring in serum is measurement of prednisolone and prednisone levels in saliva.669 
Saliva sampling is painless, non-invasive, can be performed easily at home and does 
not require time demanding sample preparation steps before measurement. For 
cortisol, the relationship between salivary levels and free serum levels is well 
established and prednisolone shares great similarity with endogenous cortisol.670-672 
In population PK studies performed by Teeninga et al. free (nonprotein bound) 
prednisolone concentrations correlated well with salivary concentrations in healthy 
subjects and children with nephrotic syndrome.345, 673 In contrast, in a cohort of 
kidney transplant recipients in the early post-transplant period a poor correlation 
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between both total and free plasma prednisolone AUC and saliva prednisolone AUC 
was observed.674 In future studies, effort should be made to identify the optimal 
targets for prednisolone and investigate the role of prednisolone monitoring using 
saliva in larger cohorts of nephrotic syndrome patients to ultimately implement TDM 
for prednisolone in clinical practice. Moreover, previous research has shown that 
genetic factors can have a major influence on the PK and PD profile of the individual 
patient.321 Currently, pediatric patients with a first manifestation or infrequent relapse 
of nephrotic syndrome are treated with largely standardized steroid regimens, while 
significant inter-individual variation is present in the clinical course of disease and 
adverse effects of steroid treatment. Although the evidence is limited, available data 
(shown in Chapter 6) suggest a role for pharmacogenetics to improve individualization 
of steroid therapy.675 Moreover, pharmacogenetics may have a role in the choice of 
immunomodulatory and/or immunosuppressive drugs as genetic factors may 
predispose to drug efficacy and side effects.676, 677 Several second-line immunosup-
pressive drugs are available, all with their own toxicity profiles and adverse drug 
reactions.46, 52 As evidence to guide the optimal treatment strategy in patients with 
SDNS, FRNS, and SRNS is lacking, the choice of second-line immunosuppressive agents 
is mostly based on the physician’s experience with and knowledge of a drug instead of 
individual patient characteristics. Discriminating which patient would benefit or could 
expect harm from any of the treatments on forehand would be particularly interesting 
(Figure 13.2). Adverse drug reactions are an important cause of morbidity and 
mortality. The use of cyclophosphamide, for example, is currently limited due to the 
potential for carcinogenesis and infertility. However, over one third of patients with 
SDNS appear relapse free after cyclophosphamide therapy which makes cyclophos-
phamide an effective therapy for a subgroup of nephrotic syndrome patients.678 
Helsby et al. reviewed the role of germline pharmacogenetic variation in both plasma 
PK and clinical outcomes and found a potential role for CYP2C19 and CYP2B6 in the 
bioactivation of cyclophosphamide.679 Moreover, the correlation between genetic 
CYP2C19 polymorphisms and toxicity of, and clinical response to, cyclophosphamide 
was evaluated patients with lupus nephritis.680, 681 For MMF, adverse events, especially 
diarrhea and hematological adverse effects, have also been linked to polymorphisms 
in genes association with drug transportation (ABCB1 and SLC01B1) and drug 
metabolism (UGT1A8 and UGT2B7).682-684 Studies in large cohorts of patients with 
nephrotic syndrome and other diseases for which immunosuppressive drugs are used 
are necessary to draw final conclusions about the influence of genetic polymorphisms 
on drug response and drug-related toxicities to ultimately implement pharmacogenet-
ics in clinical practice. Moreover, a better understanding of the pathogenesis of SSNS 
could be a step towards to more targeted therapies as well. Interestingly, Stone et al. 
recently reviewed the genetic risk loci and transcriptional regulators involved in 
SSNS.685 Several transcriptional regulators were identified which may play a role in the 
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etiology of SSNS. Furthermore, this review highlights the important role for the human 
leukocyte antigen gene complex in SSNS.685 The currently available genome-wide 
association studies and candidate gene studies have been small. Studies using large 
populations are therefore needed to identify robust associations.
Chronic kidney disease 
Prescribing drugs in pediatric CKD patients is a great challenge due to the fact that 1. 
the impact of kidney impairment on the PK of drugs is not limited to a decreased 
elimination of drugs excreted by the kidneys and 2. the impact of maturation should be 
taken into account when dosing drugs in children. Drug dosage guidelines are mostly 
based on the assumption that systemic clearance primarily reflects kidney clearance 
and is proportional to kidney function. However, the response to drug therapy is often 
less predictable, which is illustrated by the fact that the frequency of adverse drug 
reactions and other medication related problems is higher in patients with kidney 
disease than in those with normal kidney function.459, 460 In Chapter 10 we describe 
the known PK changes in relation to CKD and extrapolate available knowledge to the 
pediatric CKD population to provide guidance for clinical practice.686 Notably, very 
limited information was available on PK changes in pediatric CKD patients. 
After ingestion, a drug reaches the lumen of the gut, where it may either diffuse 
passively or be actively transported by uptake transporters across the apical 
membrane. Inside the enterocyte, drugs can be actively excreted by transporters or 
Figure 13.2 Population diversity of drug response phenotypes 
Therapeutic response and adverse drug reactions are often apparent among a group of patients with 
seemingly the same diagnosis. Pharmacogenetics may aid in the identification of patients who will benefit or 
will experience significant toxicity from a specific therapy.
response, not toxic
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metabolized by intestinal enzymes. We found limited information on the ontogeny of 
the different influx and efflux transporters and even less information on the impact of 
CKD in children on the presence and functionality of the influx and efflux transporters. 
Moreover, we found that the bioavailability of drugs may be decreased due to increased 
gastric pH and formation of insoluble salts, necessitating a dose increase. In contrast, 
bioavailability of other drugs may be increased in CKD due to downregulation of 
transporters and enzymes in enterocytes, and a lower dose should be administered. 
After absorption, drugs distribute to target tissues and sites of elimination in the 
systemic circulation. Alterations in protein and tissue binding and body composition 
are known to potentially impact Vd, requiring an increase or decrease in dose. 
Nevertheless, no clinical data of drug distribution were available for pediatric CKD 
patients. Furthermore, it was found that CKD may have a direct effect on drug 
metabolizing enzymes and transporters, leading to a decreased functional expression. 
Maturational changes are well known to occur in the drug metabolizing enzymes and 
have a clear impact on drug disposition.543 Evidence on the ontogeny of hepatic phase 
II metabolism appeared especially limited and no data were available on the impact of 
CKD in pediatric patients. Similarly, very little information is available on the ontogeny 
of metabolism in the kidney.687 Finally, a well-known effect of CKD is a decreased GFR. 
However, depending on the cause of kidney dysfunction, tubular secretion can be 
affected to a variable extent in CKD. Biliary excretion eliminates substances from the 
body when the secreted drug is not reabsorbed from the intestine. Interestingly, little 
is known about the developmental changes in biliary excretion in children, even though 
alterations in various biliary efflux transporters have been identified in experimental 
models of CKD. In vivo data in pediatric CKD patients are lacking. Taken together, it is 
difficult to develop generic drug dosing guidelines for pediatric CKD patients due to a 
large variability in PK changes in CKD and maturational changes in children. Current 
dosing guidance for pediatric CKD patients in the Dutch Pediatric Formulary is derived 
from adult data and often excludes young infants and neonates. In general, dose 
adjustments are considered necessary in CKD patients in case the drug is >30% renally 
excreted in the healthy reference population.688 However, this general principle does 
not take into account the potential significant impact on non-renal clearance. Finally, 
dose adjustment and dose individualization is especially important for drugs with a 
small therapeutic range and drugs with well-defined PK-PD relationships.688
Future perspectives
To improve the understanding of PK and PD parameters in CKD patients, national and 
international research groups should ensure adequate representation of CKD patients 
in clinical trials. PBPK modeling can be used to predict the PK behavior of drugs in 
humans using preclinical data. For the pediatric (CKD) population, we believe that PK 
studies and PBPK modeling should be used to incorporate pediatric developmental 
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physiology and disease to predict drug exposure in these vulnerable patient groups. 
Kidney transplantation
Over the past three decades, the CNI tacrolimus has become a cornerstone of immu-
nosuppressive therapy after kidney transplantation in both the adult and pediatric 
population.7, 94 Tacrolimus has a narrow therapeutic index and wide inter- and 
intrapatient PK variability is present, necessitating close TDM.689-691 Both under- and 
overdosing are associated with significant morbidity and mortality.81 In clinical 
practice, the initial tacrolimus dose is generally based on body weight alone. 
Subsequent doses are adjusted using TDM to reach target concentrations. The in-
ter-individual differences in tacrolimus PK are in large part determined genetically.370 
The most common genetic variant associated with tacrolimus dose requirements is a 
single SNP in CYP3A5 (rs 776746), also designated as CYP3A5*1, that leads to an 
increased (functional) protein expression resulting in higher capacity to metabolize 
tacrolimus and an almost 2-fold higher tacrolimus dose requirement in patients.692 
Therefore, the efficacy of CYP3A5 genotype-based tacrolimus dosing was investigated 
in several studies, however no improvement in short- and long-term clinical outcomes 
was observed.94, 693-695 An alternative factor to take into account when determining 
the tacrolimus dose in pediatric kidney transplant patients is drug formulation. In the 
Netherlands, an extemporaneously prepared tacrolimus formulation is often used in 
pediatric kidney transplant patients. A lower, and age-dependent, bioavailability for 
oral liquid formulations in children, compared to the original formulation in adults, is a 
well-known issue.639 In Chapter 12 we investigated the relative bioavailability of 
tacrolimus oral suspension versus oral capsules. Using rich PK data from 38 pediatric 
kidney transplant patients from our clinic, we found a relative bioavailability of the oral 
suspension of approximately 50% compared with the solid oral formulation.696 
Similarly, Reding et al. showed a lower absolute bioavailability of an oral suspension 
based on the contents of the 5 mg tacrolimus capsules compared with oral capsules 
(12.9% versus 25%, respectively) in pediatric liver transplant patients.641 We 
hypothesize that the difference in absolute bioavailability between the formulation 
may be due to a decreased intestinal transit time for the oral suspension, due to the 
sweeteners used in the solution causing an osmotic effect.639 In addition, an age 
related effect may be hypothesized as children taking the liquid formulation are 
generally younger than those taking oral capsules. Hence, the observed lower absolute 
bioavailability of the tacrolimus suspension may have resulted from an increased first 
pass effect due to intestinal metabolism in the gut lumen and enterocytes. CYP 
enzymes are among the most important drug metabolizing enzymes in human 
enterocytes.697 Interestingly, data regarding CYP3A4 expression in the gut wall of children 
are contradictory and range from an increase with age to the opposite pattern of a 
decrease with age.502, 504 Finally, variation in the CYP3A5 genotype as an explanation 
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for the decreased bioavailability was considered unlikely as only two CYP3A5 intermediate 
expressors were present in our study population and both were taking capsules. 
We believe that clinicians should take the difference in bioavailability between oral 
suspension and capsules into account, especially when switching between formulations. 
Furthermore, one could argue that in predicting the first dose, a higher dose of oral 
suspension should be prescribed compared to capsules. 
Another factor indicated to have significant effects on the PK variability is hematocrit 
as tacrolimus extensively binds to erythrocytes. Currently, tacrolimus is measured as 
total concentrations in whole blood, whereas only the unbound concentration in 
plasma is pharmacologically active as it is available for cellular diffusion and 
distribution.77 Especially in the first months after transplantation, hematocrit levels 
tend to change significantly.86, 617 A change in hematocrit will affect the whole blood 
concentration, without affecting the pharmacologically active unbound plasma 
concentration. In Chapter 11 we show the importance of hematocrit correction in 
tacrolimus target evaluation in pediatric kidney transplant patients.698 Several 
population PK studies have identified hematocrit as a key factor for interpretation of 
tacrolimus whole blood concentrations.699 The majority of our patients had a lower 
hematocrit value than the reference value of adult kidney transplant patients and 
thereby especially toxicity may be prevented. Using hematocrit corrected target 
concentrations, a different interpretation of tacrolimus target exposure was found in 
42% of our patients. The use of hematocrit corrected targets could prevent incorrect 
dose adjustments of tacrolimus based on whole blood concentrations. ‘Hard’ clinical 
endpoints such as toxicity and graft rejection are rarely reached in pediatric kidney 
transplant patients due to tight monitoring and rapid intervention. Nevertheless, 
every effort should be made to optimize treatment in this vulnerable patient group to 
ensure long-term graft survival. The use of the nomograph presented in Chapter 11, 
showing the relationship between whole blood tacrolimus concentrations and plasma 
tacrolimus concentrations for different hematocrit levels, can be helpful to guide TDM 
of tacrolimus. Tacrolimus is widely used as a second-line immunosuppressive agent in 
children with nephrotic syndrome as well. However, tacrolimus PK studies in patients 
with nephrotic syndrome are limited.700 Several physiological changes can be present 
in patient with nephrotic syndrome including intestinal edema secondary to hypoalbu-
minemia.93 Interestingly, Medeiros et al. performed PK profiles in children with SRNS 
treated with tacrolimus during a relapse and remission and concluded that most of our 
knowledge regarding transplant recipients can be applied to nephrotic syndrome as 
the PK parameters did not differ and were not affected by the nephrotic state.701
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Several factors are known to affect tacrolimus PK including genotype, age, body 
weight, ethnicity, albumin concentration, hematocrit, and concomitant drugs.77 
Combining these factors in a population PK model is expected to result in an improved 
prediction of an individual patient’s tacrolimus dose requirement. To date, multiple 
models predicting the tacrolimus starting dose have been developed.86, 702 Importantly, 
these models need to be tested prospectively to assess accuracy and clinical benefit of 
validated population PK models. In most population PK models, CYP3A5 genotype is 
taken into account, whereas additional tacrolimus PK related genes have emerged, 
including CYP3A4, CYB5R2, PPARA, and POR.703-705 Tacrolimus is also a P-gp substrate 
and common ABCB1 SNPs have been associated with decreased P-gp activity or 
decreased efflux. Despite the prominent role of P-gp in tacrolimus transport, 
associations between ABCB1 SNPs and tacrolimus PK remain inconclusive.706-708 
Future research into polygenic models is needed to advance pharmacogenetic-guided 
tacrolimus strategies.707 In addition to building a comprehensive PK profile, the future 
of tacrolimus precision dosing should also be driven by PD data. PD data presented as 
clinical outcomes (i.e. graft rejection and toxicity) are hard to use in clinical practice, as 
these do not allow clinicians to make timely decisions to adjust the dose early in 
treatment. The use of surrogate biomarkers, such as calcineurin inhibition activity, has 
been proposed.709, 710 Future studies should focus on investigating and implementing 
PD and immunologic biomarkers to aid in identifying kidney transplant patients at risk 
of rejection, infections, and malignancy. 
Conclusions
Taken together, the ultimate goal is to provide optimal therapy for pediatric nephrology 
patients. With the studies presented in this thesis, we took small steps down the road 
towards treatment optimization in patients with CKD, kidney transplantation, and 
nephrotic syndrome. We described PK changes in relation to CKD and provided 
guidance for clinical practice. Moreover, we highlighted the importance of drug 
formulation and hematocrit correction in pediatric kidney transplant patients treated 
with tacrolimus. For nephrotic syndrome, several areas for improvement in clinical 
care were identified and possibilities for treatment optimization and individualization 
were investigated. Finally, in a few years we hope to provide a definite answer to the 
important question on steroid reduction for the treatment of relapses of nephrotic 
syndrome with the results of the RESTERN study. 
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The aim of the research presented in this thesis is to improve diagnosis and treatment 
in pediatric nephrology patients with a special focus on nephrotic syndrome. Part I 
focuses on the diagnosis and classification of nephrotic syndrome. In Part II treatment 
optimization in pediatric patients with nephrotic syndrome, CKD, and kidney trans-
plantation is studied. Chapter 1 includes a general background and outline of the 
thesis.
PART I Diagnosis and classification of nephrotic syndrome
In the Netherlands, approximately 55-60 children are diagnosed with nephrotic 
syndrome each year. Nephrotic syndrome is characterized by the triad of edema, hy-
poalbuminemia (<25 g/l), and proteinuria (≥200 mg protein per mmol creatinine). 
Patients typically present at the general practitioners’ office with periorbital edema, 
mostly noticeable in the morning. These symptoms are initially often attributed to 
allergy, partly due to frequently coexisting atopic constitution, which causes a delay in 
accurate diagnosis. In Chapter 2 we present a clinical lecture for general practitioners 
to emphasize the use of dipstick analysis in pediatric patients with facial edema to 
enhance rapid referral to a pediatrician in case of nephrotic syndrome and initiation of 
adequate therapy. Children with nephrotic syndrome are treated with high doses of 
steroids. Most patients show an excellent response. Nevertheless, approximately 
10-15% of patient do not respond to the initial 4 or 6 week course of steroids and are 
considered steroid resistant. Genetic analysis is generally performed in these children. 
Interestingly, variants in nuclear genes encoding mitochondrial proteins involved in the 
CoQ10 biosynthesis pathway account for 1% of genetic SRNS cases. In Chapter 3 we 
included a case description of three patients with CoQ10 deficiency and reviewed the 
literature on mitochondrial diseases and the kidney with a special focus on CoQ10 
deficiency. Early recognition of defects in the CoQ10 biosynthesis is important as 
patients with primary CoQ10 deficiency may be responsive to timely treatment with 
oral CoQ10 supplementation. 
After diagnosis, nephrotic syndrome is mostly classified based on the response to 
steroids and course of disease. Interestingly, we identified significant variation in the 
definitions used to classify these responses. This has hampered uniformity of clinical 
care and research. In Chapter 4 we stress the importance of uniformity in definitions 
to allow comparison of data across different centers, harmonization of research 
protocols, and implementation of clinical practice guidelines.
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PART II Optimization of pharmacotherapy in pediatric nephrology patients
Nephrotic syndrome 
Steroids have been the cornerstone of the treatment of nephrotic syndrome for over 
sixty years. The optimal dose and duration of steroid treatment, and choice of steroid 
sparing agents in pediatric nephrotic syndrome patients are often debated. Current 
recommendations are mostly based on empirical experience and small randomized 
clinical trials and leave room for interpretation. Consequently, significant variation is 
present in the management of nephrotic syndrome. In Chapter 5 we describe substantial 
variation found in steroid tapering after alternate day dosing among pediatricians and 
pediatric nephrologists in the Netherlands. Additionally, wide variation was found in 
the choice of steroid sparing agents, biopsy practice, the use of steroid coverage during 
stress, and supportive treatment. Currently, pediatric patients with a first manifestation 
or infrequent relapse of nephrotic syndrome are treated in a non-individualized 
manner with a one dose fits all steroid regimen, while significant inter-individual 
variation is present in the clinical course of disease and adverse effects of steroid 
treatment. Previous research has shown that genetic factors can have a major influence 
on the PK and PD profile of the individual patient. Although the evidence is limited, 
available data (shown in Chapter 6) suggest a role for pharmacogenetics to improve 
individualization of steroid therapy. Moreover, the mechanisms of steroid action and 
clinical PK and PD of prednisone in nephrotic syndrome patients are outlined in this 
chapter. Despite these opportunities for treatment individualization, patients are 
currently treated according to largely standardized treatment regimens. However, a 
clear recommendation is lacking and the optimal treatment strategy remains a matter 
of debate. In Europe, the 8 weeks ISKDC protocol (4 weeks of daily steroids and 4 
weeks of alternate day steroids) and 12 weeks APN protocol (6 weeks of daily steroids 
and 6 weeks of alternate day steroids) are among the most frequently used protocols, 
however it is currently unknown if these treatment regimens are equally effective. 
Using an IPD meta-analysis, we found that children treated with a 12 week steroid 
regimen for a first episode of nephrotic syndrome may have a less complicated disease 
course compared to children who were treated according to the 8 weeks steroid 
regimen (Chapter 7). The time to first relapse after cessation of prednisolone therapy 
was significantly shorter for the 8 weeks steroid regimen in comparison to the 12 
weeks steroid regimen. Moreover, relapse rates were significantly higher in the 8 
weeks group at one year and at final follow-up. Therefore, we recommend to adhere 
to the 12 weeks steroid protocol for the treatment of a first presentation of nephrotic 
syndrome. 
There is also equipoise on the optimal treatment for a relapse of nephrotic syndrome. 
We designed the REducing STEroids in Relapsing Nephrotic syndrome (RESTERN) 
randomized controlled trial to study the effectiveness and efficacy of a reduced steroid 
regimen for a relapse of nephrotic syndrome. The hypothesis of the RESTERN study is 
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that relapses of nephrotic syndrome in children can be treated adequately with a 
reduced duration of alternate day prednisolone (2 weeks instead of the currently used 
4-6 weeks) after a similar induction of remission. Chapter 8 outlines the protocol of 
the RESTERN study and provides an update on the trial. During the design and conduct 
of the trial, we encountered several obstacles, which hampered timely patient 
recruitment. We discuss these obstacles and potential solutions to overcome similar 
obstacles for future trials in Chapters 8 and 13. 
Chronic kidney disease 
CKD is a general term for multiple, heterogeneous disorders affecting kidney structure 
and function with variable clinical presentation, severity and rate of progression. 
Glomerular disorders, including nephrotic syndrome, are an important cause of CKD in 
children. A great challenge in pediatric CKD patients is to find the right drug at the right 
dose. The common adage in pediatrics that children are not little adults, definitely 
applies to pediatric CKD patients as well. For instance, causes of CKD in children are 
different from adults. Moreover, large differences exist in the PK and PD of drugs 
between the adult and pediatric population. CKD is associated with multiple 
physiological changes and may therefore influence various PK parameters. For 
pediatric patients, the impact of maturation on drug disposition and action should be 
taken into account as well. Little information is available on the exact interplay between 
age and disease on PK, PD and dose requirements. In Chapter 10 we describe the 
known PK changes in relation to CKD and extrapolate available knowledge to the 
pediatric CKD population to provide guidance for clinical practice. Important principles 
to consider include the therapeutic index of the drug, the presence of active 
metabolites that are eliminated by the kidneys, and the extent of reduction in kidney 
function.
Kidney transplantation
Kidney failure is the final stage of CKD and defined as a GFR <15ml/min/1.73m2 or the 
requirement for kidney replacement therapy. Kidney transplantation is the preferred 
treatment for children in need of kidney replacement therapy. Approximately 25-35 
patients below the age of nineteen receive a kidney transplant each year in the 
Netherlands. CNIs, including tacrolimus, are the cornerstone of immunosuppressive 
therapy after kidney transplantation. Tacrolimus is characterized by a narrow 
therapeutic index: low concentrations are associated with an increased risk of acute 
rejection of the transplanted organ, while high concentrations are associated with 
toxicity, malignancy, and infection. Moreover, wide inter- and intrapatient PK variability 
is present, necessitating close TDM to optimize the therapeutic effect and minimize 
adverse effects. Several factors are known to affect tacrolimus PK including hematocrit. 
In Chapter 11 we show the importance of hematocrit correction in tacrolimus target 
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evaluation in pediatric kidney transplant patients. Using hematocrit corrected target 
concentrations, a different interpretation of tacrolimus target exposure was found in 
42% of our patients. As the majority of our patients had a lower hematocrit value than 
the reference value of adult kidney transplant patients, which causes an underestima-
tion of the pharmacologically active concentration, toxicity in particular may be 
prevented. An additional factor to take into account when determining the tacrolimus 
dose in pediatric kidney transplant patients is drug formulation. In the Netherlands, an 
extemporaneously prepared tacrolimus formulation is often used in pediatric kidney 
transplant patients. A lower and age-dependent bioavailability for oral liquid 
formulations in children, compared to the original solid formulation in adults, is a 
well-known issue. In Chapter 12 we investigated the relative bioavailability of 
tacrolimus oral suspension versus oral capsules and found a relative bioavailability of 
the oral suspension of approximately 50% compared with the solid oral formulation. 
We advise that clinicians should take the difference in bioavailability between oral 
suspension and capsules into account, especially when switching between formulations.
Conclusion
Taken together, the optimal treatment of pediatric nephrology patients is often 
debated. Chapter 13 provides a general discussion in which the main findings of this 
thesis are discussed, followed by implications and recommendations for future studies. 
Large clinical trials such as the RESTERN trial, are indispensable to optimize treatment 
strategies and effort should be made to establish and join research networks to 
improve the quality of pediatric research. Steroid treatment strategies for children 
with nephrotic syndrome currently involve a one dose fits all approach. In future 
studies, effort should be made to work towards a more personalized approach which 
includes pharmacogenetics and TDM. Moreover, we believe that population PK studies 
and PBPK modeling should be used to incorporate pediatric developmental physiology 
and disease to predict drug exposure in vulnerable patient groups, including pediatric 
CKD and kidney transplant patients. 
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11β-HSD  11β-hydroxysteroid dehydrogenase
AAG Alpha 1-acid glycoprotein
ACE Angiotensin converting enzyme
AKI Acute kidney injury
APN Arbeitsgemeinschaft für Pädiatrische Nephrologie
ARB Angiotensin-II receptor blocker
ATP Adenosine triphosphate
AUC Area under the concentration time curve
Bmax Maximum binding concentration
c4c Conect4children
CCMO Central committee on research involving human subjects
CKD Chronic kidney disease
CL Clearance
CNI Calcineurin inhibitor
CONSORT Consolidated Standards of Reporting Trials
CoQ10 Coenzyme Q10
Css Concentration at steady state
Cwb Whole blood concentration
CYP Cytochrome P450
ESRD End stage renal disease
DNA Deoxyribonucleic acid 
FHCT Fraction of hematocrit
FRNS Frequently relapsing nephrotic syndrome
FSGS Focal segmental glomerulosclerosis
GFR Glomerular filtration rate 
GLCCI1 Glucocorticoid-induced transcript 1 
GPN Gesellschaft für Pädiatrische Nephrologie
GR  Glucocorticoid receptor
GR/GC Glucocorticoid receptor/glucocorticoid
IPNA International Pediatric Nephrology Association
IPD Individual patient data
ISKDC International Study of Kidney Disease in Children
IQR Interquartile range
KD Dissociation constant
KDIGO Kidney Disease: Improving Global Outcomes
LC-MS/MS Liquid chromatography–tandem mass spectrometry
MDR1 Multidrug resistance protein 1 
MELAS  Mitochondrial myopathy encephalopathy with lactic acidosis and stroke-like episodes
MIC Minimum inhibitory concentration
MIF Macrophage migration inhibitory factor
MMF Mycophenolate mofetil
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mRNA Messenger ribonucleic acid
MRP Multidrug resistance-associated protein 
Nat N-acetyltransferases
OATP Organic anion-transporting polypeptide






RAAS Renin angiotensin aldosterone system
RESTERN REducing STEroids in Relapsing Nephrotic syndrome
RNA  Ribonucleic acid 
ROS Reactive oxygen species
RSE Relative standard error of the estimate
SD Standard deviation
SDNS Steroid dependent nephrotic syndrome
SNP Single nucleotide polymorphism
SRNS Steroid resistant nephrotic syndrome
SSNS  Steroid sensitive nephrotic syndrome
TDM Therapeutic drug monitoring
UDP-GT Uridine 5’-diphospho-glucuronosyltransferases
Vd Volume of distribution
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Nederlandse samenvatting (Dutch summary)
Optimaliseren van de behandeling van kinderen met een nierziekte, met speciale 
aandacht voor het nefrotisch syndroom 
Het nefrotisch syndroom is een van de meest voorkomende aandoeningen van de 
nierfilters op de kinderleeftijd. Over het algemeen heeft deze ziekte een goede 
prognose met behoud van nierfunctie. Prednisolon vormt de hoeksteen van de 
behandeling, echter over de optimale duur en dosering is nog veel discussie. Chronische 
nierinsufficiëntie is een overkoepelende term voor verschillende ziekten die de 
structuur van de nier en de nierfunctie aantasten, waarbij de klinische presentatie, 
ernst en mate van progressie kan variëren. Bij een deel van de patiënten leidt 
chronische nierinsufficiëntie uiteindelijk tot nierfalen, waarbij een niertransplantatie 
de behandeling van voorkeur is. De onderzoeken gepresenteerd in dit proefschrift 
hebben als doel om de behandeling van kinderen met een nierziekte te optimaliseren, 
waarbij de focus ligt op het nefrotisch syndroom. In deel I van dit proefschrift wordt de 
diagnose en de classificatie van het nefrotisch syndroom besproken. In deel II gaan we 
in op de behandeling van het nefrotisch syndroom, het voorschrijven van medicatie bij 
kinderen met chronische nierinsufficiëntie en de behandeling met tacrolimus bij 
kinderen na een niertransplantatie. De achtergronden van dit proefschrift zijn 
beschreven in Hoofdstuk 1.
Deel I  Diagnose en classificatie van het nefrotisch syndroom
In Nederland wordt de diagnose nefrotisch syndroom jaarlijks bij ongeveer 55 tot 60 
kinderen gesteld. Bij het nefrotisch syndroom lekken de nierfilters eiwit vanuit het 
bloed naar de urine. Dit zorgt voor de klassieke kenmerken proteïnurie (eiwit in de 
urine), hypoalbuminemie (laag eiwitgehalte in het bloed) en oedeem. Kinderen met 
het nefrotisch syndroom presenteren zich bij de huisarts meestal met klachten van 
zwelling van de oogleden en/of het gelaat. In eerste instantie worden deze klachten 
vaak toegewezen aan een allergie. Dit veroorzaakt een forse vertraging in het stellen 
van de juiste diagnose en verwijzing van de patiënt naar een kinderarts of kindernefro-
loog voor adequate behandeling. In hoofdstuk 2 wordt een klinische les voor huisartsen 
gepresenteerd, waarin we benadrukken dat beperkt aanvullend onderzoek in de vorm 
van simpel urineonderzoek (dipstick) snel tot de juiste diagnose kan leiden, zodat 
gerichte verwijzing en behandeling kunnen worden ingezet. De behandeling van 
kinderen met het nefrotisch syndroom bestaat uit hoge doseringen prednisolon. Deze 
behandeling wordt al ruim 60 jaar toegepast en het overgrote deel van de kinderen 
reageert hier goed op. Als kinderen niet goed reageren op prednisolon, kan genetische 
analyse (analyse van het erfelijke materiaal) worden ingezet om te zoeken naar een 
onderliggende genetische (erfelijke) oorzaak van het nefrotisch syndroom. Een 
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zeldzame genetische oorzaak is de mitochondriële ziekte genaamd co-enzym Q10 
(CoQ10) deficiëntie (tekort). In hoofdstuk 3 geven we een overzicht van alle patiënten 
die beschreven zijn in de literatuur met dit ziektebeeld met betrokkenheid van de 
nieren. Daarin beschrijven we in detail het ziektebeloop van drie kinderen uit het 
Radboudumc met uiteenlopende symptomen waarbij de diagnose CoQ10 deficiëntie is 
gesteld. Het is belangrijk om de ziekte in een vroeg stadium te onderkennen, omdat 
CoQ10 deficiëntie, in tegenstelling tot de meeste mitochondriële ziekten, potentieel 
behandelbaar is. 
Het nefrotisch syndroom wordt vaak ingedeeld op basis van de reactie op prednisolon 
en het beloop van de ziekte. Ondanks dat deze indeling het meest gehanteerd wordt, 
zijn de definities die gebruikt worden lang niet altijd eenduidig. In hoofdstuk 4 
beschrijven we de verschillen in de definities die worden gebruikt voor de verschillende 
vormen van het nefrotisch syndroom in de klinische praktijk en in klinische trials, te 
weten: steroïd afhankelijk nefrotisch syndroom, frequent recidiverend nefrotisch 
syndroom en steroïd resistent nefrotisch syndroom. We benadrukken dat het gebruik 
van eenduidige definities essentieel is om patiëntgegevens te vergelijken, onder-
zoeksprotocollen te harmoniseren en klinische richtlijnen te implementeren. 
Deel II  Optimaliseren van de behandeling van kinderen met een nierziekte
Nefrotisch syndroom
De optimale behandelduur en dosering van prednisolon en keuze voor aanvullende 
afweer onderdrukkende medicatie bij kinderen met het nefrotisch syndroom is niet 
bekend. De huidige richtlijnen zijn met name gebaseerd op eerdere ervaringen en 
kleine studies. Hierdoor is er veel variatie in behandelprotocollen per land, per centrum 
en zelfs per zorgverlener. In hoofdstuk 5 worden de resultaten beschreven van een 
enquête die we hebben afgenomen bij kinderartsen en kindernefrologen in Nederland 
om de behandeling van het nefrotisch syndroom in kaart te brengen. We zien daarin 
grote verschillen in het afbouwen van prednisolon, de keuze van tweedelijns afweer 
onderdrukkende medicatie, de reden voor een nierbiopt, het gebruik van prednisolon 
stress-schema’s en de ondersteunde behandeling van kinderen met het nefrotisch 
syndroom. Uit de enquête kwam naar voren dat de prednisolon behandelschema’s 
voor de eerste presentatie of een recidief nefrotisch syndroom wel redelijk uniform 
zijn in Nederland. 
Op dit moment wordt de behandeling nog niet afgestemd op de individuele patiënt. 
Er is echter veel variatie tussen patiënten in het klinisch beloop van de ziekte, de 
bijwerkingen van de behandeling en de reactie op prednisolon. Een deel van deze 
variatie kan verklaard worden door erfelijke factoren. Farmacogenetica beschrijft het 
onderzoek naar genetische variaties in relatie tot de respons en bijwerkingen van 
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geneesmiddelen. Er kan daarnaast ook variatie zijn in de farmacokinetiek en farmaco-
dynamiek tussen individuen en binnen individuen. Farmacokinetiek beschrijft wat het 
lichaam doet met het medicament (opnemen, afbreken en uitscheiden) en andersom 
is de farmacodynamiek hetgeen wat het medicament doet met het lichaam (werking 
en bijwerking). In hoofdstuk 6 beschrijven we op welke manier prednisolon werkzaam 
is en beschrijven we de farmacokinetische, farmacodynamische en farmacogenetische 
eigenschappen van prednisolon bij het nefrotisch syndroom. Deze informatie is 
noodzakelijk om op termijn toe te werken naar meer geïndividualiseerde therapie. 
De huidige aanbeveling vanuit de internationale richtlijn voor de behandeling van een 
eerste presentatie nefrotisch syndroom is om dagelijks prednisolon te geven 
gedurende 4-6 weken, gevolgd door om-de-dag prednisolon gedurende 2-5 maanden 
met een afbouwschema van de prednisolon. Deze aanbeveling laat ruimte voor 
interpretatie en dit zorgt ervoor dat er verschillende behandelschema’s worden 
gebruikt in Europa. De meeste kinderen met het nefrotisch syndroom worden 
behandeld met een prednisolonschema van 8 of 12 weken. Omdat de behandeling 
met prednisolon kan zorgen voor veel bijwerkingen en negatieve lange termijneffec-
ten, waaronder groeivertraging, botontkalking, gedragsproblemen en hoge bloeddruk, 
is het belangrijk om zo min mogelijk prednisolon te geven. In hoofdstuk 7 beantwoorden 
we de vraag of het 8 weken prednisolonschema net zo effectief is als het 12 weken 
prednisolonschema voor een eerste presentatie van het nefrotisch syndroom en we 
zouden moeten switchen naar het 8 weken schema, omdat dit minder prednisolonbe-
lasting geeft. Om dit te onderzoeken hebben we de individuele patiëntgegevens van 
twee grote gerandomiseerde studies vergeleken. Uit deze vergelijking blijkt dat de tijd 
tot het eerste recidief significant korter is in de 8 weken groep. Daarnaast hebben de 
kinderen die met 8 weken prednisolon behandeld worden vaker recidieven, gemeten 
na 1 jaar en bij de totale follow-up. Dit maakt dat ons advies is om kinderen met een 
eerste presentatie van het nefrotisch syndroom met 12 weken prednisolon te 
behandelen. 
Ook de optimale behandeling van een recidief nefrotisch syndroom is nog niet bekend. 
De internationale, dubbelblinde, placebogecontroleerde RESTERN studie is opgezet 
om de effectiviteit en de veiligheid van een verkorte prednisolonkuur voor een recidief 
nefrotisch syndroom te onderzoeken. RESTERN is een acroniem voor REduceren van 
STEroiden voor een Recidief Nefrotisch syndroom. In hoofdstuk 8 wordt het onder-
zoeksprotocol beschreven. De planning was aanvankelijk om deze studie in 4 jaar af te 
ronden, echter hebben een aantal logistieke (medicatie)problemen ervoor gezorgd dat 
deze studie nog niet afgerond is. Naast de beschrijving van het onderzoeksprotocol 
geven we een update van de studie en een inzicht in de obstakels die we zijn 
tegengekomen in de opzet en de uitvoering van dit onderzoek. 
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Een andere uitdaging binnen de kindernefrologie is het voorschrijven van medicatie bij 
kinderen met chronische nierinsufficiëntie. Een veelgebruikte stelling binnen de kin-
dergeneeskunde is ‘kinderen zijn geen kleine volwassenen’. Deze stelling is ook zeker 
van toepassing op verschillende facetten binnen de kindernefrologie. De oorzaken 
voor chronische nierinsufficiëntie zijn beduidend anders voor kinderen dan voor 
volwassenen. Ook bij het voorschrijven van medicatie zijn er grote verschillen tussen 
kinderen en volwassenen. De doseringsadviezen bij kinderen zijn vaak gebaseerd op 
gegevens van volwassenen. Van oudsher worden de doseringen bij kinderen vaak 
uitgedrukt in mg/kg wat inhoudt dat een kind dat twee keer zo zwaar is, twee keer 
zoveel van een geneesmiddel krijgt. Dit blijkt in de praktijk echter geen goed schema. 
Het is essentieel om bij kinderen rekening te houden met de leeftijdsafhankelijke 
veranderingen op de verwerking van medicatie in het lichaam. Daarnaast is het in het 
geval van chronische nierinsufficiëntie belangrijk om de effecten van een verminderde 
nierfunctie op de verwerking en uitscheiding van medicatie mee te nemen. Een logisch 
effect van nierinsufficiëntie is een verminderde uitscheiding van geneesmiddelen door 
de nieren. Onderzoek bij volwassenen met chronische nierinsufficiëntie heeft laten 
zien dat er ook andere effecten kunnen plaatsvinden die meewegen in het bepalen van 
het doseringsadvies. Over de combinatie van de leeftijdsafhankelijke veranderingen en 
de effecten van chronische nierinsufficiëntie op de verwerking van geneesmiddelen bij 
kinderen is nog weinig bekend. In hoofdstuk 10 hebben we resultaten van onderzoeken 
hierover samengebracht om op deze manier een advies te geven voor het doseren van 
geneesmiddelen bij kinderen met chronische nierinsufficiëntie. 
Niertransplantatie
Jaarlijks ondergaan ongeveer 25-35 kinderen in Nederland een niertransplantatie. 
Deze kinderen worden nadien levenslang behandeld met afweer onderdrukkende 
medicijnen. Tacrolimus is één van de middelen die hiervoor vaak gebruikt wordt. 
Tacrolimus is een effectief middel tegen afstoting, echter heeft dit middel een 
zogenaamde smalle therapeutische breedte. Dat betekent dat een te hoge dosering 
kan leiden tot schade in de nieren en hersenen en het risico op het krijgen van ernstige 
infecties en kanker kan verhogen. Lage doseringen geven een risico op acute afstoting 
van de transplantaatnier. Om de concentratie van tacrolimus goed te houden wordt 
frequent bloed afgenomen en de dosering zo nodig aangepast. Er zijn veel factoren 
beschreven die de farmacokinetiek van tacrolimus beïnvloeden, waaronder het 
bloedgehalte van de patiënt (hematocriet). In hoofdstuk 11 beschrijven we de invloed 
van hematocrietcorrectie op het evalueren van de tacrolimusspiegels bij kinderen na 
een niertransplantatie. De meerderheid van de onderzochte kinderen had een lager 
bloedgehalte dan de referentiewaarde van volwassen niertransplantatiepatiënten op 
basis waarvan de huidige streefwaarden zijn geformuleerd. Met behulp van voor he-
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matocriet-gecorrigeerde streefconcentraties, bleek in 42% van de onderzochte 
kinderen de blootstelling niet goed geïnterpreteerd. Tenslotte is het voor kinderen 
essentieel dat medicatie ook in drankvorm aangeboden kan worden. Voor tacrolimus 
is deze vorm helaas niet in de handel verkrijgbaar en daarom maken de apotheken 
deze drank zelf. In hoofdstuk 12 hebben we de biologische beschikbaarheid van 
tacrolimus in drankvorm vergeleken met tacrolimus capsules, die ook frequent 
gebruikt worden. De relatieve biologische beschikbaarheid van tacrolimus in 
drankvorm was ongeveer 50% vergeleken met tacrolimus capsules. Artsen moeten op 
de hoogte zijn van dit verschil, zodat de voorgeschreven dosering aangepast kan 
worden, met name als er tussen de formuleringen gewisseld wordt. 
Conclusie
De behandeling van kinderen met een nierziekte kan nog op vele fronten geoptimali-
seerd worden. In hoofdstuk 13 beschrijven we een algemene discussie waarin de 
belangrijkste bevindingen van onderzoeken verricht in het kader van deze thesis staan 
beschreven, gevolgd door aanbevelingen voor toekomstig onderzoek. Grote klinische 
studies, zoals de RESTERN studie, zijn hard nodig om de behandeling van kinderen met 
een nierziekte te verbeteren. Op dit moment worden kinderen met het nefrotisch 
syndroom (bijna) allemaal op dezelfde manier behandeld met hoge doseringen 
prednisolon. Met de resultaten van de RESTERN studie hopen we over een aantal jaar 
het antwoord te geven op de belangrijke vraag of kinderen met een recidief van het 
nefrotisch syndroom behandeld kunnen worden met minder prednisolon. In de 
toekomst zal verder onderzocht worden op welke manier we de prednisolonbelasting 
bij kinderen verder kunnen minimaliseren en hoe we kunnen toewerken naar een 
individueel behandelplan voor de patiënt. Om dit te bereiken zijn een goede 
infrastructuur, onderzoeksnetwerken en (inter)nationale samenwerkingsverbanden 
essentieel. 
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Research data presented in this thesis and obtained during this PhD at the department 
of pediatric nephrology at the Radboudumc, Nijmegen, were obtained according to 
the Findable, Accessible, Interoperable and Reusable (FAIR) principles. This thesis is 
based on the results of human studies, which were conducted in accordance with the 
principles of the Declaration of Helsinki, Dutch code of conduct, and Dutch Personal 
Data protection Act. The medical ethical committee of Arnhem-Nijmegen, has given 
approval to conduct these studies. The RESTERN trial has been approved by the Dutch 
Competent Authority (Central Committee on Research Involving Human Subjects, 
CCMO) as well. Study data of the RESTERN trial are collected and stored on the secure 
Castor servers and the departments’ H-drive (H:\KG - Klinisch WO). Data are organized 
under anonymous coding (consecutively assigned study numbers at the moment of 
enrollment, e.g. RESTERN_001, RESTERN_002 etc.). Back-ups are made twice a day on 
the Castor servers. Data are stored separately from the participant’s identifying 
information. The code list is located electronically on the Radboudumc server which 
is password protected and safe from unauthorized use. Data management and 
monitoring are also performed within Castor. An audit trail is incorporated to provide 
evidence of the activities that has altered the original data. The privacy of the 
participants in this study is warranted by use of encrypted and unique individual 
subject codes. The patient data for the analyses of the studies as presented in chapter 
5, 7, 11, and 12 is stored on the secure Castor servers and/or the departments’ H-drive 
(H:\KG - Klinisch WO). Data are kept until fifteen years after publication. Using the 
patient data of the RESTERN study in future research is possible if the patient has given 
specific permission in the informed consent form. Data generated in this thesis are 
available from the associated corresponding authors upon reasonable request. The 
datasets analyzed in the IPD meta-analysis are available from the corresponding 
author in consultation with the primary investigators of the trials on reasonable 
request.
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Anne Merel Schijvens, dochter van Anna van Strien en John Schijvens, werd op zondag 
3 maart 1991 geboren in Oosterhout (NB). Na een moeizame start is ze opgegroeid in 
Dongen samen met haar broertje Max. Na het Cum Laude behalen van haar gymnasium-
diploma op het Cambreur College in Dongen in 2009, startte zij met de opleiding 
Geneeskunde aan de Radboud Universiteit in Nijmegen. Tijdens haar studie heeft zij 
gewerkt bij Active Work Arbodienst, waar zij zich met name heeft bezig gehouden met 
het uitvoeren van medische keuringen. Gedurende de masterfase van de studie 
geneeskunde heeft Anne onderzoek gedaan bij de afdeling neonatologie van het 
Amalia Kinderziekenhuis onder begeleiding van dr. D. Liem. In het laatste jaar van de 
opleiding heeft Anne haar onderzoeksstage en seniorcoschap met veel plezier en 
succes verricht bij de afdeling kindernefrologie van het Amalia Kinderziekenhuis. 
Na het afronden van haar studie Geneeskunde in september 2016, is Anne haar 
promotie onderzoek gestart op de afdeling kindernefrologie in het Radboudumc 
Amalia Kinderziekenhuis. Onder begeleiding van prof. dr. Michiel Schreuder is Anne gestart 
met de opzet en coördinatie van de RESTERN studie, een klinische geneesmiddelen-
studie naar de behandeling van recidieven van het nefrotisch syndroom. Dit onderzoek 
wordt gefinancierd door de Nederlandse Nierstichting. Gedurende haar promotie-
onderzoek heeft Anne deelgenomen aan verschillende cursussen en curricula, 
waaronder het TULIPS PhD curriculum. Daarnaast heeft zij studenten begeleid en 
plaatsgenomen in het landelijk bestuur van PLAN (Platform AIOS en postdocs 
nefrologie). Haar promotietraject heeft zij gecombineerd met de opleiding tot klinisch 
farmacoloog bij opleiders prof. dr. Kees Kramers en prof. dr. Saskia de Wildt. Van 
oktober 2020 tot maart 2021 heeft zij de afronding van haar promotieonderzoek 
gecombineerd met een ANIOS-functie bij de kinderrevalidatie bij Libra Revalidatie & 
Audiologie. In maart 2021 is zij gestart als revalidatiearts in opleiding bij Libra 
Revalidatie & Audiologie. Anne woont samen met Job en hun kinderen Maas (2018) 
en Saar (2019) in Dongen. 
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Name PhD student:  Anne M. Schijvens
Department:  Pediatrics
Graduate school:  Radboud Institute for Molecular Life Sciences
PhD period:  1-9-2016 until 1-3-2021
Promotors: Prof. dr. M.F. Schreuder
  Prof. dr. L.P.W.J. van den Heuvel
  Prof. dr. S.N. de Wildt
Training activities Year(s) ECTS
a. Courses & workshops
RIMLS Introductory course ‘In the lead’ 2016 1.0
Basic course on Regulations and Organisation for clinical 
investigators (BROK)
2016 1.5
TULIPS Young Investigators Day 2016 0.25
Workshop - How to sell your sciences 2016 0.25
RU Course - Management for PhD students 2016 2.0
Dutch Kidney Foundation – Winterschool 2017 1.0
RU Course - The art of presenting science 2017 1.5
RU Course - Scientific writing 2017 3.0
RU Course - Refresher course statistics 2017 2.0
IPNA – ESPN Master for Junior Class 2017 0.8
Workshop – PopPK modelling 2017 0.5
RUMC – Scientific Integrity Course 2018 1.0
Pharmacokinetics course – Vennlife sciences 2018 0.75
Radboud Summer School ‘Ins and outs kidneys’ 2019 2.0
Course – teach the teacher 2019 0.4
TULIPS PhD curriculum 2019 - 2021
b. Seminars & lectures
Radboud Research Rounds 2016 - 2020 1.0
Renal Disorders Theme lunch^ 2016 - 2020 1.0
(Pediatric) pharmacology lectures 2016 - 2020 1.0
Amalia Research meetings^^^ 2016 - 2020 1.5
c. (Inter)national symposia & congresses
Radboud Frontiers 2016, 2018 0.75
RIMLS PhD retreat**^ 2017, 2019, 2020 2.25
PLAN scientific symposia (including co-organization of PLAN 
symposium Nijmegen)^
2016 - 2020 1.5
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Dutch Nephrology Days*^ 2017 1.0
European Society for Developmental, Perinatal and Paediatric 
Pharmacology (ESDPPP) congress*
2017, 2019 2.0
Pediatric Association of the Netherlands (NVK) symposium^ 2017 0.5
European Society of Pediatric Nephrology (ESPN) congress** 2017 1.5
Dutch federation of Nephrology (NfN) Fall symposium^* 2017, 2018 0.5
Nierpatiënten Vereniging Nederland (NVN) – patient day^ 2017 0.25
Gesellschaft Pädiatrische Nephrologie – Herbsttagung / 
Studientag^^**
2017, 2018, 2019 2.25
Vijfde Lage Landensymposium Intoxicaties – University Hospital 
Ghent
2019 0.25
American Society of Nephrology (ASN) – kidney week (online)* 2020 0.75
d. Other
Committee member Research Training Internships Amalia 
Children’s Hospital
2017 - 2019 1.5
Committee member PLAN (Platform Aios Nefrologie) 2018 - 2020 1.5
Journal club pediatric nephrology 2017 - 2020 2.0
Review scientific publications 2017 - 2020 0.2
Teaching activities Years ECTS
e. Lecturing
Student meets patient lectures 2017 - 2019 0.5
Transferable skills lessons 2017 - 2018 0.4
Minor ‘Human Embryology in Perspective’ 2017 - 2019 1.4
Pharmacology lectures (Physician Assistants in training, bachelor 
and master students medicine and biomedical sciences)
2017 - 2020 5.0
f. Supervision of internships/other
Supervision of 2 master students and 2 bachelor students 
(Medicine)
2017 - 2020 4.0
Total 52.45
Oral^ or poster* presentations as indicated
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En nu is het moment daar: het dankwoord! Ongetwijfeld het meest gelezen onderdeel 
van het boekje en ik denk dat ik hier dan ook het langst over heb gedaan van alle 
onderdelen van dit proefschrift. 
Allereerst wil ik alle kinderen en ouders bedanken die hebben meegedaan aan de RESTERN 
studie. Dank voor jullie enthousiasme om mee te doen, het invullen van de vele 
vragenlijsten, het kauwen op watjes, spugen in buisjes etc. Door jullie inzet gaat het 
lukken om stappen vooruit te zetten in de behandeling van het nefrotisch syndroom. 
Graag wil ik de kinderartsen en kindernefrologen uit de verschillende ziekenhuizen in 
Nederland, België en Duitsland bedanken voor de alertheid om aan onze studie te 
denken en deze studie mogelijk te maken. Speciale dank wil ik uitspreken aan WINS en 
in het bijzonder Eiske, Tonny, Mandy en Ans voor het meedenken en meedoen aan de 
verschillende projecten en de kritische blik op onze gezamenlijke artikelen.
Prof. dr. Schreuder, lieve Michiel, 
Wat begon als een seniorcoschap, eindigt hier met een promotieboekje. Wat een feest 
is het geweest om van je te leren en met je samen te werken. Inmiddels is deze, door 
jou benoemde, labrador pup uitgegroeid tot een toch wel volwassen(er) exemplaar. Ik 
sta nog steeds versteld van jouw voorspellende gaven omtrent het vroegtijdig 
aankaarten van diverse mijlpalen. Mijn (ongetwijfeld vele) opvolgers zijn bij dezen 
alvast gewaarschuwd. We hebben samen hard gewerkt om de RESTERN studie op te 
kaart te zetten en om deze te laten slagen. Ik weet zeker dat het je gaat lukken om de 
trial ook tot een goede afronding te brengen. Je zou toch denken dat we inmiddels alle 
obstakels gehad hebben?! Dankjewel voor je immer positieve insteek en aanstekelijke 
enthousiasme. Mijn promotietraject was een feest en dat heb ik voor het overgrote 
deel aan jou te danken. 
Prof. dr. De Wildt, beste Saskia, 
Wat een geweldig moment toen jij naar Nijmegen kwam: een professor in de klinische 
farmacologie en dan ook nog met speciale aandacht voor kinderfarmacologie. Je was 
een grote aanwinst voor mijn promotieteam. Ik bewonder jouw talent om kartrekker 
te zijn van zo veel mooie projecten. Dankjewel dat ik veel van je heb mogen leren! Ik zal 
de kinderen-voor-kinderen voordracht tijdens de ESDPPP met jou in haaienpak niet 
snel vergeten. 
Prof. dr. Van den Heuvel, beste Bert, 
Jouw frisse blik tijdens onze jaarlijkse voortgangsgesprekken was waardevol. Fijn dat je 
steeds het einddoel voor ogen wist te houden en met nieuwe ideeën kwam om mijn 
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projecten verder te helpen. Voor het CoQ10 project hebben we intensief samengewerkt 
en dit had ik niet zonder jouw hulp gekund. Dank voor het delen van al je kennis en 
kunde! 
Hierbij wil ik de leden van de manuscriptcommissie, prof. dr. Wetzels, prof. dr. Vande 
Walle en dr. Bökenkamp bedanken voor de beoordeling van mijn manuscript. Ik kijk 
er naar uit om tijdens de verdediging met jullie van gedachten te wisselen over de 
verschillende onderwerpen. 
 Prof. dr. Vande Walle, ik wil u daarnaast bedanken dat we de RESTERN studie ook 
in UZ Gent hebben mogen opstarten. Het heeft even geduurd voordat alle logistieke 
zaken rond zijn gekomen, maar de eerste patiënten zijn inmiddels geïncludeerd. Dit 
alles hadden we niet kunnen volbrengen zonder Daphné Christiaens. Daphné, ik wens 
iedereen een studieverpleegkundige zoals u toe. Uw betrokkenheid en organisatorisch 
vermogen zijn fantastisch. 
 Dr. Ehren, dear Rasmus, thank you for all your help with the RESTERN study in 
Germany. It has been a bumpy ride with many drug related obstacles and therefore I’m 
especially grateful for your dedication, patience, and willingness to include patients in 
our trial. Thank you for all the great work. Prof. dr. Weber, dear Lutz, I still clearly 
remember our first meeting at my RESTERN poster at the EPSN congress in Glasgow. 
I was impressed by your kindness and patience and in fact, I still am. Thank you for your 
sincere interest and always making time for small talk during the GPN meetings. 
 Mariëtte & Nicole, wat een opluchting toen jullie een jaar geleden het RESTERN 
team kwamen versterken met jullie enthousiasme en toewijding. Het was fijn om het 
afgelopen jaar de successen en de obstakels van de RESTERN studie met jullie te 
kunnen delen. Ik weet dat de studie in goede handen is en wens jullie heel veel succes 
om de laatste 100? patiënten te includeren. Het gaat lukken, dat weet ik zeker. 
 Nienke & Yvet, ik wil jullie bedanken voor het opzetten en zeer veelvuldig 
aanpassen van onze databases in Castor. Ik durfde bijna niet aan te komen met de 
vraag of alles ook nog in het Duits erin gezet kon worden, maar ook dat hebben jullie 
perfect geregeld. Fijn dat ik op jullie kon rekenen.
 Dr. Rob ter Heine, Rob, wat hebben we veel strubbelingen gehad in de medicatie 
voor de RESTERN studie. Wie had ooit kunnen denken dat prednisolon vs placebo zo’n 
opgave zou zijn? Dankjewel voor alle kansen die je me hebt gegeven, je snelle revisies 
op de artikelen, goede ideeën en mooie uitleg over (voor mij) ingewikkelde farmacolo-
gische tacrolimus vraagstukken.
Team kindernefrologie, Marlies, Linda, Charlotte, Nicole, Nynke, Jacqueline en Femke. 
Wat zijn jullie toch een speciaal team en wat heb ik me welkom gevoeld bij jullie. 
Marlies, dankjewel voor je lieve, attente kaartjes en cadeautjes op verschillende 
momenten. Ik heb genoten van onze samenwerking, dankjewel voor je hulp bij mijn 
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transplantatiestukken. Jacqueline, fijn om regelmatig even binnen te wandelen en te 
kletsen over onze (oppas)kindjes! Nynke, aan het begin van mijn PhD kreeg ik al wat 
tips en tricks over het runnen van een grote klinische studie bij kinderen met het 
nefrotisch syndroom. Fijn dat ik jouw eerdere werk als inspiratie mocht gebruiken! 
Prof. dr. Van de Kar, lieve Nicole, jij bent voor mij een groot voorbeeld. Ik ken niemand 
die anderen zo goed de waardering kan geven die ze verdienen als jij. Het getuigt van 
groot leiderschap dat jij je op deze manier positioneert. Als ik ooit in de positie kom om 
anderen te begeleiden, dan ga ik daar aan denken. Lieve Charlotte, vaak hadden we 
aan één blik genoeg. Wat vond ik het fijn om op de vrijdagmiddag te komen kletsen, ik 
ga onze gesprekken missen!
 Laboratorium kindernefrologie, Thea, Elena, Sanne, Monique en Joop: dat jullie 
mij destijds als student hebben leren pipetteren, is een klein wonder op zich. 
Dankjulliewel dat ik welkom was bij jullie en dat jullie zorg hebben gedragen voor de 
nefrotisch syndroom samples die ik de afgelopen jaren heb binnengebracht. Laura, fijn 
dat jij vanaf nu het lab-stukje van de RESTERN studie op je wil nemen.
 Mede-PhD studenten en onderzoekers van de kindernefrologie, we zijn klein 
begonnen, maar de afgelopen jaren is onze club steeds verder uitgebreid. Susan, we 
zijn samen begonnen als studenten bij Kioa en uiteindelijk ook allebei naar het 
allermooiste kindernefrologisch onderwerp geswitcht. Ik bewonder je doorzettings-
vermogen en wens je heel veel succes met de afronding van je PhD en vooral ook veel 
geluk met je gezin. Romy, door COVID was onze tijd samen veel korter dan we hadden 
kunnen denken. Ik kijk terug op een hele fijne tijd samen. Jitske, wat een aanwinst voor 
de groep ben jij, ik heb genoten van je prachtige presentaties en plaatjes van de 
organoïden. Wouter, Alessandro, Sander, Marloes, bedankt voor de fijne samenwerking 
en veel succes met (de afronding van) jullie PhD projecten. Tijdens mijn PhD traject heb 
ik verschillende studenten mogen begeleiden en daarvan wil ik Lucie in het bijzonder 
noemen. Lieve Lucie, het was een feestje om met je samen te werken, jij komt er wel! 
Dankjewel voor al je hulp en je enthousiasme. In Curaçao is iemand nog steeds naar de 
medische informatie aan het zoeken. 
 De afgelopen 2 jaar heb ik het geluk gehad mee te mogen doen aan het TULIPS-PhD 
curriculum. Lieve Lisanne, Tim, Lisa, Elise, Fleur, Kelly, Maud, Victoria, Jessica, Yvette, 
Hanneke, Marijn, Anne-Fleur, Jenneke, Myrthe, Nicole, Josine & Emma, ik heb genoten 
van de TULIPS dagen en de mooie weekenden! Dat er maar veel promotiefeestjes 
mogen volgen.
 Pippa & Saskia, de eerste jaren samen op de kamer waren geweldig. Mooi om te 
zien dat we nu allen op verschillende, mooie plekken terecht zijn gekomen. Ik wens 
jullie heel veel geluk! Daan & Roel, wat heerlijk om jullie op gepaste afstand als collega 
PhD studenten te hebben gehad. Ik denk met heel veel plezier terug aan onze etentjes 
met Kioa. De herinnering aan een zeker dinertje in Utrecht passeert hier thuis nog 
regelmatig de revue.. (Miaaauuw?) 
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 Lieve Nori & Anne, farmacologiemaatjes, ESDPPP-leukerds, dank voor de gezelligheid 
de afgelopen jaren! Ik heb genoten van onze gezamenlijke etentjes en de kaasfondue 
in en na Bazel (en de ene keer wat smakelijker dan de andere). Hopelijk gaan we hier 
lekker mee door!
 Lieve Coralien, net nadat we met onze PhD-trajecten begonnen waren mochten 
we tijdens de Winterschool van de Nierstichting een kamer delen. Wat was dat een 
goede match en het begin van een mooie vriendschap. Ik heb heel erg genoten van 
onze fijne lunch- en theemomenten samen, onze aankondigingen (het liefst een week 
of 2-4 na elkaar) en alle fijne gesprekken. Je hebt een hele mooie kijk op de wereld en 
ik ken weinig mensen die zo goed kunnen luisteren als jij. 
Revalidatie-collega’s
Marco, ik wil graag bij jou beginnen. Wat een geluk dat ik bij jou terecht kwam voor 
mijn kennismaking met de kinderrevalidatie. Ik ben dankbaar voor de kansen die je me 
hebt gegeven en ik heb genoten van onze samenwerking. Yvette, Joyce, Marianne, 
Lisette, Annemieke en Marian: dank voor het warme welkom, jullie zijn een geweldig 
team. Fred & Iris, dankjulliewel voor het vertrouwen om met de opleiding te mogen 
starten. José & Dianne, mijn eerste revalidatiestage was bij jullie en ik had me geen 
fijnere start kunnen bedenken.
Lieve vrienden en vriendinnen
Ik mag me gelukkig prijzen met jullie aan mijn zijde. Gelukkig niet alleen tijdens deze 
promotiejaren, maar ongetwijfeld nog vele jaren hierna. Ik wil een aantal van jullie 
even in het bijzonder noemen:
Sjors & Dees, dank voor de talloze play-dates, vriendenweekenden 1.0 – 6.0 (?), 
het aanhoren van mijn promotieverhalen en jullie pogingen om bij te houden waar ik 
mee bezig ben. Fijn dat jullie er zijn! Corné & Sophie, jullie oprechte interesse is heel 
fijn en bijzonder en ik ben heel blij dat jullie onze lieve vrienden zijn. Lieve FLACAMS en 
vrienden van de ultra-epische onderwaterdanseressen (wie kan ik deze groepsnaam 
ook alweer aanrekenen?), Cailin, Laura, Martijn, Rico, Mike, Jaco, Bas, Sidney & Jim, 
ik ben dankbaar voor onze al jarenlange vriendschap, ultra-epic-uitjes, Efteling-bezoeken 
en Dongense Dorpsquizen. Ik ben ervan overtuigd dat we hier de komende 30 jaar nog 
wel mee door zullen gaan. 
Lieve Kioa, 
Ook ik herinner me onze eerste ontmoeting nog. En die tussen jou en Job overigens 
ook.. Ik was onder de indruk van jouw onderzoek- en presentatieskills tijdens een van 
de Amalia Research meetings en dat ben ik, na al die jaren, nog steeds. Inmiddels heeft 
de bewondering ook plaats gemaakt voor trots: trots op hoe je met mensen omgaat, 
hoe je leert en geleerd hebt steeds meer van jezelf te laten zien, en op hoe je bouwt 
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aan een team, aan je gezin en aan je carrière binnen het prachtige kindernefro-team. 
Wat hebben we een geweldige tijd gehad samen. Gelukkig eindigt dit niet met dit 
boekje, alhoewel, dat gezamenlijke congres moeten we nog zien te vinden.. Ik heb het 
je al vaak gezegd, maar voor de zekerheid nog één keer: ik ga nergens heen. 
Lieve Len, 
Ik bewonder jouw luister-capaciteiten, je rust en je kijk op het leven. Dankjewel voor 
onze jarenlange vriendschap, waarbij je in de afgelopen jaren tevens regelmatig de rol 
van PhD klaagmuur hebt ingevuld. Deze rol zal ik de komende jaren met verve proberen 
te vervullen voor jou. Ik vind het heerlijk om te zien hoe jij en Wouter elkaar hebben 
gevonden en ik weet dat wij altijd verbonden zullen blijven.
 
Lieve An, 
Oké, voor dit stukje moest ik even de tijd nemen. Alles met jou is voor mij zo vanzelf-
sprekend en gaat zo natuurlijk dat ik het moeilijk vind om hierover iets op papier te 
zetten. Ik bewonder jouw (en jullie) veerkracht. Ik ben zo dankbaar voor onze 
vriendschap. Ik vind het heerlijk hoe verschillend en hetzelfde we zijn. Ik geniet van alle 
momenten samen, maar ook van de momenten met onze mannen en kids. Ik hoop dat 
we voor altijd samen blijven groeien. 
Lieve Myrthe & Dennis, ik mag me gelukkig prijzen met zo’n schoonzus en zwager. 
Dankjulliewel voor alle interesse de afgelopen jaren. Ik heb genoten van onze 
gesprekken (soms met wat omzwervingen en zijstraten) aan de tafel bij jullie thuis. 
Heel fijn dat we allemaal onze weg gevonden hebben! Dikke kus voor jullie lieve Kee. 
Lieve Christel, ik denk dat ik met recht kan zeggen dat er zonder jou maar een half 
boekje was geweest. Dankjewel voor al je goede zorgen en extra oppasmomenten 
voor Maas en Saar. Ik ben heel dankbaar voor jouw liefde voor onze kids en dat we 
altijd op je kunnen rekenen! René, natuurlijk wil ik ook jou bedanken voor je onvoor-
waardelijke liefde voor onze kinderen en de goede zorgen de afgelopen jaren. Ik heb 
genoten van onze gesprekken over het wel en wee in de zorg, over wat belangrijk is in 
het leven en mijn toekomstplannen als dokter.
Lieve Max, we hebben elkaar in de afgelopen 27 jaar wat wisselend kunnen vinden. Ik 
heb enorme bewondering voor hoe je je door moeilijke perioden heen worstelt en ik 
weet zeker dat je je eigen weg gaat vinden. Dankjewel dat je een lieve oom voor Maas 
en Saar bent.
Lieve papa en mama, ik heb zo lang mogelijk uitgesteld om dit stuk te schrijven, maar 
nu moet ik er toch aan geloven. Papa, de afgelopen jaren is onze band alleen maar 
sterker geworden. Ik heb bewondering voor hoe je in het leven staat en ik geniet ervan 
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om te zien hoe gelukkig jij en Cecile samen zijn. Ik ken niemand die zo goed kan 
bijhouden wanneer ik een presentatie, toets, deadline, noem maar op, heb. Dankjewel 
voor je (on)gevraagde adviezen, dat je altijd binnen 10 min. op de stoep staat om 
dingen in ons huis te repareren of apparatuur uit te lenen. Maar boven alles dankjewel 
voor je onvoorwaardelijke steun en liefde. Ik weet dat je altijd achter me staat. Mama, 
al zolang ik me kan herinneren sta je voor mij (en Max) klaar. Ik weet dat je veel zorgen 
hebt gehad de afgelopen jaren en ik ben er trots op dat je, ondanks alles, bent blijven 
staan en dat je altijd voor mij en de kids klaar staat. Dankjewel voor je onvoorwaardelijke 
liefde, ik weet dat ik altijd bij je terecht kan. Om nog even luchtig te eindigen: dank ook 
voor je Engelse adviezen, ik zal mijn eerste oefenpresentatie in het Engels voor jou 
nooit meer vergeten. 
Lieve Job, jij kunt mijn presentaties beter geven dan ikzelf, ook zonder de finesses van 
het onderwerp te begrijpen. Dankjewel voor je steun, je altijd positieve insteek. Jij bent 
mijn thuis en ik houd ontelbaar (maar niet 0) veel van je! Lieve Maas & Saar, jullie laten 
me zien waar het leven echt om gaat, jullie maken het verschil. 


